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 II  
Summary 
 
Topic I  
Molecular basis of RNA polymerase III transcription repression by Maf1 
 
RNA polymerase III (RNAP III) is a conserved 17-subunit enzyme that transcribes genes encoding short 
untranslated RNAs such as transfer RNAs (tRNAs) and 5S ribosomal RNA (rRNA). These genes are essential 
and involved in fundamental processes like protein biogenesis; hence RNAP III activity needs to be tightly 
regulated. RNAP III is repressed upon stress and this is regulated by Maf1, a protein conserved from yeast to 
humans. Many stress pathways were shown to converge on Maf1 and result in its phosphorylation, followed by 
its nuclear import and eventual repression of RNAP III activity. However, the molecular mechanisms of this 
repression activity were not known at the beginning of these studies. 
 
 This work establishes the mechanism of RNAP III specific transcription repression by Maf1. The 
crystal structure of Maf1 was solved. It has a globular fold with surface accessible NLS sequences, which sheds 
new light on already published results and explains how stress-induced phopshorylation leads to import of Maf1 
into the nucleus. Additionally, cryo EM studies and competition assays show that Maf1 binds RNAP III at its 
clamp domain and thereby induces structural rearrangements of RNAP III, which inhibits the interaction with 
Brf1, a subunit of the transcription initiation factor TFIIIB. This specifically impairs recruitment of RNAP III to 
its promoters and implies that Maf1 is a repressor of transcription initiation. Competition and transcription 
assays show that Maf1 also binds RNAP III that is engaged in transcription, leaving RNAP III activity intact but 
preventing re-initiation.  
 
 
Topic II  
Structure of human mitochondrial RNA polymerase 
 
The nuclear-encoded human mitochondrial RNAP (mitoRNAP) transcribes the mitochondrial genome, which 
encodes rRNA, tRNAs and mRNAs. MitoRNAP is a single subunit (ss) polymerase, related to T7 bacteriophage 
and chloroplast polymerases. All share a conserved C-terminal core, whereas the N-terminal parts of mitoRNAP 
do not show any homology to other ss RNAPs. Unlike phage RNAPs, which are self-sufficient, human 
mitoRNAP needs two essential transcription factors for initiation, TFAM and TFB2M. Both of these factors are 
likely to control the major steps of transcription initiation, promoter binding and melting. Thus human 
mitoRNAP has evolved a different mechanism for transcription initiation and exhibits a unique transcription 
system. Structural studies thus far concentrated on the nuclear enzymes or phage RNAPs, whereas the structure 
of mitochondrial RNA polymerase remained unknown. The structural organization of human mitoRNAP and the 
molecular mechanisms of promoter recognition, binding and melting were subject of interest in these studies. 
 
 In this work the crystal structure of human mitoRNAP was solved at 2.4 Å resolution and reveals a 
T7-like C-terminal catalytic domain, a N-terminal domain that remotely resembles the T7 promoter-binding 
domain (PBD), a novel pentatricopeptide repeat (PPR) domain, and a flexible N-terminal extension. 
MitoRNAP specific adaptions in the N-terminus include the sequestering of one of the key promoter binding 
elements in T7 RNAP, the AT-rich recognition loop, by the PPR domain. This sequestration and repositioning of 
the N-terminal domain explain the need for the additional initiation factor TFAM. The highly conserved active 
site within the C-terminal core was observed to bind a sulphate ion, a well known phosphate mimic, and thereby 
suggests conserved substrate binding and selection mechanisms between ss RNAPs. However, conformational 
changes of the active site were observed due to a movement of the adjacent fingers subdomain. The structure 
reveals a clenching of the active site by a repositioned fingers subdomain and an alternative position of the 
intercalating -hairpin. This explains why the conserved transcription factor TFB2M is required for promoter 
melting and initiation. A model of the mitochondrial initiation complex was build to further explore the initiation 
mechanism, and to rationalize the available biochemical and genetic data. 
 
 The structure of mitoRNAP shows how this enzyme uses mechanisms for transcription initiation that 
differ from those used by phage and cellular RNAPs, and which may have enabled regulation of mitochondrial 
gene transcription and adaptation of mitochondrial function to changes in the environment. 
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1 Transcription by DNA-dependent RNA polymerases 
Transcription is the process of reading DNA into RNA, which for mRNA can be translated by 
ribosomes into proteins, or used for regulation of cellular processes by non-coding RNAs. 
Transcription is fundamental to all living organisms and is carried out by DNA-dependent RNA 
polymerases (RNAPs).  
1.1 Transcription by multisubunit RNAPs 
Gene expression across the three kingdoms of life is predominantly performed by multisubunit 
RNAPs. Whereas bacteria and archaea have one multisubunit RNAP, which transcribe the entire gene 
repertoire in the cell, eukaryotes have three multisubunit RNAPs, which transcribe mainly the nuclear 
genome (Cramer, 2002; Kwapisz et al., 2008). RNAP I is responsible for the synthesis of ribosomal 
RNA, RNAP II for pre-messenger RNA and RNAP III for small RNAs including transfer RNAs 
synthesis. Two additional closely related RNAPs, RNAP IV and V, were found in plants and are 
involved in RNA-dependent DNA methylation and heterochromatin formation (Dalmay et al., 2000; 
Herr et al., 2005; Pontier et al., 2005). 
 
 Multisubunit RNAPs differ in their subunit composition (Table 1) and enzyme surfaces are 
specialized for interactions with initiation or elongation factors. High resolution data from 
multisubunit RNAPs from all three kingdoms of life show a conserved catalytic core formed by Rpb1 
and Rpb2 or their corresponding subunits (Cramer et al., 2001; Hirata et al., 2008; Zhang et al., 1999) 
whereas subunits specific to RNAP I and III are homologous to transcription factors from the RNAP II 
system (Table 1 (Carter and Drouin, 2010; Geiger et al., 2010; Kassavetis et al., 2010; Kuhn et al., 
2007)). 
 
Table 1. Subunit composition of RNAPs 
 
 Eukaryotes   Archaea Bacteria 
 RNAP I RNAP II RNAP III   
A190 Rpb1 C160 A' + A" ' 
A135 Rpb2 C128 B (B' + B")  
AC40 Rpb3 AC40 D 
Rpb5 Rpb5 Rpb5 H - 
Rpb6 Rpb6 Rpb6 K 
Rpb8 Rpb8 Rpb8 - - 
A12.2 Rpb9 C11 - - 
Rpb10 Rpb10 Rpb10 N - 
AC19 Rpb11 AC19 L  
core 
Rpb12 Rpb12 Rpb12 P - 
A14 Rpb4 C17 F - Rbp4/7-
like A43 Rbp7 C25 E´ - 
A49 (N-ter.) - C37 - - TFIIF-
like A34.5 - C53 - - 
- - C82 - - 
A49 (C-ter.) - C34 - - TFIIE-like 
- - C31 - - 
no. SU 14 12 17 11 (12) 5 
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1.2 Transcription by single subunit RNAPs 
Single subunit (ss) RNAPs can be found in bacteriophages and eukaryotic cell organelles, such as T7 
phage (Sousa et al., 1993; Steitz, 2009) and mitochondria (Gaspari et al., 2004b), respectively. 
Notably, mitochondrial RNAP (mitoRNAP) is responsible for transcribing the mitochondrial genome, 
which encodes several subunits of key enzymes involved in oxidative phosphorylation, the major 
source of energy production during respiration (Sologub et al., 2009). Therefore an understanding of 
the molecular mechanisms underlying transcription and transcription regulation in mitochondria is 
critical.  
 
 No structure of a mitoRNAP has yet been published. Sequence similarities within structural 
elements of the T7 RNAP and the mitoRNAP catalytic C-terminus strongly suggest that they have a 
conserved structure (Cermakian et al., 1997; Jeruzalmi and Steitz, 1998). In contrast the N-terminus of 
mitoRNAPs does not show any sequence homology to T7 RNAP and is predicted to feature a new 
class of protein fold containing two PPR motifs, whose function remains unknown (Small and Peeters, 
2000; Tiranti et al., 1997).  
 
 T7 RNAP is one of the best understood RNAPs, since several structures were solved over 
the last 17 years in different functional states using different scaffolds to mimick the initiation state, 
the transition state from initiation to elongation, four different elongation states showing structural 
changes during a single nucleotide addition cycle, and an inhibited state, where T7 RNAP is bound to 
T7 Lysozyme (Cheetham et al., 1999; Jeruzalmi and Steitz, 1998; Sousa et al., 1993; Tahirov et al., 
2002; Durniak et al., 2008; Temiakov et al., 2004; Yin and Steitz, 2002; Yin and Steitz, 2004). Single 
subunit RNAPs are probably very ancient RNAPs and therefore do not show homologies to the 
multisubunit RNAPs of the nucleus (Sousa, 1996). Only the mechanism of transcription, the 
nucleotide addition cycle, is comparable between these enzymes (Sousa, 1996; Temiakov et al., 2000).  
1.3 A common transcription cycle 
Each cycle of transcription by RNAPs involves three phases: promoter binding and duplex opening 
during initiation, processive synthesis of RNA during elongation, and release of the transcript and 
dissociation of RNAP during termination.  
 
 Initiation starts by binding of the RNAP to a specific promoter DNA sequence upstream of 
the transcription start site (TSS) and formation of a transcription bubble by melting the duplex DNA at 
the TSS. RNA synthesis has to start de novo using the downstream DNA as a template and a single 
ribonucleotide as a primer, whereupon RNAP stays bound to the promoter during initial formation of 
first DNA-RNA hybrids (Brieba and Sousa, 2001).  
In the elongation phase, single nucleotide addition takes place by binding of the substrate NTP in a 
pre-insertion mode, followed by NTP insertion into the NTP-binding site (N-site) and a phosphoryl-
transfer reaction to extend the RNA transcript and release pyrophosphate (PPi). Subsequently, the 
RNA 3´-end sits in the N-site and translocation is required to shift the 3´-end of the elongated primer-
template to the priming site (P-site) thereby vacating the N-site for the next round of nucleotide 
addition (Steitz and Yin, 2004; Yin and Steitz, 2004).  
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Termination finally stops transcription at the correct site and is linked to RNA transcript release, 
allowing the RNAP to be released from the template and to reengage in another round of transcription 
(Birse et al., 1997; Dye and Proudfoot, 2001; Evers and Grummt, 1995; Landrieux et al., 2006). 
 
 These mechanistic features are shared between multisubunit and ss RNAPs, hence parts of 
the core enzyme from both types of RNAP show similarities (Cramer et al., 2008). These include the 
conserved configuration of the nucleic acid scaffold of the ternary complexes, similar lengths of the 
DNA/RNA heteroduplexes and conserved residues in the active site, and closing of the catalytic site 
by movement of a particular functional element (the O-helix in T7-like RNAPs and the trigger loop in 
multisubunit RNAPs) (Steitz, 2004; Temiakov et al., 2004).  
 
 
2 Transcription initation and regulation 
Transcription initiation has to be tighly regulated to allow promoter-specific transcription by the 
cognate RNAP (Schramm and Hernandez, 2002). Additionally, gene expression is not static but 
dynamically altered in response to the changing cellular environment. In higher eukaryotes regulation 
of transcription is needed for development and cellular differentiation. So each differentiation stage 
shows altered expression profiles (Levine and Tjian, 2003). Also cell-type-specific expression 
programs have to be co-ordinated (Goodrich and Tjian, 2010). Additionally, cells have to adapt 
according to environmental signals and stresses, subsequentially changing their expression profiles 
(Fraser and Germain, 2009; White and Sharrocks, 2010). Large differences beween multisubunit and 
ss RNAPs are apparent during transcription initiation and regulation.  
2.1 Transcription initiation and regulation of multisubunit RNAPs 
Multisubunit RNAPs depend on accessory factors for the transcription of genes. They act with their 
cognate RNAP as activators, adaptors, inhibitors, terminators, or anti-terminators (Tjian, 1996). 
 
 
General transcription factors enable the general mechanism of transcription 
 
The general transcription factors (GTFs) serve to help with promoter recognition, recruitment of the 
RNAP, and with subsequent activation of the RNAP by promoting transcriptional initiation and 
elongation (Chedin et al., 1998a; Geiduschek and Kassavetis, 2001). Since each RNAP differs in its 
subunit composition and has to transcribe specific sets of genes, each RNAP uses a large number and 
own set of GTFs.  
The structure and function of some transcription factors are conserved across the three kingdoms of 
life, whereas other factors that are non-homologous by sequence show an intringuing level of 
structural and functional similarity, suggestive of convergent evolution (Werner and Grohmann, 
2011). For example, TATA binding protein (TBP) is present in archeal and eukaryotic organisms but 
absent from prokaryotes, whereas the elongation factor Spt5/NusG is conserved in all three kingdoms 
of life (Khoo et al., 1994; Martinez-Rucobo et al., 2011). Additionally, TFIIB, a factor essential for 
RNAP II transcription initiation has homologs in archaea and in the RNAP III system as TFB and 
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TFIIIB respectively, yet features of this protein strongly resemble the unrelated sigma factors used by 
prokaryotic RNAP. 
 
 The general mechanism of transcription initiation starts with core promoter recognition and 
building of a pre-initation complex (PIC). However, due to the different subunit composition of each 
of the RNAPs, their usage of GTFs, and the varying promoter structures of their transcribed genes, the 
PIC compositions are highly variable. 
In the well characterized RNAP II system, the general transcription factors TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH, the major coactivator, termed Mediator, and RNAP II build the general 
transcription machinery (Carey et al., 2009). The PIC of RNAP II is constituted by the GTFs TFIIB, 
TFIID, TFIIE, TFIIF and TFIIH (Kostrewa et al., 2009). The structure of RNAP II-TFIIB was solved 
recently and when combined with chemical probing experiments to locate TFIIE, -F and -H, allowed 
the first modelling of an eukaryotic PIC (Chen et al., 2007; Kim et al., 2000; Kostrewa et al., 2009). In 
the model of Kostrewa et al. TFIIH, which opens dsDNA, binds near the jaws and cleft close to 
downstream DNA (Kim et al., 2000); TFIIE binds to the clamp and is probably involved in non-
template DNA binding and open complex stabilization (Chen et al., 2007), and TFIIF binds to the 
opposite side of the cleft.  
 
 RNAP III is much larger than RNAP II and has consequently integrated some of its required 
transcription factors into the enzyme (Table 1). RNAP III can transcribe three distinct types of class III 
genes, which vary in their promoter control elements, and uses varying transcription factor 
compositions at each type of gene. For type III promoters RNAP III needs just the TFIIIB complex, 
which is composed of TBP, Brf1 and BdpI, to form a minimal functional initiation complex 
(Kassavetis et al., 1990). On type II promoters the transcription factor TFIIIC and on type I promoters 
TFIIIC and TFIIIA, are needed to recruit TFIIIB and subsequentially RNAP III to build a functional 
PIC (Dieci et al., 2007). This illustrates nicely how different promoters rely on different DNA-protein 
and protein-protein interactions to ultimately recruit the same RNAP. Despite knowing which factors 
were present at each class III promoter, no structure or model of a RNAP III PIC was published at the 
beginning of this study, although a crystal structure of the Brf1-TBP-DNA complex (Juo et al., 2003) 
and a low resolution cryo EM reconstruction of RNAP III (Fernandez-Tornero et al., 2007) were 
available. 
 
 Transcriptional activity of RNAPs can be affected by nucleosomes, which associate with the 
coding regions of many RNAP II and III transcribed genes. The susceptibility of class III genes to 
nucleosomal repression is extremely template-dependent. Whereas tRNA genes and U6 genes are 
significantly resistant to chromatin-mediated repression, others are highly susceptible (Paule and 
White, 2000). In vitro studies have shown that TFIIIC weakens the interaction of nucleosomes with 
the transcribed region of these resistant genes (Burnol et al., 1993). 
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Cofactors link transcription to extracellular signals 
 
In addition to the general transcription machineries, cofactors also play an important role in 
transducing different regulatory signals and influencing transcription according to the cellular 
condition. In the case of RNAP III, cofactors like the growth suppressors RB (retinoblastoma) and p53 
in metazoa or Dr1 and Maf1 in human and yeast serve to integrate the transcriptional response to 
extracellular signals (Paule and White, 2000; White and Sharrocks, 2010). Coordination of these 
processes is crucial and is achieved by signalling pathways.  
 
 Maf1 is an inhibitor of RNAP III transcription and various signalling pathways converge on 
Maf1 to regulate RNAP III-dependent transcription. Growth factors and oncogenic mutations lead to 
inhibition of Maf1 and thereby promote RNAP III-dependent transcription, whereas nutrient limitation 
and DNA damage result in Maf1 activation and following RNAP III transcription repression (White, 
2008; Willis et al., 2004; Johnson et al., 2007). Well studied signalling pathways, which converge on 
Maf1, are the target of rapamycin complex (TORC) pathway and the Ras/cAMP pathway (Moir et al., 
2006; Wei et al., 2009).  
TOR is an evolutionary conserved PI3K-related kinase with a large impact on the protein synthesis 
machinery and growth, including the stimulation of tRNA and 5S rRNA gene transcription (Mayer 
and Grummt, 2006; Woiwode et al., 2008). TORC1 is one of two complexes containing the TOR 
kinase and is sensitive to the antibiotic rapamycin. Rapamycin is often used to induce the 
transcriptional effects of nutrient limitation (Rohde et al., 2001). Growth factors like insulin activate 
the pathway by extracellular signal-regulated kinases (ERK) –mediated and ERK-independent steps, 
leading to activation of the small GTPase Rheb, which in turn can activate TORC1. Nutrient 
limitations can be detected in the cell by the AMP/ATP ratio. These lead to activation of the AMP 
kinase, which can phosphorylate and inhibit TORC1 (White and Sharrocks, 2010). The Sch9 kinase is 
a direct target of TORC1 (Urban et al., 2007) and found in yeast to target Maf1 at a subset of protein 
kinase A (PKA) sites, thereby leading to location of Maf1 in the cytoplasm (Lee et al., 2009). TORC1 
itself was shown to inactivate Maf1 in the nucleolus (Wei et al., 2009). Additionally, the phosphatase 
PP2A acts downstream of TORC1 and dephosphorylates Maf1 (Oficjalska-Pham et al., 2006). This 
shows that the TORC pathways controls many steps of Maf1 activity and enables a coordinated RNAP 
III transcription activity in response to the cellular environment. 
 
Another well characterized pathway, which influences Maf1 activity, is the Ras/cAMP pathway. Ras 
is a small GTPase that gets activated in cells upon growth factor or hormone binding to cell receptors 
and can in turn activate several pathways like the mitogen activated protein kinase (MAPK) pathway 
(Zhong et al., 2004). This pathway can influence all three eukaryotic RNAPs by phosphorylation of 
the transcription factor Elk1 and thereby activation of TBP transcription (Johnson et al., 2007). In 
yeast one of many effectors of activated Ras is adenylate cyclase, which causes cAMP accumulation. 
cAMP binds to the regulatory subunits of PKA and thereby activates PKA (Chiaradonna et al., 2008). 
PKA itself was shown to phosphorylate and inactivate Maf1 both in the cytoplasm and the nucleus and 
thereby represents an additional signal mediator mechanism for RNAP III transcription (Moir et al., 
2006). 
 
 Although much is known about the signal pathways that influence RNAP III transcription 
repression by Maf1, few molecular details are known. Uncovering these details promises great insights 
into basic regulatory interactions and mechanisms in the RNAP III system.  
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2.2 Transcription initiation and regulation of single subunit RNAPs 
Transcription regulation of ss RNAPs is diverse. Whereas T7 RNAPs do not need any accessory factor 
for initiation (Chamberlin et al., 1983), mitoRNAPs can only recognize its promoters in a self-
sufficient manner like T7 RNAPs, but need the transcription factor Mtf1 (in yeast) or TFAM and 
TFB2M (in human) for efficient initiation (Cheetham et al., 1999; Litonin et al., 2010). 
 
 
The basal transcription machinery in mitochondria 
 
The basal transcription machinery in mammalian mitochondria consists of TFAM, TFB2M and 
mitoRNAP. These three proteins are sufficient to reconstitute transcription from promoter-containing 
DNA in vitro (Litonin et al., 2010).  
TFAM, a protein consisting of two HMG-boxes, can specifically recognize and unspecifically bind 
and unwind DNA and is suggested to enable transcription initiation (Dairaghi et al., 1995b). TFAM 
binds and bends DNA 15-40 bps upstream of the TSS (Dairaghi et al., 1995b) and genetic and 
biochmemical data suggest that the C-terminus of TFAM interacts with TFB2M and thereby recruits 
the initiation complex (Falkenberg et al., 2007; McCulloch and Shadel, 2003; Sologub et al., 2009). 
However, the high abundance of TFAM in human mitochondria supports a rather unspecific 
mechanism (Cotney et al., 2007). TFAM generally functions in maintenance of the mitochondrial 
genome, but its function in transcription is not conserved in yeast, where it lacks a C-terminal region 
required for transcription in human mitochondria (Antoshechkin et al., 1997; Dairaghi et al., 1995a; 
Shadel and Clayton, 1996). 
In contrast, the function of TFB2M, a member of a large family of dimethyltransferases, is preserved 
in mitochondria of many eukaryotes (Antoshechkin and Bogenhagen, 1995; Cotney et al., 2007; 
Falkenberg et al., 2002; Jang and Jaehning, 1991). In mammals, TFB2M assists mitoRNAP in DNA 
melting and reaches the active site of mitoRNAP to make direct interactions with promoter DNA at 
the first bp of the RNA/DNA hybrid (Sologub et al., 2009). A similar role was shown for the yeast 
TFB2M analog Mtf1 (Savkina et al., 2010). Consistent, mitoRNAP can transcribe single-stranded and 
bubble templates, but not double stranded promoters, explaining the factor-dependency for ds DNA 
melting.  
 
The fact that TFB2M was found to act as a transient component of the catalytic site of the 
mitochondrial initiation complex and helps binding of the priming nucleotide, which is a unique 
feature compared to cellular and T7 RNAPs (Sologub et al., 2009). The promoter release of 
mitoRNAP is thought to require the dissociation of TFB2M or Mtf1 (Mangus et al., 1994; Sologub et 
al., 2009). In this respect, mitoRNAPs resemble the structurally unrelated multisubunit RNAPs.  
 
 In summary, mitochondrial transcription shares a number of features with phage, bacterial, 
and eukaryotic transcription and forms a unique system among well studied bacteriophage and 
multisubunit RNAPs (Table 2).  
 
Table 2. Transcription initiation of single- and multisubunit RNAPs 
 Single subunit RNAPs Multisubunit RNAPs 
 T7 RNAP mito RNAP Bacterial RNAP Eukaryotic RNAP 
promoter 
recognition core core holo holo 
promoter melting core core +TFB2M/TFAM holo holo 
NTP interactions core TFB2M core core 
promoter 
clearance 
refolding of Nt-
domain release of TFB2M release of -subunit 
release of TFIIB/ 
TFIIIB/ core factor 
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 Additional regulatory mechanisms are needed in mitochondria, since mtDNA forms a higher 
structure called nucleoid, which corresponds to the nucleosomes of nuclear DNA. These nucleoids 
contain 2–10 mtDNA molecules and affect the accessibility of mtDNA. TFAM was found to bind to 
nucleoids (Legros et al., 2004) and it is suggested that different amounts of bound TFAM influence the 
promoter usage in human mitochondria (Shutt et al., 2011). In yeast mitochondria nucleoids comprise 
many different proteins in addition to the TFAM ortholog Abf2p. Therefore nucleoids play a role in 
transcription regulation by changing their protein composition in response to metabolic signals to 
adjust mtDNA expression (Kucej et al., 2008). 
 
 
Extracellular signals affect mitochondrial transcription 
 
Like in multisubunit RNAPs, a number of regulatory cofactors play an important role for the activity 
of mitoRNAPs (Woo and Shadel, 2011). Since mitochondria generate energy through oxidative 
catabolism and provide substrates for the synthesis of fatty acids and multiple amino acids, their 
activity has to be tightly linked to cellular nutrient availability. This signal-dependent regulation takes 
place by transcriptional control in the nucleus as well as in mitochondria (Scheffler, 2001; Woo and 
Shadel, 2011). 
 
 In mitochondria some cofactors directly interact with the RNAP. The N-terminal non-
conserved part of yeast mitoRNAPs is suggested to couple factors like Nam1, a protein involved in 
RNA processing and translation (Rodeheffer et al., 2001). Importantly, the loss of the N-terminal part 
of mitoRNAP is characterized in yeasts by an increased instability and eventual loss of the 
mitochondrial genome, which indicates functional N-terminal domains that couple additional activities 
to the transcription process in mitochondria (Wang and Shadel, 1999). However, a recent publication 
revealed that also a larger deletion (first 270 AA) in yeast mitoRNAP has no effect on transcription 
activity in vitro (Paratkar et al., 2011). In human cells, a nuclear active splicing variant of the 
mitoRNAP was found, which has its N-terminal 262 AA deleted (Kravchenko et al., 2005; Wang and 
Shadel, 1999). 
 
 Mitochondrial transcription is also regulated at the level of termination to enable different 
steady-state levels of promoter-proximal and distal transcripts. The mTERF (mitochondrial 
transcription termination factor) protein can modulate mitochondrial transcription in humans and 
D.melanogaster (Linder et al., 2005). A DNA-binding protein (mDBP) was identified in mitochondria 
of P. lividus and found to arrest elongating RNAP (Loguercio et al., 1999). These termination factors 
bind at the 3’-end of blocks of genes transcribed on opposite strands (Fernandez-Silva et al., 2001). 
 
 
 The exact sequence of events in initiation and regulation of mitochondrial gene expression, 
the molecular transcription mechanism by mitoRNAPs and the structural background for these unique 
mechanisms in promoter binding and melting still remain unknown.  
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3 Evolution of DNA-dependent RNA polymerases  
The molecular basis of complexity in higher organisms cannot be simply explained with an enlarged 
number of genes (just 30,000 protein-coding genes in humans compared to 20,000 in C. elegans) but 
rather with an increased complexity in gene expression regulation (Levine and Tjian, 2003). The yeast 
genome encodes about 300 transcription factors (Wyrick and Young, 2002), C. elegans about 1,000 
transcription factors (Ruvkun and Hobert, 1998), and humans about 3,000 transcription factors 
(Lander et al., 2001). These varying degrees of relationships in gene expression regulation are also 
reflected in the structures and mechanisms of multisubunit and ss RNAPs. 
 
 RNAPs show similar mechanistic features and therefore conservations in some parts of the 
enzyme core (Cramer et al., 2008). Since five structurally discrete and evolutionary unrelated folds of 
RNAP active sites exist, polymerization of ribonucleotides has probably been invented several times 
during evolution, pointing to a convergent evolution of these RNAP classes (Werner and Grohmann, 
2011). It is possible that both the multisubunit RNAPs in the three kingdoms of life and the ss RNAPs 
from phages and subcellular organelles each have a unique and separate ancestory (Cermakian et al., 
1997; Werner and Grohmann, 2011). 
3.1 Evolution of multisubunit RNAPs 
All multisubunit RNAPs have a common structural framework and show conserved molecular 
mechanisms like the usage of three key aspartic residues in the active site. This could be explained 
according to the ´RNA-world hypothesis´ by their evolution from one ancestral ribonucleic acid 
polymerase, which is thought to have existed very early in evolution (Steitz and Steitz, 1993). The 
contemporary multisubunit RNAPs may have derived from a common ancestral ribozyme that 
contained a non-catalytic homodimeric RNA-binding protein (Iyer et al., 2003). It is suggested that 
evolution of multisubunit RNAPs emerged by duplication and diversification of this homodimeric 
RNA-binding protein followed by its acquisition of a polymerase activity, and subsequently losing its 
RNA compounds and acting as a platform to evolve more complex multisubunit RNAPs (Iyer et al., 
2003). Subunit complexity of multisubunit RNAPs increased from bacteria to archaea and eukaryotes 
by recruitment and incorporation of existing transcription factors, like TFS (Carter and Drouin, 2010), 
which illustrates the divergent evolution from the last common ancestor within this class of 
multisubunit RNAPs. This can be also seen in the subunit composition of multisubunit RNAPs, where 
some homologous proteins are permanently incorporated into RNAPs in one system but just reversibly 
incorporated in another RNAP (Table 1) and the associated use of RNAP-specific subsets of GTFs.    
 
 By recruitment of existing transcription factors, multisubunit RNAPs expanded. This 
allowed better regulation and explains diversification and specialization into RNAP I, II and III. 
Comparing the eukaryotic subunits A49/A34.5 of RNAP I and C53/C37 of RNAP III, they show 
homology to TFIIF of the RNAP II system (Geiger et al., 2010; Kassavetis et al., 2010; Werner and 
Grohmann, 2011) and the C-terminus of A49 as well as regions of C34 and C82 structurally resemble 
TFIIE (Geiger et al., 2010), also of the RNAP II system. Consequentially, RNAP-specific cofactors, 
like Maf1 in the RNAP III system, evolved in a later step of evolution as it can be seen in sequence 
comparisons and phylogenetic trees (Pluta et al., 2001). Therefore understanding the molecular 
mechanisms of those specific cofactors not only offers insights into the activity of one special 
regulatory protein but also into RNAP-specific mechanisms.  
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3.2 Evolution of single subunit RNAPs 
The evolution of ss RNAPs is also an enigma. As described, strong sequence similarities of 
bacteriophage T7 with mitoRNAP and other ss RNAPs were found widespread within eukaryotic 
genomes (Cermakian et al., 1996). Sequence alignments as well as structure-function analysis of 
highly conserved amino acids point to a common ancestral sequence (Cermakian et al., 1997; Delarue 
et al., 1990; Sousa, 1996). Since ss RNAPs do not share homologies to multisubunit RNAPs but rather 
expose a handshape-like structure, which is comparable with the Klenow fragment of E.coli DNA 
polymerase I (DNAP) it is suggested that ss RNAPs and DNAP I-like enzymes arosed by divergent 
evolution (Cermakian et al., 1996; Sousa, 1996). Nevertheless, the timing of the appereance of an 
ancestral ss RNAP gene is unknown, or even if this ancestor occurred in a cellular or virus-like 
genome (Cermakian et al., 1996).   
Additional implications can be derived from analysis of ss DNAPs. These proteins can be devided into 
six families, namely A, B, C, D, X, Y, which can also be grouped based on their structures into 
proteins containing either classic (Klenow fragment like) or -nucleotidyltransferase-like palm 
domains (Baley et al., 2006).  
 
 It is almost certain that the ancestor of the mitochondrion was an -proteobacterium, which 
was incorporated by endosymbiosis into an unknown host (Gray et al., 2004) and that the complete 
mitochondrial transcription machinery composed of the mitoRNAP, the replicative primase-helicase 
Twinkle, and the DNAP, shows ancestry with T7 bacteriophages. Possibly, the mitoRNAP was 
acquired as part of the endosymbiont genome rather than directly from an accompying phage-like 
entity, since phage-like genes were found in bacterial genomes (Shutt and Gray, 2006). The broad 
phylogenetic distribution suggests an appearance of mitoRNAP early in evolution and that at some 
point during early evolution the unique ss mitoRNAP replaced the multisubunit bacteria-like RNAP 
that was originally brought into the eukaryotic cell by the proto-mitochondrial genome (Shutt and 
Gray, 2006). So the mitoRNAP evolved from interaction of three distinct entities, namely the host cell, 
a bacterium and a phage.  
 
 Therefore mitoRNAPs use a unique transcription system and investigation of its molecular 
transcription and regulation mechanisms establishes ties between the evolutionary diversification of 
RNAPs and is a highly important area of research. 
 
 
 11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II  
 
 
■ ■ ■ 
 
 
Molecular basis of RNA polymerase III transcription 
repression by Maf1 
 
 
 
 
 
 
 
 
 
 
II ■ Molecular basis of RNAP III transcription repression by Maf1                                                      Introduction 
12  
1 Introduction 
1.1 RNA Polymerase III 
1.1.1 RNA Polymerase III structure 
RNAP III, with its 17 subunits and nearly 700 kDa mass, is the most complex nuclear RNAP 
(Schramm and Hernandez, 2002). No X-ray crystal structure is available so far (Cramer et al., 2008). 
Five subunits, Rpb5, 6, 8, 10, and 12, are common to RNAP I, II and III. Subunits AC40 and AC19 
are common to RNAP I and III, and homologous to RNAP II subunits Rpb3 and Rpb11, respectively. 
The two largest RNAP III subunits C160 and C128 are homologous to RNAP II subunits Rpb1 and 
Rpb2, respectively, and encompass the active center of the enzyme. Subunits C17 and C25 form a 
heterodimeric subcomplex, whose structure is solved, and shows homology to the RNAP II 
subcomplex Rpb4/7 (Ferri et al., 2000; Jasiak et al., 2006; Sadhale and Woychik, 1994). Subunit C11 
shares homology with RNAP II subunit Rpb9. The RNAP III-specific subunits C82, C53, C37, C34 
and C31 form two subcomplexes. The C53/37 subcomplex shows limited homology to the RNAP II 
initiation factor TFIIF and is involved in promoter opening, elongation, correct termination and re-
initiation (Carter and Drouin, 2010; Cramer et al., 2008; Kassavetis et al., 2010; Landrieux et al., 
2006). The structure of its RNAP I homologue A49/34.5 was solved recently and indeed shows 
homology to TFIIF (Geiger et al., 2010). The C-terminal region of A49 forms a tandem winged helix 
(tWH) domain and is predicted in TFIIE. The subcomplex C82/34/31 is involved in promoter 
recognition and initiation. C34 interacts with TFIIIB, the initiation factor that recruits RNAP III to 
promoters (Thuillier et al., 1995; Wang and Roeder, 1997; Werner et al., 1993) and plays a subsequent 
role in open complex formation (Brun et al., 1997). NMR structures of two WH domains of C34 were 
solved (PDB codes 2dk5 and 2dk8). Also the structure of the human homologue of C82, hC62, was 
solved recently, and shows in two of its four extended WH domains homology to TFE/ eukaryotic 
TFIIE (Lefevre et al., 2011). So regions of C34 and C82 structurally resemble TFIIE (Geiger et al., 
2010). 
1.1.2 The function and regulation of RNAP III 
RNAP III transcribes genes encoding short, untranslated RNAs such as tRNAs, 5S rRNA, the 
spliceosomal U6 snRNA, the signal recognition particle 7SL RNA, and short regulatory RNAs. RNAP 
III genes are essential in all cells and involved in fundamental processes such as ribosome and protein 
biogenesis, RNA processing, and protein transport. RNAP III transcription is tightly co-regulated with 
RNAP I activity, accounting together for up to 80% of nuclear gene transcription in growing cells 
(Grummt, 2003; Paule and White, 2000; Willis et al., 2004). Therefore RNAP III has to be tightly 
regulated. 
 
In humans deregulation of RNAP I and III transcription is a hallmark of many cancer cells and 
therefore became an important research target over the last years. Namely, overexpression of RNAP 
III products is oncogenic (Marshall, 2008) and RNAP III transcription machineries are targeted by 
several oncogene products like Erk and c-Myc and by tumor suppressors like RB and p53 in metazoan 
(White, 2005). This indicates a critical role of RNAP III in tumorigenesis. Maf1, as a negative 
regulator of RNAP III transcription repression, is thereby a potential tumor suppressor (White, 2008). 
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1.2 The Maf1 protein 
1.2.1 Maf1 is a mediator of signalling pathways 
Because of the central role of RNAP III transcripts in basal cellular processes, the level of RNAP III 
transcription is a critical determinant of cell growth. In yeast, the ability to rapidly shut off synthesis of 
tRNAs and rRNAs during environmental stress conditions ensures cell survival (Warner, 1999).  
 
 Stress conditions lead to RNAP III repression by Maf1, a phosphoprotein that is 
phylogenetically conserved from yeast to human (Pluta et al., 2001; Upadhya et al., 2002). Maf1 is an 
essential and specific regulator of transcriptional repression in the RNAP III system and provides a 
critical link between diverse stress signaling pathways and the RNAP III transcriptional machinery. 
Signaling pathways activated in response to rapamycin-induced nutrient limitation (TOR pathway), 
DNA-damage (MMS treatment), and secretory pathway defects (Tunicamycin treatment) all need 
Maf1 in order to affect RNAP III transcriptional repression (Upadhya et al., 2002). Also conditions of 
carbon source starvation, endoplasmatic reticulum stress (DTT treatment) and oxidative stress 
(peroxide treatment) require Maf1 to cause RNAP III transcription repression (Boguta et al., 1997; 
Upadhya et al., 2002). Additionally, not only stress signals but also the switch between fermentation 
and respiration in yeast induces Maf1 activity (Willis et al., 2004). Under respiratory conditions, Maf1 
is activated by dephosphorylation (1.2.3), and transition to a glucose media induces Maf1 deactivation 
again, thereby leading to a Maf1-dependent cell activity. An example effect is the induction of tRNA-
synthesis rate on glucose media. It was shown several times, that the inactivation of Maf1 (maf1), 
results in higher tRNA-levels due to deregulated RNAP III activity (Pluta et al., 2001; Upadhya et al., 
2002) and posited that the temperature-sensitive growth phenotype can be explained by the toxic effect 
of accumulated tRNAs (Ciesla and Boguta, 2008).  
Importantly, in human cells Maf1 overexpression inhibits oncogenic transformation, likely due to 
Maf1´s ability to restrain RNAP III-dependent transcription (Johnson et al., 2007). 
1.2.2 Maf1 architecture and interaction properties 
Maf1 is phylogenetically highly conserved and lacks homology to any known motifs. Its size ranges 
from 45 kDa (S. cerevisiae.) to 26 kDa (human, S.pombe) and sequence alignments reveal among 
different species four conserved regions, the A-, B- and C-box and a C-terminal acidic tail with 
varying length (Pluta et al., 2001).  
 
 Two nuclear localization sequences (NLS) have been found to affect Maf1 localization in 
yeast and sit at position K205-K208 (Nt-NLS) and R328-R332 (Ct-NLS) (Moir et al., 2006). Human 
NLS sequences can be predicted at the same positions. Recent studies have identified several 
phosphorylation sites in yeast and human Maf1, and most of these phospho-serines occur in the region 
between the A- and B-boxes. The six yeast phosphorylation sites (S90, S101, S177/178, S209/210) are 
targeted by PKA and/or Sch9 kinases (Lee et al., 2009; Moir et al., 2006). Human phosphorylation 
sites (S60, S68, S75) were detected by phospho-proteomic analysis, and their biological relevance has 
been determined recently (Michels et al., 2010).  
 
 First hints for functional aminoacids and regions were determined by point mutation 
analysis. Measurements of in vivo point mutation effects like growth on glycerol, tRNA gene-
mediated (tgm) silencing, antisupression, cellular localization, binding to RNAP III, phosphorylation 
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state of Maf1 and repression of RNAP III transcription activity after rapamycin treatment revealed 
various essential aminoacids for Maf1 activity (Moir et al., 2006; Roberts et al., 2006; Towpik et al., 
2008). Such residues are part of predicted folded regions, of signal sequences like the N-terminal and 
C-terminal NLS-sequences or of a conserved so-called PDxDFS-motif.  
 
 To investigate Maf1 activity, physical interactions were analyzed. Pull-down experiments 
confirmed a direct binding of Maf1 to the N-terminal 235 residues of RPC160, the largest subunit of 
RNAP III. Also other subunits of RNAP III, namely C128, C82, AC40, C34, AC19, C17, and 
ABC14.5, co-immunoprecipitated from yeast lysate (Oficjalska-Pham et al., 2006; Pluta et al., 2001). 
Brf1, a subunit of the transcription factor TFIIIB, interacts weakly but specifically with Maf1, in 
contrast to to the TFIIIB subunits TBP and Bdp1 or TFIIIC, which do not interact (Desai et al., 2005).  
1.2.3 Regulation of Maf1-mediated Polymerase III transcription repression 
In growing yeast, Maf1 is phosphorylated and localized mainly in the cytoplasm. Stress conditions 
lead to rapid Maf1 dephosphorylation and import into the nucleus (Oficjalska-Pham et al., 2006; 
Roberts et al., 2006). Here, Maf1 is signal-dependently phosphorylated by PKA and/ or Sch9 and 
dephosphorylated by protein phosphatase 2A (PP2A) (Moir et al., 2006; Oficjalska-Pham et al., 2006; 
Lee et al., 2009).  
 
 Nuclear import of yeast Maf1 is directed by the two independent NLS sequences. This 
nuclear import is impared by phosphorylation of the six phospho-serine sites (Lee et al., 2009; Moir et 
al., 2006).  
Once in the nucleus another regulatory mechanism has to take place, since Maf1 mutants, which are 
constitutively nuclear, remain regulated by the rapamycin-sensitive kinase TORC1 (Moir et al., 2006; 
Wei et al., 2009). Recent data show that rapamycin treatment leads to localization of Maf1 from the 
nucleus into the nucleolus, where 5s rRNA is located (Wei et al., 2009). TORC1 acts as an essential 
second control step of Maf1 activity in the nucleus. Under normal conditions TORC1 is active, 
phosphorylates and thereby inactivates Maf1, which could still be in the nucleolus but gets 
subsequentially excluded. Rapamycin treatment leads to inactivation of TORC1 and thereby active, 
dephosphorylated Maf1. This demonstrates a new control mechanism (Wei et al., 2009). 
Dephosphorylated Maf1 binds to RNAP III, blocking its interaction with TFIIIB, thus preventing 
recruitment of RNAP III to promoters (Desai et al., 2005; Moir et al., 2006; Roberts et al., 2006).  
 
 Maf1 also inhibits TFIIIB assembly at RNAP III promoters by binding Brf1, a subunit of 
TFIIIB that resembles TFIIB in its N-terminal half but also contains a RNAP III-specific C-terminal 
domain (Desai et al., 2005). Maf1 leads to reduced genome-wide occupancy of RNAP III genes by 
Brf1 and RNAP III (Oficjalska-Pham et al., 2006; Roberts et al., 2006).  
 
 Similar results have been obtained in human cells, where also additional factors (e.g. p53, 
RB and c-Myc) regulate RNAP III activity. Equally, human Maf1 acts as a RNAP III transcription 
repressor in vivo and in vitro (Goodfellow et al., 2008; Reina et al., 2006). After stress signals, 
transcription from promoter types 1, 2 and 3 are downregulated in human cells and phosphorylation-
dependent association of Maf1 with RNAP III and Brf1 could be detected (Reina et al., 2006), as well 
as an additional weak interaction with Brf2 (Rollins et al., 2007). Human Maf1 activity is also 
regulated in a signal-dependent manner by its phosphorylation or dephosphorylation state.  
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 Thus Maf1 is established as a conserved global repressor of RNAP III transcription (Reina et 
al., 2006). Recently, the effect of human Maf1 on facilitated recycled transcription of RNAP III was 
investigated in vitro. It was shown that RNAP III multiple-round transcription but not single-round 
transcription is inhibited by Maf1 (Cabart et al., 2008). 
 
 Inactivation of Maf1 is connected to its re-phosphorylation, which takes place in a signal-
dependent manner in the nucleus. Concomitantly, Msn5 carries Maf1 back to the cytoplasm. Notably, 
despite the constitutive presence of Maf1 in msn5 strains, its regulation is not affected, which can be 
explained by the essential TORC1-dependent regulation inside the nucleus. This indicates a direct and 
indirect phosphorylation-dependent inactivation of Maf1, decreasing Maf1-mediated repression and 
stimulating Msn5-mediated nuclear export, respectively (Towpik et al., 2008). 
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1.3 Aims and scope 
Signal-dependent regulation of cells is necessary to control the consumption of metabolic energy, to 
enable normal cell growth and development and to avoid oncogenic dysregulation (Marshall, 2008; 
White, 2005). Repression of RNAP III transcription, which together with RNAP I accounts up to 80% 
of nuclear gene transcription (Grummt, 2003; Paule and White, 2000; Willis et al., 2004), and whose 
products are oncogenic (Marshall, 2008), is robust and coordinated in all organisms studied to date 
(White and Sharrocks, 2010). Whereas in higher eukaryotes tumor suppressors like RB and p53 are 
well characterized as direct repressors of RNAP I and III transcription (White, 2005), less is known 
about the highly conserved key regulator of RNAP III transcription, Maf1. Functional data emphasize 
the role of Maf1 in yeast and human as a mediator of several signal pathways and as a direct repressor 
of RNAP III transcription (Goodfellow et al., 2008; Upadhya et al., 2002).  
 
 Understanding the molecular mechanisms of Maf1 as a transcription regulator will offer 
insights into the activity of an essential RNAP III regulator protein, which integrates many signal 
pathways and is highly conserved in eukaryotes, thereby explaining a globally used regulation 
mechanism (Goodfellow et al., 2008; Pluta et al., 2001). This will also help to elucidate the 
mechanism of transcription by RNAP III in general. Additionally, as Maf1 exhibits exclusive 
specificity for the RNAP III system in yeast, understanding transcription regulation by Maf1 also 
promises insights into basic regulatory interactions and mechanisms specific for the RNAP III system.  
 
 Furthermore, Maf1 is a potential tumor suppressor (Johnson et al., 2007; Marshall, 2008) and 
understanding its activity and the complex activation and regulation mechanisms could assist future 
research approaches in this direction. Potentially, it could be investigated if Maf1/RNAP III could be 
usefully targeted for therapeutic benefits. 
 
 
The aim of this study was to elucidate the molecular mechanism of the Maf1 mediated repression 
mechanism for RNAP III. Several strategies were chosen to achieve this goal.   
 
 A crystal structure of Maf1 was the initial priority in this study, potentially explaining Maf1 
activation, which is dependent on phosphorylation and dephosphorylation. A structure gives insights 
into the regulatory mechanism of the cellular Maf1 distribution and serves as a basis for structure 
based interaction analysis with RNAP III and other regulatory proteins, thereby giving the first 
molecular details for Maf1 activity as a RNAP III transcription repressor. 
 
 Following a successful structure determination, the interaction of Maf1 with RNAP III can 
be investigated. In vitro binding studies with different Maf1 variants and mutants can elucidate 
binding surfaces and conserved essential residues. Also in vivo complementation assays can be used to 
analyze and understand the Maf1 structure. 
 
 Thirdly, the activity of Maf1 as a repressor of RNAP III transcription can be explored by 
functional assays. Therefore transcription assays as well as competitive binding assays with 
components of the RNAP III minimal PIC were performed. 
 
 Finally, cryo EM reconstructions of Maf1 bound to RNAP III were attempted, and the 
crystal structure of Maf1 used for docking into any potential difference densities. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains 
Table 2. E. coli strains. 
 
Strain Genotype Source 
XL-1 Blue rec1A; endA1; gyrA96 ; thi-1 ; hsdR17; supE44 ; relA1 ; lac[F´proAB 
lacI qZDM15 Tn10(Tetr)] 
Stratagene 
 
BL21-CodonPlus 
(DE3)RIL 
B; F−; ompT; hsdS(rB− mB−); dcm+; Tetr; gal _(DE3); 
endA; Hte [argU, ileY, leuW, Camr] 
Stratagene 
 
BL21-(DE3)pLysS F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS (CamR) Invitrogen 
 
2.1.2 Yeast strains 
Table 3. List of S. cerevisiae strains used or generated within this study. 
 
Strain Genotype Source 
wt  BY4741; MATa; his3D1; leu2D0; met15D0; ura3D0 Euroscarf 
Y00000 
wt BY4742; MAT_ ; his3D1; leu2D0; lys2D0; ura3D0 Euroscarf 
Y10000 
maf1  BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 
Euroscarf 
Y03945 
maf1 scMaf1 fl BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 
this work 
maf1 hsMaf1 fl BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-hsMaf1 1-256 
this work 
maf1 
scMaf1 1-345 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-345 
this work 
maf1 
scMaf1 fl 36-52 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-39536-52 
this work 
maf1 
scMaf1 fl 36-224 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-39536-224 
this work 
maf1 
scMaf1 1-345 36-224 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-34536-224 
this work 
maf1 scMaf1 fl 
D40A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 D40A 
this work 
maf1 scMaf1 fl 
E272A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 E272A 
this work 
maf1 scMaf1 fl 
K233A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 K233A 
this work 
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maf1 scMaf1 fl 
R232H 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 R232H 
this work 
maf1 scMaf1 fl 
G316E 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 G316E 
this work 
maf1 scMaf1 fl 
S263R 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 S263R 
this work 
maf1 scMaf1 fl 
D250A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 D250A 
this work 
maf1 scMaf1 fl 
D248A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 D248A 
this work 
maf1 scMaf1 fl 
D248A/D250A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 D248A/D250A 
this work 
maf1 scMaf1 fl 
K329A/K331A 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 K329A/K331A 
this work 
maf1 scMaf1 fl 
D40N/R232H 
BY4741; Mat a; his3D1; leu2D0; met15D0; ura3D0; 
YDR005c::kanMX4 pRS316-scMaf1 1-395 D40N/R232H 
this work 
 
2.1.3 Plasmids and primers 
Table 4. List of vectors used in this study. 
 
Vector Inserts/ Description Type Tag Restr. 
sites 
Primer 
RR008 saccharomyces cerevisiae Maf1 1-395 
(=fulllenght) 
pET28b(+) Nt His NotI, 
NdeI 
scMaf1 1 for NdeI               
scMaf1 395 rev 
RR009 human Maf1 1-256 (=fulllenght) pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev 
RR010 human Maf1 1-205 36-82 (=X-tal 
construct) 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for                 
hMaf11-205 NotI Stop rev     
hMaf1 D36-82 for                 
hMaf1 D36-82 rev 
RR011 sc Maf1 1-345 36-224 (=X-tal assigned 
to yeast); insert ordered at mr gene with 
optimized sequence  
pET28b(+) Nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 345 rev opt NotI Stop 
RR012 human Maf1 1-256 (=fulllenght) pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev 
RR013 human Maf1 82-213 (= "BC-box") pET21b(+) _ NotI, 
NdeI 
hMaf1 BC NdeI for                
hMaf1 BC NotI rev 
RR014 human Maf1 82-213 (= "BC-box") pET28b(+) Nt His NotI, 
NdeI 
hMaf1 BC NdeI for                
hMaf1 BC NotI rev 
RR015 human Maf1 1-213 (="ABC-box") pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 BC NotI rev 
RR016 human Maf1 1-213 (="ABC-box") pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 BC NotI rev 
RR017 human Maf1 1-81 (="A-box") pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 1-81 NotI Stop rev 
RR018 human Maf1 1-81 (="A-box") pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 1-81 NotI Stop rev 
RR019 human Maf1 1-205 (="ABC-box - 
complete acidic tail") 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 1-205 NotI Stop rev 
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RR020 human Maf1 82-205 (="BC-box - 
complete acidic tail") 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 BC NdeI for                 
hMaf1 1-205 NotI Stop rev 
RR021 human Maf1 1-205 (="ABC-box - 
complete acidic tail") 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for                
hMaf1 1-205 NotI Stop rev 
RR022 human Maf1 52-213 (="mobile insertion 
+ BC-box") 
pET21b(+) _ NotI, 
NdeI 
hMaf1 52 NdeI for                 
hMaf1 BC NotI rev 
RR023 human Maf1 52-213 (="mobile insertion 
+ BC-box") 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 52 NdeI for                 
hMaf1 BC NotI rev 
RR024 human Maf1 1-213 63-78 (= -part of 
mobile insertion and -part of acidic tail) 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 BC NotI rev                
hMaf1 D63-78 for                 
hMaf1 D63-78 rev 
RR025 human Maf1 1-213  63-82 (= -part of 
mobile insertion and -part of acidic tail) 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 BC NotI rev                
hMaf1 D63-82 for                 
hMaf1 D63-82 rev 
RR026 human Maf1 1-256  63-82 (= -part of 
mobile insertion and fulllenght) 
pET28b(+) Nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev             
hMaf1 D63-82 for                 
hMaf1 D63-82 rev 
RR027 human Maf1 1-256  55-78 (= -part of 
mobile insertion and fulllenght) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev             
hMaf1 D55-78 for                 
hMaf1 D55-78 rev 
RR028 human Maf1 1-205 55-78 (= -part of 
mobile insertion and -complete acidic 
tail) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D55-78 for                 
hMaf1 D55-78 rev 
RR029 human Maf1 1-205 55-82 (= -part of 
mobile insertion and -complete acidic 
tail) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D55-82 for                 
hMaf1 D55-82 rev 
RR030 human Maf1 52-256 (="+ mobile 
insertion + BC-box + acidic tail") 
pET21b(+) _ NotI, 
NdeI 
hMaf1 52 NdeI for                 
hMaf1 f.l. NotI Stop rev            
RR031 human Maf1 52-205 (="+ mobile 
insertion + BC-box - complete acidic 
tail") 
pET21b(+) _ NotI, 
NdeI 
hMaf1 52 NdeI for                 
hMaf1 1-205 NotI Stop rev       
RR032 human Maf1 1-205 63-82 (= -part of 
mobile insertion and -complete acidic 
tail) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D63-82 for                 
hMaf1 D63-82 rev 
RR033 human Maf1 1-205 63-78 (= -part of 
mobile insertion and -complete acidic 
tail) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D63-78 for                 
hMaf1 D63-78 rev 
RR034 human Maf1 1-256 55-82 (= -part of 
mobile insertion and fulllenght) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev             
hMaf1 D55-82 for                 
hMaf1 D55-82 rev 
RR035 human Maf1 1-205 63-78 (= -part of 
mobile insertion and -complete acidic 
tail) 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D63-78 for                 
hMaf1 D63-78 rev 
RR036 human Maf1 82-256 (="- mobile 
insertion + BC-box + acidic tail") 
pET21b(+) _ NotI, 
NdeI 
hMaf1 BC NdeI for                
hMaf1 f.l. NotI Stop rev 
RR037 human Maf1 82-256 (="- mobile 
insertion + BC-box + acidic tail") 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 BC NdeI for                
hMaf1 f.l. NotI Stop rev 
RR038 human Maf1 1-256 49-82 (= -part of 
mobile insertion and fulllenght) 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 f.l. NotI Stop rev             
hMaf1 D49-82 for                 
hMaf1 D49-82 rev 
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RR039 human Maf1 1-205 49-82 (= -part of 
mobile insertion -complete acidic tail) 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D49-82 for                 
hMaf1 D49-82 rev 
RR040 human Maf1 1-205 49-82 (= -part of 
mobile insertion -complete acidic tail) 
pET21b(+) _ NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D49-82 for                 
hMaf1 D49-82 rev 
RR041 human Maf1 1-205 36-82 (= -mobile 
insertion -complete acidic tail) 
crystallized construct 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 ABC NdeI for             
hMaf1 1-205 NotI Stop rev        
hMaf1 D36-82 for                 
hMaf1 D36-82 rev 
RR042 human Maf1 82-205 (="BC-box" -
mobile insertion -complete acidic tail) 
pET28b(+) nt His NotI, 
NdeI 
hMaf1 BC NdeI for                
hMaf1 1-205 NotI Stop rev        
RR043 sc Maf1 1-395 41-224 (= -part of 
mobile insertion, adapted to crystallized 
human construct, fulllenght) (achieved as 
unspecific product of cloning) 
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 NdeI for               
scMaf1 395 NotI rev Stop          
scMaf1 D36-224 for           
scMaf1 D36-224 rev            
RR044 sc Maf1 1-340 41-224 (= -part of 
mobile insertion, adapted to crystallized 
human construct, -acidic tail) (achieved 
as unspecific product of cloning) 
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 NdeI for               
scMaf1 340 rev NotI Stop          
scMaf1 D36-224 for           
scMaf1 D36-224 rev            
RR045 based on RR086: sc Maf1 1-345 36-224 
(= -mobile insertion, -acidic tail) equates 
to crystallized human construct 
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 395 rev opt.  NotI 
stop  
RR046 based on RR087: sc Maf1 1-340 52-224 
(= -mobile insertion, including predicted 
helix, -acidic tail)  
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 340 rev opt NotI Stop 
RR047 based on RR086: sc Maf1 1-340 36-224 
(= -mobile insertion, -acidic tail)  
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 340 rev opt NotI Stop 
RR048 based on RR086: sc Maf1 1-340 36-224 
(= -mobile insertion, -acidic tail)  
pET21b(+) _ NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 340 rev opt NotI Stop 
RR049 based on RR087: sc Maf1 1-395 52-224 
(= -mobile insertion, including predicted 
helix, fulllenght)  
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 395 rev opt NotI Stop 
RR050 based on RR087: sc Maf1 1-39552-224 
(= -mobile insertion, including predicted 
helix, fulllenght)  
pET21b(+) _ NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 395 rev opt NotI Stop 
RR051 based on RR087: sc Maf1 1-34552-224 
(= -mobile insertion, including predicted 
helix, -acidic tail)  
pET28b(+) nt His NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 345 rev opt NotI Stop 
RR052 based on RR087: sc Maf1 1-34552-224 
(= -mobile insertion, including predicted 
helix, -acidic tail)  
pET21b(+) _ NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 345 rev opt NotI Stop 
RR053 based on RR086: sc Maf1 1-39536-224 
(= -mobile insertion, fulllenght)  
pET21b(+) _ NotI, 
NdeI 
scMaf1 1 for opt. NdeI        
scMaf1 f.l. rev opt NotI Stop 
RR054 sc Maf1 1-395 D248A /D250A pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 D248A D250A 
for yeast Maf1 D248A 
D250A rev 
RR055 sc Maf1 1-395 D250A pET28b(+) nt His NotI, 
NdeI        
quick  
yeast Maf1 D250A for           
yeast Maf1  D250A rev 
RR056 sc Maf1 1-395 D40N pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 D40N for             
yeast Maf1  D40N rev 
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RR057 sc Maf1 1-395 R232H pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 R232H for             
yeast Maf1 R232H rev 
RR058 sc Maf1 1-395 E314A pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 E314A for             
yeast Maf1 E314A rev 
RR059 sc Maf1 1-395 E314A pET21b(+) _ NotI, 
NdeI        
yeast Maf1 E314A for             
yeast Maf1 E314A rev 
RR060 sc Maf1 1-395 A240R pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 A240R for             
yeast Maf1 A240R rev 
RR061 sc Maf1 1-395 A240R pET21b(+) _ NotI, 
NdeI        
yeast Maf1 A240R for             
yeast Maf1 A240R rev 
RR062 sc Maf1 1-395 E272A pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 E272A for             
yeast Maf1 E272A rev 
RR063 sc Maf1 1-395 R280A pET28b(+) nt His NotI, 
NdeI        
quick  
yeast Maf1 R280A for             
yeast Maf1 R280A rev 
RR064 sc Maf1 1-395 G316E pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 G316E for             
yeast Maf1 G316E rev 
RR065 sc Maf1 1-395 K233A pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 K233A for             
yeast Maf1 K233A rev 
RR066 sc Maf1 1-395 K329A/K331A pET28b(+) nt His NotI, 
NdeI        
yeast Maf1 K329A/K331A 
for             yeast Maf1 
K329A/K331A rev 
RR067 C160 1-235 (=N-terminal 235 AA of 
C160 RNAP III) 
pET28b(+) nt His NotI, 
NdeI        
C160 1 NdeI for                      
C160 235 NotI Stop rev 
RR068 scMaf1 1-395 pET21b(+) nt Strep NotI, 
NdeI        
scMaf1 1 for STREP NdeI     
scMaf1 f.l. NotI Stop rev 
RR069 scMaf1 1-395 A240R pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 A240R for             
yeast Maf1 A240R rev 
RR070 sc Maf1 1-395 G316E pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 G316E for             
yeast Maf1 G316E rev 
RR071 sc Maf1 1-395 K233A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 K233A for             
yeast Maf1 K233A rev 
RR072 sc Maf1 1-395 E272A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 E272A for             
yeast Maf1 E272A rev 
RR073 sc Maf1 1-395 S263R pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 S263R for             
yeast Maf1 S263R rev 
RR074 sc Maf1 1-395 K329A/K331A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 K329A/K331A 
for             yeast Maf1 
K329A/K331A rev 
RR075 sc Maf1 1-395 D248A  pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 D248A for           
yeast Maf1 D248A rev 
RR076 sc Maf1 1-395 E314A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 E314A for             
yeast Maf1 E314A rev 
RR077 sc Maf1 1-395 R280A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 R280A for             
yeast Maf1 R280A rev 
RR078 sc Maf1 1-395 D250A pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 D250A for           
yeast Maf1  D250A rev 
RR079 sc Maf1 1-34536-224 (=X-tal assigned 
to yeast); insert with optimized sequence 
for Ecoli expr 
pET21b(+) nt Strep NotI, 
NdeI        
scMaf1 opt 1 for STREP 
NdeI scMaf1 345 rev opt.  
NotI stop 
RR080 sc Maf1 1-34552-224; insert optimized 
sequence for Ecoli expr 
pET21b(+) nt Strep NotI, 
NdeI        
scMaf1 opt 1 for STREP 
NdeI scMaf1 345 rev opt.  
NotI stop 
RR081 sc Maf1 1-39536-224 insert optimized pET21b(+) nt Strep NotI, scMaf1 opt 1 for STREP 
NdeI scMaf1 395 rev opt.  
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sequence for Ecoli expr NdeI        NotI stop 
RR082 sc Maf1 1-395 D248A/H249Q 
(unspecific cloning product) 
pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 D248A for           
yeast Maf1 D248A rev 
RR083 sc Maf1 1-395 E314/D40N  pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 D40A for             
yeast Maf1 D40A rev 
RR084 sc Maf1 1-395 R232H/D248A 
(unspecific cloning product) 
pET21b(+) nt Strep NotI, 
NdeI        
yeast Maf1 R232H for             
yeast Maf1 R232H rev 
RR085 sc Maf1 1-395 pET21b(+) _ NotI, 
NdeI        
scMaf1 1 for NdeI               
scMaf1 395 rev 
RR086 ordered at Mr gene: scMaf1 1-39536-
224; optimized sequece for E.Coli 
expression (= -mobile insertion, 
fulllenght)  
pAM  - NotI, 
NdeI        
scMaf1 opt for 
scMaf1 395 opt rev 
RR087 ordered at Mr gene: scMaf1 1-39552-
224; optimized sequence for E.Coli 
expression (= -mobile insertion incl. 
Predicted helix, fulllenght)  
pAM -  NotI, 
NdeI        
scMaf1 opt for 
scMaf1 395 opt rev 
RR088  pRS316      
RR089 human Maf1 52-256 (="+ mobile 
insertion + BC-box + acidic tail") 
pET28b(+) nt His NotI, 
NdeI        
hMaf1 52 NdeI for                 
hMaf1 f.l. NotI Stop rev            
RR090 Brf/TBP/Brf triple fusion (George 
Kassavetis) 
pET28b(+) nt His   - 
RR091 C53 NH 2°/ C37 f.l.1° (Alessandro 
Vannini) 
pDuet His    - 
RR092 scMaf1 1-395 52-122 188-224 
(ordered at Mr Gene) 
pMA -  NotI, 
NdeI        
scMaf1 for 
scMaf1 395 rev 
RR093 scMaf1 1-395 123-187 (ordered at Mr 
Gene) 
pMA -  NotI, 
NdeI        
scMaf1for 
scMaf1 395 rev 
RR094 scMaf1 1-395 52-224 (ordered at Mr 
Gene), optimized sequence for E.Coli 
expression =RR087 
pAM -  NotI, 
NdeI        
scMaf1 opt for 
scMaf1 395 opt rev 
RR095 scMaf1 1-395 36-224 (ordered at Mr 
Gene), optimized sequence for E.Coli 
expression =RR086 
pAM -  NotI, 
NdeI        
scMaf1 opt for 
scMaf1 395 opt rev 
RR002 scMaf1 1-395 with endogenous s.cer. 
promoter and terminator sequence – 
homologous recombination 
pRS316 - SacI 
(only 
vector 
cutting) 
Iv_HR_scPromotor_NotI_for 
Iv_HR_scTerminator_SalI_re
v 
Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_395_overlap-
rev 
RR001 hMaf1 1-256 with endogenous s.cer. 
promoter and terminator sequence 
(cut with HindIII in scMaf1 sequence of 
RR…) - homologous recombination 
pRS316 - HindIII Iv_HR_hMaf1_overlap_for 
Iv_HR_hMaf1_overlap-rev 
RR003 scMaf1 1-395D36-52 with endogenous 
s.cer. promoter and terminator sequence 
– homologous recombination (="+ 
mobile insertion -helix + acidic tail") 
pRS316 - HindIII Iv_HR_scMaf1_D36-52_for 
Iv_HR_scMaf1_D36-52_rev 
Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_395_overlap-
rev 
RR004 scMaf1 1-395D36-224 with endogenous 
s.cer. promoter and terminator sequence 
– homologous recombination (="- mobile 
insertion -helix +acidic tail") 
pRS316 - HindIII Iv_HR_scMaf1_D36-224_for 
Iv_HR_scMaf1_D36-224_rev 
Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_395_overlap-
rev 
II ■ Molecular basis of RNAP III transcription repression by Maf1                                        Materials & Methods 
23  
RR005 scMaf1 1-345 with endogenous s.cer. 
promoter and terminator sequence – 
homologous recombination (="-acidic 
tail") 
pRS316 - HindIII Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_345_overlap-
rev 
RR006 scMaf1 1-345 D36-224 with endogenous 
s.cer. promoter and terminator sequence 
– homologous recombination (="- mobile 
insertion-helix -acidic tail") 
pRS316 - HindIII Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_345_overlap-
rev 
 
RR007 scMaf1 1-345 D41-224 with endogenous 
s.cer. promoter and terminator sequence 
– homologous recombination (="- mobile 
insertion –part of helix -acidic tail") 
pRS316 - HindIII Iv_HR_scMaf1_overlap_for 
Iv_HR_scMaf1_345_overlap-
rev 
 
RR098 scMaf1 1-395 K329A/K331A with 
endogenous s.cer. promoter and 
terminator sequence  
pRS316 - - yeast Maf1 K329A/K331A 
for              
yeast Maf1 K329A/K331A 
rev             
RR099 scMaf1 1-395 R232H with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 R232H for             
yeast Maf1 R232H rev             
RR100 scMaf1 1-395 S263R with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 S263R for             
yeast Maf1 S263R rev             
RR101 scMaf1 1-395 G316E with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 G316E for             
yeast Maf1 G316E rev             
RR102 scMaf1 1-395 K233A with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 K233A for             
yeast Maf1 K233A rev             
RR103 scMaf1 1-395 D250 with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 D250A for             
yeast Maf1 D250A rev             
RR104 scMaf1 1-395 S263R/G316E with 
endogenous s.cer. promoter and 
terminator sequence  
pRS316 - - yeast Maf1 S263R/G316E for    
yeast Maf1 S263R/G316E rev    
RR106 scMaf1 1-395 D248A/D250A with 
endogenous s.cer. promoter and 
terminator sequence  
pRS316 - - yeast Maf1 D248A/D250A 
for              
yeast Maf1 D248A/D250A 
rev             
RR107 scMaf1 1-395 D40N/R232H with 
endogenous s.cer. promoter and 
terminator sequence (unspecific cloning 
product) 
pRS316 - - yeast Maf1 D40N for             
yeast Maf1 D40N rev 
RR108 scMaf1 1-395 E272A with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 E272A for             
yeast Maf1 E272A rev 
RR109 scMaf1 1-395 D40N with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 D40A for             
yeast Maf1 D40A rev 
RR110 scMaf1 1-395 D248A with endogenous 
s.cer. promoter and terminator sequence  
pRS316 - - yeast Maf1 D248A for             
yeast Maf1 D248A rev 
RR111 scMaf1 1-395 T111P/D248A with 
endogenous s.cer. promoter and 
terminator sequence (unspecific cloning 
product) 
pRS316 - - - 
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Table 5. List of primers used in this study. 
 
ID Primer Sequenz (5´-3´) 
RRP01 scMaf1 1 NdeI for                GGAGGAGGACATATGAAGCTATTGGAGAACTCGAGCTTG 
RRP02 scMaf1 395 rev GGAGGAGGAGCGGCCGCCTACTGTAGGGATTCTTC 
RRP03 hMaf1 ABC NdeI for              GGAGGAGGACATATGAAGCTATTGGAGAACTCGAGCTTG 
RRP04 hMaf1 f.l. NotI Stop rev GGAGGAGGAGCGGCCGCCTATCAAATACAGATCACTGG 
RRP05 hMaf11-205 NotI Stop rev GGAGGAGGAGCGGCCGCTCAGGAACGGCAGCTAAA 
RRP06 hMaf1 D36-82 for          AGCTACTCATGTAAGCCCCTCAGTGACAAG 
RRP07 hMaf1 D36-82 rev CTTGTCACTGAGGGGCTTACATGAGTAGCT 
RRP08 scMaf1 1 for opt. NdeI         GGAGGTACCCATATGATGAAATTCATTGACGAGCTGGAC 
RRP09 scMaf1 345 rev opt NotI Stop GGAGGAGGAGCGGCCGCTTAACTATTCAGGCGGCTACAGATCAG 
RRP10 hMaf1 BC NdeI for                 GGAGGAGGACATATGGGCCCCCTCAGTGACAAGTGC 
RRP11 hMaf1 BC NotI rev GGAGGAGCGGCCGCTCAGGGTGTGTAGGTGGAG 
RRP12 hMaf1 1-81 NotI Stop rev GGAGGAGGAGCGGCCGCTCACTCCTCCTCACCGCCTTG 
RRP13 hMaf1 1-205 NotI Stop rev GGAGGAGGAGCGGCCGCTCAGGAACGGCAGCTAAA 
RRP14 hMaf1 52 NdeI for                  GGAGGAGGACATATGCAGCCCCACGTGCTGGAGGCACTT 
RRP15 hMaf1 D63-78 for                  GCACTTTCTCCACCCGAGGAGGAGGGCCCC 
RRP16 hMaf1 D63-78 rev GGGGCCCTCCTCCTCGGGTGGAGAAAGTGC 
RRP17 hMaf1 D63-82 for                  GCACTTTCTCCACCCCCCCTCAGTGACAAG 
RRP18 hMaf1 D63-82 rev CTTGTCACTGAGGGGGGGTGGAGAAAGTGC 
RRP19 hMaf1 D55-78 for               GGCCAGCCCCACGAGGAGGAGGGC 
RRP20 hMaf1 D55-78 rev GCCCTCCTCCTCGTGGGGCTGGCC 
RRP21 hMaf1 D55-82 for          GAGGGCCAGCCCCACCCCCTCAGTGACAAG 
RRP22 hMaf1 D55-82 rev CTTGTCACTGAGGGGGTGGGGCTGGCCCTC 
RRP23 hMaf1 D49-82 for TTCAAGCAGTTCTGCCCCCTCAGTGACAAG 
RRP24 hMaf1 D49-82 rev CTTGTCACTGAGGGGGCAGAACTGCTTGAA 
RRP27 scMaf1 D36-224 for            GCGGTTGCATCAGATCCCATAAACGAACCG 
RRP28 scMaf1 D36-224 rev            CGGTTCGTTTATGGGATCTGATGCAACCGC 
RRP29 scMaf1 340 rev NotI Stop        GGAGGAGGAGCGGCCGCTCAGCAAATCAAGTAAAGGTA 
RRP30 scMaf1 395 rev opt.  NotI stop  GGAGAGCTCGCGGCCGCTTACTGCAGTGACTCCTCTTGGTCGCT 
RRP31 scMaf1 340 rev opt NotI Stop GGAGGAGGAGCGGCCGCTTAACAGATCAGATACAGATAGGCCAC 
RRP34 yeast Maf1 D248A D250A for  GCTTCTTATCCTGCCCATGCTTTTTCATCGGTT 
RRP35 yeast Maf1 D248A D250A rev AACCGATGAAAAAGCATGGGCAGGATAAGAAGC 
RRP36 yeast Maf1 D250A for            TCTTATCCTGACCATGCTTTTTCATCGGTTGAG 
RRP37 yeast Maf1 D250A rev CTCAACCGATGAAAAAGCATGGTCAGGATAAGA 
RRP38 yeast Maf1 D40N for             AAGGCGGTTGCATCAAATAGAAAATTATATAAA 
RRP39 yeast Maf1 D40N rev TTT TAT TAA TTT TCT ATT TGA TGC AAC CGC CTT 
RRP40 yeast Maf1 R232H for              AAC GAA CCG TCA AGC CAC AAA ATA TTT GCT TAT 
RRP41 yeast Maf1 R232H rev ATAAGCAAATATTTTGTGGCTTGACGGTTCGTT 
RRP42 yeast Maf1 E314A for              TTGGAAGATGCGCCTGGCTATCTT 
RRP43 yeast Maf1 E314A rev AAGATAGCCAGGCGCATCTTCCAA 
RRP44 yeast Maf1 A240R for              TTTGCTTATCTGATTCGTATCCTCAACGCTTCT 
RRP45 yeast Maf1 A240R rev AGAAGCGTTGAGGATACGAATCAGATAAGCAAA 
RRP46 yeast Maf1 E272A for              TTTATTTCCAAATTTGCAAACACCTTATATTCT 
RRP47 yeast Maf1 E272A rev AGAATATAAGGTGTTTGCAAATTTGGAAATAAA 
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RRP48 yeast Maf1 R280A for              TATTCTCTTGGTGCACAACCAGAGGAA 
RRP49 yeast Maf1 R280A rev TTCCTCTGGTTGTGCACCAAGAGAATA 
RRP50 yeast Maf1 G316E for              TTGGAAGATGAGCCTGAATATCTTTGGAATCTT 
RRP51 yeast Maf1 G316E rev AAGATTCCAAAGATATTCAGGCTCATCTTCCAA 
RRP52 yeast Maf1 K233A for              CCGTCAAGCCGCGCAATATTTGCTTAT 
RRP53 yeast Maf1 K233A rev ATAAGCAAATATTGCGCGGCTTGACGG 
RRP54 yeast Maf1 K329A/K331A for  CTTTACAACAGGGCAAGGGCAAGAGTGGCTTAC 
RRP55 yeast Maf1 K329A/K331A rev GTAAGCCACTCTTGCCCTTGCCCTGTTGTAAAG 
RRP56 C160 1 NdeI for                       GGAGGAGGACATATGAAGGAAGTCGTTGTAAGTGAA 
RRP57 C160 235 NotI Stop rev GGAGGAGCGGCCGCTCACTTAATTTGCTTGAAAAGATTTAAAGT 
RRP58 scMaf1 1 for STREP NdeI GGAGGTACCCATATGGCAAGCTGGAGCCACCCGCAGTTCGAA AAGGGTGCAATGAAATTTATTGATGAG 
RRP60 yeast Maf1 S263R for              GATTTTGTCAAAACACGATTGAAAACTTTTATT 
RRP61 yeast Maf1 S263R rev AATAAAAGTTTTCAATCGTGTTTTGACAAAATC 
RRP62 yeast Maf1 D248A for          AACGCTTCTTATCCTGCCCATGATTTTTCATCG 
RRP63 yeast Maf1 D248A rev CGATGAAAAATCATGGGCAGGATAAGAAGCGTT 
RRP64 scMaf1 opt 1 for STREP NdeI GGAGGTACCCATATGGCAAGCTGGAGCCACCCGCAGTTCGAA AAGGGTGCAATGAAATTCATTGACGAG 
RRP65 yeast Maf1 D40A for         AAGGCGGTTGCATCAGCTAGAAAATTATATAAA 
RRP66 yeast Maf1 D40A rev TTTTATTAATTTTCTAGCTGATGCAACCGCCTT 
RRP70 C160 1 NdeI for                       GGAGGAGGACATATGAAGGAAGTCGTTGTAAGTGAA 
RRP71 C160 235 NotI Stop rev GGAGGAGCGGCCGCTCACTTAATTTGCTTGAAAAGATTTAAAGT 
RRP72 
Iv_HR_scPromotor_NotI_for  Acggccagtgaattgtaatacgactcactatagggcgaattggagctcgcggccgc 
TCCGTATTCGGTCCTCATTATATCG 
RRP73 
Iv_HR_scTerminator_SalI_rev Atgattacgccaagctcggaattaaccctcactaaagggaacaaaagctgggtacc 
GTCGACTTGAAGTTCCGTATTCGAAAGAAACT 
RRP74 
Iv_HR_scMaf1_overlap_for TAACCGCTCATTACTCCAAACGGATTTTTTTGCCTAAAGAATCACGACA 
ATGAAAGTATGTTATCACTCTAAAACTGCCA 
RRP75 
Iv_HR_scMaf1_395_overlap-
rev 
AACGATTATAGGTGTAAGACAAGGAAAATTCACAAATTAAAGTTTAAAA 
ctactgtagggattcttcttgatctgat 
RRP76 
Iv_HR_hMaf1_overlap_for  TAACCGCTCATTACTCCAAACGGATTTTTTTGCCTAAAGAATCACGACA 
ATGaagctattggagaactcgagctttgaa 
RRP77 
Iv_HR_hMaf1_overlap-rev AACGATTATAGGTGTAAGACAAGGAAAATTCACAAATTAAAGTTTAAAA 
tcaaatacagatcactgggaccctgtcctcc 
RRP78 
Iv_HR_scMaf1_345_overlap-
rev 
AACGATTATAGGTGTAAGACAAGGAAAATTCACAAATTAAAGTTTAAAA 
ctacgaatttagacgcgagcaaatcaa 
RRP79 Iv_HR_scMaf1_D36-52_for CAGTTGCGATATTTTCACAACAAAGACTATTTTACAGGAAAATGAGAATTACAATGCTA
RRP80 Iv_HR_scMaf1_D36-52_rev TAGCATTGTAATTCTCATTTTCCTGTAAAATAGTCTTTGTTGTGAAAATATCGCAACTG 
 
2.1.4 Reagents and Consumables 
Chemicals were obtained from Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) or Sigma-
Aldrich (Seelze, Germany), unless otherwise stated. Cloning enzymes and reagents were obtained 
from Fermentas (St. Leonrot, Germany), New England Biolabs (Frankfurt am Main, Germany) or 
Agilent/Stratagene (Waldbronn, Germany). For DNA preparation commercial kits from Qiagen 
(Hilden, Germany) were used. DNA oligonucleotides were ordered at ThermoScientifc (Ulm, 
Germany), RNA at Metabion (Planegg, Germany). Crystallization reagents were ordered at Hampton 
Research (Aliso Viejo, CA, USA) and Qiagen (Hilden, Germany). Reagents and consumables were 
ordered at standard laboratory suppliers. 
 
II ■ Molecular basis of RNAP III transcription repression by Maf1                                        Materials & Methods 
26  
2.1.5 Media and additives 
Table 6. Media for E. coli and S. cerevisiae. 
 
Media Application Description 
LB E. coli culture 1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) NaCl 
LSSB E. coli culture 1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) NaCl; 0.7M 
Sorbitol; 2.5 mM Betaine 
SOB E. coli transformation 2% (w/v) tryptone; 0.5% (w/v) yeast extract; 8.55 mM NaCl;  
2.5 mM KCl; 10 mM MgCl2 
SOC E. coli transformation SOB + 20 mM glucose (before use) 
YPD Yeast culture 2% (w/v) peptone; 2% (w/v) glucose; 1% (w/v) yeast extract 
YPGly Yeast culture 2% (w/v) peptone; 2% (w/v) glycerol; 1% (w/v) yeast extract 
Synthetic 
defined (SD) 
Yeast culture Nitrogen and carbon sources, vitamins, trace elements, minerals 
according to specific drop outs; only essential amino acids; pH 5.6-
6.0 
Synthetic 
complete (SC) 
Yeast culture 0.69% (w/v) nitrogen base; 0.6% (w/v) CSM amino acid drop out 
mix; 2% (w/v) glucose; pH 5.6-6.0 
 
 
Table 7. Media additives for E. coli and S. cerevisiae. 
 
Additive Description Stock Solution Applied concentration 
IPTG E. coli induction 1M in H2O 0.5 mM 
Ampicillin Antibiotic 100 mg/ml in H20 100 μg/ml for E. coli culture, 
50 μg/ml for yeast culture 
Kanamycin Antibiotic 30 mg/ml in H20 30 μg/ml for E. coli culture 
Chloramphenicol Antibiotic 50 mg/ml in EtOH 50 μg/ml for E. coli culture 
Streptomycin Antibiotic 50 mg/ml in EtOH 50 μg/ml for E. coli culture 
Tetracyclin Antibiotic 12.5 mg/ml in 70% EtOH 12.5 μg/ml for yeast culture 
 
2.1.6 Buffers and solutions 
Standard buffers and solutions were prepared according to Sambrook and Russell (2001). 
 
Table 8. General buffers, dyes and solutions. 
 
Name Description Application 
4x Stacking gel buffer 0.5 M Tris; 0.4% (w/v) SDS; pH 6.8 at 25°C SDS-PAGE 
4x Separation gel buffer 3 M Tris; 0.4% (w/v) SDS; pH 8.9 at 25°C SDS-PAGE 
Electrophoresis buffer 25 mM Tris; 0.1% (w/v) SDS; 250 mM glycine SDS-PAGE 
5x SDS sample buffer 250 mM Tris/HCl pH 7.0 at 25°C; 50% (v/v); glycerol; 
0.5% (w/v) bromophenol blue; 7.5% (w/v) SDS; 12.5% 
(w/v) ß-mercaptoethanol 
SDS-PAGE 
Gel staining solution 50% (v/v) Ethanol; 7% (v/v) acetic acid; 0.125% (w/v) 
Coomassie Brilliant Blue R-250 
Coomassie staining 
Gel destaining solution 5% (v/v) Ethanol; 7% (v/v) acetic acid Coomassie staining 
Fix solution 50% MeOH, 12% HAc, 0.05% formalin (35% Silver staining 
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Formaldehyde) 
Silver nitrate solution 0.2% AgNO3, 0.076% formalin (35% Formaldehyde) Silver staining 
Developer Solution 6% Na2CO3, 0.05% formalin (35% Formaldehyde), 
0.0004% Na2S2O3 
Silver staining 
Silver stop solution 50% MeOH, 12% HAc Silver staining 
2x Western transfer 
buffer 
2.4% (w/v) glycin; 0.8% (w/v) Tris; 40% (v/v) methanol Western blotting 
 
Blotting buffer 10% (v/v) methanol in ddH2O Edman sequencing 
Swelling buffer 200 mM Tris/HCl pH 8.5 at 25°C; 2% (w/v) SDS Edman sequencing 
MOPS running buffer 40 mM MOPS (buffering); 10 mM NaAc; 1 mM EDTA; 
pH 7.0 
Gradient Bis-Tris Gels 
(NuPAGE, Invitrogen) 
MES running buffer 50 mM Tris base, 50 mM 3–(N-
Morpholino)propanesulfonic acid, 1 mM EDTA, 0.01% 
SDS at pH 7.3) 
Gradient Bis-Tris Gels 
(NuPAGE, Invitrogen) 
PBS buffer 137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 1.76 mM 
KH2PO4;  pH 7.4 
Protein expression 
100x PI 0.028 mg/ml leupeptin; 0.137 mg/ml pepstatin A; 0.017 
mg/ml PMSF; 0.33 mg/ml benzamidine; in 100% EtOH 
p.a. 
Protease inhibitor mix 
 
10x TBE  900 mM Tris; 900 mM boric acid; 20 mM EDTA (pH 
8.0, 25°C) 
Agarose gels 
6x Loading buffer 10 mM Tris pH 7.6; 0.0015% (w/v) bromphenol blue; 
0.0015% (w/v) xylene cyanol; 60% (v/v) glycerol; 100 
mM EDTA; 1% SDS 
Agarose gels 
 
TFB-1 30 mM KOAc; 50 mM MnCl2; 100 mM RbCl; 10 mM; 
CaCl2; 15% (v/v) glycerol; pH 5.8 at 25°C 
Chemically competent 
cells 
TFB-2 10 mM MOPS pH 7.0 at 25°C; 10 mM RbCl; 75 mM 
CaCl2; 15% (v/v) glycerol 
Chemically competent 
cells 
TE 1 mM Tris pH 8.0; 0.1 mM EDTA DNA dissolving 
TB 20 mM Hepes 7.6; 60 mM (NH4)2SO4; 8 mM MgSO4; 10 
µM ZnCl2; 10% (v/v) Glycerol; 10 mM DTT 
In vitro RNA extension 
assays 
RNAP III transcription 
buffer 
40 mM Tris 8.0; 7 mM MgCl2; 5% Glycerol; 60mM 
NaCl; 3 mM DTT 
In vitro RNA extension 
assays 
5x Breaking buffer 250 mM Tris 8.0; 750 mM NaCl; 0.5% TritonX 100; 
25% Glycerol; 2.5 mM DTT 
In vitro RNA extension 
assay 
Blocking buffer 50 mM Tris 8.0; 150 mM NaCl; 2 mM EDTA 8.0; 0.1% 
TritonX 100; 5% Glycerol; 0.5% BSA; 35 µM Insulin; 
8.3 µM Heparin; 0.5 mM DTT 
In vitro RNA extension 
assays 
Factor-independent 
transcription buffer 
40 mM Tris-HCl pH 8.0, 60 mM NaCl, 7 mM MgCl2, 7% 
glycerol, 5 mM DTT 
Initiation factor-
independent in vitro 
transcription assays 
2x Urea loading buffer 20% (v/v) 10x TBE; 8 M Urea Urea gel 
2x Urea loading dye 20% (v/v) 10x TBE; 8 M Urea; 0.03% (w/v) bromphenol 
blue; 0.03% (w/v) xylene cyanol FF 
Urea gel 
Urea polyacrylamid gel 
solution 
7 M Urea nf; 20% (v/v) Acrylamid solution nf (40%/2%); 
1x TBE; 0.1% (v/v) TEMED; 0.05% (w/v) APS  
Urea gel 
5x Transcription acetate 
buffer 
500 mM potassium acetate 7.6; 10 mM Hepes 7.6; 5 mM 
EDTA; 25 mM MgOAc 
Initiation factor-
dependent in vitro 
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transcription assays 
Stop buffer 100 mM NaAc; 10 mM EDTA; 0.5% (w/v); 0.2 g/L 
tRNA 
Initiation factor-
dependent in vitro 
transcription assays 
5x Annealing buffer 25 mM Tris 8.3; 375 mM KCl; 5mM EDTA 8.0 Initiation factor-
dependent in vitro 
transcription assays 
5x Synthesis buffer 250 mM Tris 8.3; 375 mM KCl; 22.5 mM MgCl2; 75 
mM DTT 
Initiation factor-
dependent in vitro 
transcription assays 
2x FQP loading dye 80% (v/v) deionized formamide; 0.1 % (w/v) bromphenol 
blue; 25 mM EDTA 8.0 
FQP-sequencing gel 
50x FQP running buffer 166.7 mM Bis-Tris; 280.1 mM Tricine; 3.29 mM EDTA 
(free acid); adjust to pH 7.5 with NaOH 
FQP-sequencing gel 
FQP gel solution 5% (v/v) Acrylamid solution nf (40%/2%); 1x FQP 
running buffer; 6 M Urea nf; 0.12% (v/v) TEMED; 0.1% 
(w/v) APS 
FQP-sequencing gel 
 
 
Table 8. Maf1 purification buffers. 
 
Name Description 
Buffer A 50 mM Hepes 7.8; 0.5 M NaCl; 10 mM Imidazole; 5 mM MgCl2; 10 µM EDTA; 
10% Glycerol; 10 mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer B 50 mM Hepes 7.8; 0.5 M NaCl; 20 mM Imidazole; 5 mM MgCl2; 10 µM EDTA; 
10% Glycerol; 10 mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer C 50 mM Hepes 7.8; 5 mM MgCl2; 100 µM EDTA; 10% Glycerol; 5 mM DTT 
Buffer D 50 mM Hepes 7.8; 200 mM NaCl; 5 mM DTT 
Buffer E 25 mM Hepes 7.8; 25 mM NaCl; 5 mM DTT 
Buffer F 100 mM Tris 8.0; 150 mM NaCl; 1 mM EDTA ; 2.5 mM DTT 
 
 
Table 10. RNA Polymerase III purification buffers. 
 
Name Description 
Buffer G 200 mM Tris 8.0; 10 mM MgCl2; 500 mM (NH4)2SO4; 10% Glycerol; 10 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer H 40 mM Hepes 7.8; 5 mM MgCl2; 1 mM EDTA; 10% Glycerol; 10 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer I 40 mM Hepes 7.8; 5 mM MgCl2; 500 mM KCl; 5 mM Imidazole 8.0; 10% Glycerol; 
10 mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer J 40 mM Hepes 7.8; 5 mM MgCl2; 250 mM (NH4)2SO4; 10 mM Imidazole 8.0; 10% 
Glycerol; 10 mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer K 40 mM Hepes 7.8; 5 mM MgCl2; 20% Glycerol; 500 µM EDTA; 10 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer L 40 mM Hepes 7.8; 5 mM MgCl2; 10% Glycerol; 5 mM DTT 
Buffer M 50 mM Hepes 7.8; 100 µM MgCl2; 40 mM (NH4)2SO4; 10 µM ZnCl2; 5 mM DTT 
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Table 11. C53/37 purification buffers. 
 
Name Description 
Buffer N 50 mM Tris 8.0; 200 mM NaCl; 5% Glycerin; 10 mM ß-mercaptoethanol; 1x 
protease inhibitor 
Buffer O 50 mM Tris 8.0; 500 mM NaCl; 10 mM Imidazole; 5% Glycerol; 10 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer P 50 mM Tris 8.0; 150 mM NaCl; 1 mM EDTA; 5 mM DTT 
 
 
Table 12. Brf1c/TBPc/Brf1n purification buffers. 
 
Name Description 
Buffer Q (Lysis) 20 mM Hepes 7.8; 25 µM EDTA; 1.14 M NaCl; 5% Glycerol; 10 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer R (Ni-wash1) 20 mM Hepes 7.8; 7 mM MgCl2; 0.5 M NaCl; 10 mM Imidazole; 5% Glycerol; 10 
mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer S (Ni-wash2) 20 mM Hepes 7.8; 7 mM MgCl2; 0.5 M NaCl; 20 mM Imidazole; 20% Glycerol; 10 
mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer T (Ni-elution) 20 mM Hepes 7.8; 7 mM MgCl2; 0.5 M NaCl; 200 mM Imidazole; 20% Glycerol; 
10 mM ß-mercaptoethanol; 1x protease inhibitor 
Buffer U (MonoS) 50 mM Hepes 7.8; 0.5 mM MgCl2; 50 mM NaCl; 0.2 mM EDTA; 10% Glycerol; 5 
mM DTT 
Buffer V (MonoS) 20 mM Hepes 7.8; 7 mM MgCl2; 2 M NaCl; 200 mM Imidazole; 20% Glycerol; 10 
mM ß-mercaptoethanol; 1x protease inhibitor 
 
 
 
 
 
2.2 General methods 
2.2.1 Preparation and transformation of competent cells 
Chemically competent E. coli cells were prepared from LB overnight pre-cultures. 200 ml LB medium 
(supplemented with antibiotics if appropiate) were inoculated to a start optical density at 600 nm 
(OD600 nm) of 0.05, grown at 37°C and chilled on ice for 10 min once OD600 nm of 0.5 was reached. 
Following steps were carried out at 4°C. Cells were centrifuged at 3200g for 10 min, washed with 50 
ml TFB-1 buffer, centrifuged again and the sediment resuspended in 4 ml TFB-2 buffer. Aliquots were 
frozen in liquid nitrogen and cells stored at -80°C. Cells were transformed by heat shock typically 
using 100 ng (single transformation) or 200 ng (double transformation) vector, or 5-10 μl ligation 
product. Cells were incubated on ice for 10 min prior to heat shock at 42°C for 1 min in a water bath. 
Cells were subsequently cooled on ice for 1 min, 250 μl LB medium added and incubated for 1 h at 
37°C vigorously shaking in a thermomixer (Qiagen). Cells were plated onto selective plates and 
incubated over night at 37°C. 
II ■ Molecular basis of RNAP III transcription repression by Maf1                                        Materials & Methods 
30  
Chemical competent yeast cells were prepared from precultures in YPD overnight precultures grown 
at 30°C. One hundred ml main cultures were inoculated with a start OD600 nm of 0.2 and grown until a 
OD600 nm of 0.8-1.2 was reached. Cells were centrifuged at 1250g for 5 min at room temperatur, 
washed with sterile water and centrifuged again. The sediments were resuspended in 1 ml 100 mM 
LiAc, transferred to reaction tubes, centrifuged at 18000g for 15 sec and resuspended in 100 mM LiAc 
to yield 500 μl each. Cells were aliquoted to 50 μl portions and directly used for yeast transformation 
reacions. After centrifugation, supernatants were discarded and cells covered with 240 µL PEG 3350 
(50% (v/v)), 36 μl 1 M LiAc, 50 μl pre-heated salmon sperm DNA (c= 2 mg/mL), 2 nmol PCR 
product and 1 nmol plasmid DNA. Samples were vortexed vigorously for 1 min, then incubated 30 
min at 30°C and afterwards heat shocked for 20 min at 42°C. Samples were centrifuged at 5200g for 
15 sec and sediments resuspended in 250 µL sterile H2O. Cells were plated onto selective plates and 
incubated at 30°C for 2-4 days. 
2.2.2 Molecular cloning and mutagenesis 
Polymerase Chain Reaction (PCR)  
Primers were designed by using an overhang of several nucleotides (usually 5’-ggaggagga-3’) at the 5’ 
end, followed by the restriction side and at least 20 nucleotides complementary to the sequence of the 
gene of interest. Purification-tags were introduced either by in-frame cloning into according vectors or 
by PCR. PCR reactions were carried out with the Herculase II polymerase (Stratagene), Phusion High-
Fidelity DNA polymerase (Finnzymes) or Taq polymerase (Fermentas), according to requirements, in 
a volume of 50 µl together with the respective buffer, 200 µM of dNTP mix, 0.5 µM of each primer, 
variable DMSO concentrations and 1-30 ng plasmid template or 100-200 ng genomic DNA template. 
To introduce loop-deletions, the overlap extension method was used. Here, two overlapping PCR-
products are produced with primers carrying the desired deletion flanking regions. In a second PCR 
reaction these products were used as a template to produce the gene of interest containing the loop 
deletion.  
Thermocycling programs were adjusted to the specific needs of the individual reactions in terms of 
annealing temperature and elongation times and usually contained 30 cycles (Biometra T3000 
Thermocycler). PCR products were visualized by 1% agarose gel electrophoresis and staining with 
Sybr Safe (Invitrogen). Purification of the DNA was carried out with the QIAquick gel extraction 
protocol (Quiagen). 
 
Point mutations into vectors were introduced with the site-directed mutagenesis method. Usually, 10 
ng of template vector was used in the mutational PCR with Pfu polymerase (Fermentas). Primers 
typically exhibited 20 complementary nucleotides neighbouring each site of the mutation. PCR 
reactions were performed with low annealing temperatures (40-50°C) and 2 min/kb extension time. 
The parental vector, containing methylated DNA, was digested by 10U DpnI (Fermentas) for 1 h at 
37°C and the reaction directly transformed into competent cells. 
 
Enzymatic restriction cleavage 
Purified PCR product DNA was digested using restriction endonucleases (New England Biolabs and 
Fermentas) as recommended by the producer. Cleaved PCR products were purified using the 
QIAquick PCR purification protocol, cleaved plasmids by the QIAquick gel extraction protocol (both 
Quiagen).  
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Ligation 
Ligation of digested DNA into linearized vectors was carried out for 1 hour at room temperature or 
over nught at 16°C in a volume of 20 µL using T4 DNA ligase (Fermentas) and its corresponding 
buffer. Concentrations of DNA components were varied depending on the different reactions. Usually 
a 5- to 10-fold excess of insert, relative to linearized vector was used. Ligation products were 
transformed as described in 2.2.1.  
 
Homologous recombination 
In addition to restriction enzyme based cloning, in vivo homologous recombination in yeast 
was used. Therefore yeast cells were transformed as described (see 2.2.1), using PCR-
generated inserts, which contained 50 bp homologous regions at its 5’ and 3’ ends and a 
plasmid harbouring selection markesr for both, yeast and E.coli. Growth on selective plates 
was performed. 
 
Isolation of plasmid DNA 
After transformation of ligation products into competent cells or after homologous recombination, 
single clones from selective plates were used to inoculate 5 ml overnight cultures. Yeast plasmid 
preparation was performed with a modified Qiagen protocol for DNA preparation from E. coli (Jones 
et al. 2001). Subsequentially, 5 μl of the purified yeast plasmid DNA was transformed into E. coli cells 
and plated on selective plates (see 2.2.1). Plasmids were isolated from the E. coli clones using 
Miniprep purification kits (Qiagen) and verified by restriction analysis and DNA sequencing (Eurofins 
MWG and GATC).  
 
Electrophoretic separation of DNA  
Separation of DNA was carried out in horizontal 1x TBE agarose gels containing Sybr Safe (0.7 
µg/ml). Agarose concentrations varied between 1% to 2%, depending on the size of the DNA 
molecules to seperate. Separation was carried out in PerfectBlue Gelsystem electrophoresis chambers 
from Peqlab. Samples were mixed with 6x loading dye and DNA was visualized and documented 
using a Safe Imager blue light transilluminator from Invitrogen (=470 nm). 
2.2.3 Protein expression in E. coli  
Recombinant proteins were expressed in E. coli BL21-CodonPlus (DE3)RIL (Maf1 variants, C160, 
C53/37 subcomplex), in E. coli BL21-CodonPlus (DE3)RIPL (human mitochondrial Polymerase) or in 
E. coli BL21-(DE3)pLysS cells (Brf1c/TBPc/Brf1n construct). Therefore plasmids with desired protein 
variants were transformed as described in 2.2.1. Cells were grown in LSSB- (for Brf1c-TBP-Brf1n 
protein) or LB- (for all other recombinant proteins) medium including antibiotics for E. coli cells and 
the appropriate vector at 37°C up to an OD600 nm of 0.5 to 0.8 and for human mitoRNAP up to an OD600 
nm of < 0.4. Cells were cooled on ice for 30 min, induced by addition of 0.5 mM IPTG and grown at 
18°C over night while shaking. For human mitoRNAP induction was performed with 0.1 mM IPTG 
and growth o.n. at 16°C. Cells were harvested by centrifugation at 4000g and 4°C for 20 min and 
resuspended in PBS buffer. Cells were centrifuged again and the sediments flash frozen in liquid 
nitrogen and stored at -80°C. 
Protein purification protocols for all used recombinant proteins are described in the accordant Special 
procedures. 
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2.2.4 Protein analyses 
Determination of protein concentrations 
Total protein concentrations were usually determined by a Bradford assay (Bradford, 1976) at an OD 
of 595 nm using dye reagent (Bio-Rad) according to the manufacturer’s instructions. Reference curves 
were generated for each new batch of dye reagent using bovine serum albumin (Fraktion V, Roth). 
Alternatively, protein concentrations were calculated from the absorption rate by OD280nm 
measurement using a ND-1000 (NanoDrop) spectrophotometer. Individual molar absorption 
coefficients for the used proteins were calculated with the help of the ProtParam software (Gasteiger et 
al., 2005). 
 
SDS-Polyacrylamid gel electrophoresis 
Electrophoretic separation of protein was conducted by SDS-PAGE with 15% acrylamide gels (with 
acrylamide:bisacrylamide = 37.5:1) according to Laemmli (1970) in BioRad gel systems. For protein 
samples requiring broader or higher resolution separation, pre-casted NuPAGE Novex bis-Tris 
minigels (Invitrogen) were used according to the manufacturer’s instructions. Normally, gels were 
stained with Coomassie gel staining solution for 20 min and destained over night in gel destaining 
solution. For very sensitive detections of protein samples or for simultaneous stainings of proteins and 
nucleotides silver staining of the gel was performed. Therefore, the gel was fixed 2 h in Fix solution, 
washed three times with 35 % (v/v) EtOH, sensitized in 0.02% Na2S2O3 for 2 min and washed again 
three times in H2O. For staining the gel was incubated 20 min in Silver nitrate solution, washed two 
times in H2O and developed in Developer solution. Upon reaching a sufficient staining the reaction 
was stopped by adding Silver stop solution for 5 min. 
 
Edman sequencing 
N-terminal sequencing was conducted by first separating proteins on SDS-PAGE, staining with 
Coomassie blue and either transferring by Western blotting or by passive adsorption onto PVDF 
membranes. Western blotting was performed using Western transfer buffer in Mini Trans-Blot Cells 
(Bio-Rad) according to the manufacturer’s instructions. For passive adsorption transfer, bands of 
interest were excised from the gel, dried in a speed-vac and rehydrated in 20 μl swelling buffer at 
room temperature. Next 100 μl of ddH2O was added to set up a concentration gradient together with a 
small piece of pre-wet (ethanol) PVDF membrane (Schleicher& Schuell). Once the solution turned 
blue, 10 μl of methanol was added as a catalyst and the sample incubated for 4 days. The membrane 
was washed 5 times with 10% methanol by vortexing for 30 sec each time. Second the protein was N-
terminally sequenced from the dry membrane in a PROCISE 491 sequencer (Applied Biosystems). 
2.2.5 Limited proteolysis analysis 
Limited proteolysis time course experiments were performed to identify stable protein fragments. 
Proteolysis was conducted with chymotrypsin and trypsin at 37°C and with subtilisin at 0°C. Each 
sample was analyzed at 1, 3, 10, 30 and 60 min. Digests were performed using 100 μg protein samples 
in their gel filtration buffer containing 5 mM MgCl2 and addition of 1 µg protease. The reactions were 
stopped by the addition of SDS sample buffer and were heated immediately to 95°C for 10 min. 
Sample fragments were separated on SDS-PAGE and bands analyzed by mass-spectrometry and 
Edman sequencing. 
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2.2.6 Crystallization Screening 
Initial crystallization screening was performed by the sitting-drop (vapour diffusion) method using 
commercial screens. In-house screens were set up using a Hydra II crystallization robot producing 100 
nl drops in Corning 96-well crystallization plates. Usually a reducing agent (5 mM TCEP or 10 mM 
DTT) was added to the drop or reservoir. Prior to setting up the screen, optimum protein 
concentrations for crystallization screening were determined. This was achieved by visual control of 
the behaviour of equal volume drops of protein solution and the no. 1 and 6 screening solutions of the 
Hampton Crystal Screen 1. Plates were incubated at 4 or 20°C and inspected regularly from one day 
up to 90 days. To a greater extend crystallization screening was performed by the Crystallization 
Facility at the MPI of Biochemistry, Munich. Here a number of screens were tested at 20°C and by the 
sitting-drop method, using a 100 nL protein drop size. The following screens were used: Index screen, 
Classic screen, PEG/Ion (all Hampton), Anions suite, Cations suite, Classic suite (all Qiagen), and 
Magic 1 and 2 sceens (MPI Martinsried). Potential protein crystals were tested by diffraction 
measurements with the PX Scanner from Oxford Diffraction. Promising initial crystals were refined in 
24-well hanging drop plates (Easy Xtal Tool, Qiagen) by varying the pH, precipitant and additive 
concentrations of initial conditions. 
2.2.7 Bioinformatic tools  
Protein and gene sequences were retrieved from the NCBI or Saccharomyces cerevisiae genome 
(SGD) databases. Sequence data was visualized and processed using the following software 
applications: VectorNTI (Invitrogen) and ApE (Davis and Hammarlund, 2006). Bioinformatic analysis 
were performed mostly using the Bioinformatics Toolkit (Biegert et al., 2006). Multiple sequence 
alignments were generated using Clustal2W (Larkin et al., 2007), Espript 2.2 (Gouet et al., 1999), or 
Aline (Bond and Schuttelkopf, 2009). Protein secondary structures were predicted by HHpred 
(Soeding et al., 2005). 
 
 
 
2.3 Specific procedures 
2.3.1 Recombinant Maf1 
2.3.1.1 Purification of recombinant Maf1 variants and mutants 
Variants of Maf1 from the organisms Saccharomyces cerevisiae and Homo sapiens were purified each 
from 4 L of IPTG induced expression culture (2.2.3). Cells were lysed using a Sonifier Cell Discruptor 
250 (Branson) in buffer A (see Table 8). For the purification of His-tagged Maf1-variants, imidazole 
was added to a final concentration of 20 mM after 1h centrifugation to the supernatant. The sample 
was loaded onto two 2 ml Ni-NTA columns (Qiagen) equilibrated with buffer B. The columns were 
washed with 20 column volumes (CVs) of buffer B and 10 CVs of buffer B containing 30 mM 
imidazole and 200 µM NaCl. Elution was performed with buffer B containing 300 mM imidazole and 
200 µM NaCl. The fractions were analyzed for recombinant protein by SDS-PAGE (see 2.2.5). 
Proteins were purified by anion exchange chromatography (Mono Q, GE Healthcare). The column was 
equilibrated with buffer C and proteins were eluted with a linear gradient of 20 CVs from 10 mM to 1 
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M NaCl. Peak fractions and flowthrough of this chromatography step were checked by SDS-PAGE 
(2.2.5) for the presence of recombinant protein. Fractions containing the corresponding Maf1 variant 
were pooled and concentrated (Amicon Ultra centrifugal filter devices, cutoff 10k, Millipore). 
Afterwards samples were applied to a Superdex-75 size exclusion column (GE Healthcare) 
equilibrated with buffer D or E for crystallization experiments, or buffer M for activity assays and 
binding experiments. Peak fractions were pooled and concentrated to 10-50 mg/ml for crystallization, 
respectively 5 mg/mL for other assays. 
For the purification of Strep-tagged Maf1, the supernatant after cell lysis and centrifugation was added 
with 3 nmol Avidin per L of cell lysate and loaded on two 1 mL Strep-Tactin columns (Iba) 
equilibrated in buffer F. The columns were washed with 20 CVs buffer F and Strep-tagged protein was 
eluted with 4 CVs buffer G. Subsequently, protein samples were purified by anion exchange and 
gelfiltration chromatography as described above.   
Proteins without any tag were purified by fractionated ammoniumsulfate precipitation. Therefore the 
supernatant after cell lysis and centrifugation was dealt with 25%, 40%, 60%, and 80% of ammonium 
sulphate. After each titration step the sample was stirred 30 min on ice and centrifuged at 10000g and 
4°C for 20 min. Sediments were resuspended in buffer C and analyzed on a SDS-PAGE. Fractions 
containing Maf1 were further purified with anion exchange and gelfiltration chromatography as 
described above. 
The purification protocol was the same for Saccharomyces cerevisiae Maf1 variants containing point 
mutations, which carried a His6- or streptavidin-tag. 
2.3.1.2 Crystallization of Maf1 variants  
Initial screens of crystallization conditions using different protein variants were set up and analyzed as 
described in 2.2.7. Promising initial crystals were refined in 24 well hanging drop plates (Easy Xtal 
Tool, Qiagen) by varying the concentrations of constituents of initial conditions.  
Diffraction quality crystals of the Maf1 1-205 36-82 variant of Homo sapiens were grown by mixing 
1 µL of purified protein in size exclusion buffer E with a concentration of 40 mg/mL with 1 µL of 
reservoir solution containing 50 mM MES pH 6.0 and 175 mM sodium oxalate. Crystals were grown 
within two days at 20°C in hanging drop. Native crystals were transferred into reservoir solution 
containing 25% glycerol and were flash cooled in liquid nitrogen. Crystals were soaked for 0.5-2 
minutes in a reservoir solution containing 25% glycerol and 0.5 M NaBr and flash-frozen in liquid 
nitrogen. 
Also the Maf1 1-345 52-224 variant of Saccharomyes cerevisiae produced nice shaped initial 
crystals, which were reproduced by mixing 2 µL of purified protein in size exclusion buffer D with a 
concentration of 30 mg/mL with 2 µL of reservoir solution containing 50 mM MES 6.0, 4% MPD, 80 
mM (NH4)2SO4, and 10% PEG 8000. Crystals were grown within 2 days, dipped into reservoir 
solution containing different cryo-protectants like 20-30% glycerol, 25-35% MPD, or 25-35% PEG 
200 and flash frozen in liquid nitrogen. 
2.3.1.3 Data collection and X-ray structure determination 
Diffraction data for the Maf1 1-205 36-82 variant of Homo sapiens were collected at 100 K on a 
PILATUS 6M detector at the Swiss Light Source (SLS), Villigen, Switzerland (Table 13). Three-
wavelength anomalous diffraction data were collected from a bromide-soaked crystal. Data were 
processed with MOSFLM (Leslie et al., 1986), scaled with SCALA (Evans, 2006), and data quality 
was assessed with Phenix.Xtriage (Adams et al., 2010). Program Phenix.HySS (Adams et al., 2010) 
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identified six bromide sites that were used for phasing with program SOLVE (Terwilliger and 
Berendzen, 1999). Density modification was carried out with RESOLVE (Terwilliger, 2003). The 
model was built with COOT (Emsley and Cowtan, 2004) and refined with Phenix.Refine (Adams et 
al., 2010) to a free R-factor of 21% (Table 13). The structures and diffraction data of h.s. Maf1 1-
20536-82 have been deposited in the Protein Data Bank under the accession code 3NR5. 
Diffraction data for the Maf1 1-345 52-224 variant of Saccharomyes cerevisiae were collected on an 
ADSC Q4 CCD detector at the European Synchrotron Radiation Facility (ESRF), Grenoble, France.  
2.3.1.4 Interaction assays with Maf1 variants and mutants 
Protein/ protein interactions 
Binding experiments of Maf1 variants and point mutants with RNAP III, its subunit C34, and with 
Brf1c/TBPc/Brf1n were carried out first to identify Maf1 parts sufficient for RNAP III binding, second 
to elucidate binding surfaces of Maf1 and third to investigate the functional mechanism of Maf1 
induced repression. Protein interactions were analyzed with purified samples by pulldown assays or 
gelfiltration chromatography. For pulldown assays 10-fold molar excess of untagged or strep-tagged 
Maf1 was preincubated with the respective interaction partner in buffer M and incubated 20 min on 
ice. The samples were loaded on pre-equilibrated 30 µL Ni-beads (Promega Magnetic Beads) or 20 µL 
streptavidin-beads (Iba Magnetic Beads type 1) for pulldown of His-tagged or strep-tagged protein, 
respectively. Ni-beads were washed six times with 1 mL buffer M containing 20 mM imidazole and 
eluted with 25 µL buffer M containing 500 mM imidazole. Streptavidin-beads were washed six times 
with 1 mL buffer M and eluted with 25 µL buffer M containing 10 mM d-Desthiobiotin. Samples were 
analyzed by NuPAGE (Invitrogen). For gelfiltration chromatography assays pre-assembled proteins 
were loaded on a Superose 6 10/300 GL (GE Healthcare) column in buffer M and peaks analyzed by 
NuPAGE. 
 
Competing protein/protein interactions with scaffolds 
To investigate the functional mechanism of the negative regulation of RNAP III transcription by 
Maf1, the binding behaviour of Maf1, RNAP III, Brf1c/TBPc/Brf1n and DNA scaffolds was tested in 
order of addition experiments. RNAP III-Brf1-TBP-DNA and RNAP III-Maf1 complexes were pre-
assembled using 5-fold molar excesses of Brf1-TBP-DNA and Maf1, respectively, in buffer M for 60 
min at 4°C and purified by gel-filtration (Superose 6 10/300 GL, GE Healthcare) in buffer M. Purified 
complexes were then incubated with a five-fold molar excess of the competing factors, incubated in 
buffer M for 60 min at 4°C, applied again to gel filtration, and analyzed by NuPAGE (Invitrogen). For 
the nucleic acid binding assay, size-exclusion purified complexes were analyzed by silver-stained gels. 
2.3.1.5 Coexpression and copurification  
Coexpression was performed as described in 2.2.3 with E.Coli strains carrying two plasmids, each 
with one protein of interest and with or without a His6-tag, respectively. 1L of E.coli culture was used 
for Ni-NTA purifications. Cell lysates were clarified by centrifugation and copurification performed 
by loading the sample on a 2 mL Ni-NTA column pre-equilibrated in buffer B. Washing and elution 
was performed as described in 2.3.1.1. Samples were analyzed on SDS-PAGE. 
2.3.1.6 Initiation factor-dependent in vitro transcription assays  
In vitro transcription assays for the RNAP III system with purified proteins had to be established and 
based on protocols described by the Hahn laboratory (www.fhcrc.org/labs/hahn/). A linear 145 nt U6  
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scaffold with a minimal bubble at position -9 until -5 was used as a template 
(templateDNA:5´CCTCCTGGATCCCTGATCATCTCTGTATTGTTTCAAATTGACCAAATGTCC
ACGAAGGGTTACTTCGCGAACACATAGTTGCGAAAAAAACATTTATTTATAGTAGCCGAA
AATAGTGGACGAAATACTTTTCTCGAGTCCTCC3´;nontemplateDNA:5´GGAGGACTCGAGA
AAAGTATTTCGTCCACTATTTTCGGCTACTATAAATAAATGTTTTTTTCGGTTGAATGTGTT
CGCGAAGTAACCCTTCGTGGACATTTGGTCAATTTGAAACAATACAGAGATGATCAGGGA
TCCAGGAGG3´). Transcription reactions were carried out in a 25 μL volume. The reaction mixture 
contained 75 pmol Brf1c/TBPc/Brf1n, 5 pmol RNAP III, 1 pmol template 1x Transcription acetate 
buffer, 2.5 mM DTT, 192 μg of phosphocreatine, 0.2 mg of creatine phosphokinase, 10U of RNase 
inhibitor (GE Healthcare), and 100 µM nucleoside triphosphates. Optionally, 180 pmol Maf1 were 
added together with RNAP III. The reaction was incubated at 30 °C for 30 min and then stopped with 
180 μl of Stop buffer. Samples were extracted with phenol–chloroform and precipitated with ethanol. 
Transcripts were analysed by primer extension essentially as described (Ranish and Hahn, 1991). 
Instead of the 32P labelled lacI oligo, 0.125 pmol of a fluorescently labelled Cy5-oligo (25 nt long, 
starting transcription at position +50) was used. Quantification was performed with a Typhoon 9400 
and the ImageQuant Software (GE Healthcare). 
2.3.1.7 Initiation factor-independent in vitro transcription assays 
For factor-independent transcription assays, 1.5 pmol of RNAP III or RNAP III-Maf1 complex were 
incubated for 30 min at 20ºC with 2 pmol or variable amounts of a pre-annealed tailed-template 
scaffold (nontemplate DNA: 5’- GGCTACTATAAATAAATGTTTTTTTC 
GCAACTATGTGTTCGCGAAGTAACCCTTCGTGGACATTTGGTCAATTTGAAACAATACAG
AGATGATCAGCAGT-3’; template DNA: 5’- ACTGCTGATCATCTCTGTATTG 
TTTCAAATTGACCAAATGTCCACGAAGGGTTACTTCGCGAACACATAGTTGCGAAAAAAA
CATTTATTTATAGTAGCCTGCA-3’), in the presence of 0.5 mM GpG RNA primer. Complexes 
were incubated for 30 min at 20ºC in the presence of 0.3 mM ATP, GTP, CTP, 32P-UTP in 20 µL 
Factor-independent transcription buffer. Reactions were stopped by addition of an equal volume of 2x 
Urea loading buffer and incubation for 5 min at 95°C. RNA products were separated by denaturing gel 
electrophoresis and visualized with a Typhoon 9400 phosphoimager (GE Healthcare). 
2.3.1.8 In vitro RNA extension assays 
Minimal Scaffold 
For RNA extension assays, 5 pmol of RNAP III or RNAP III pre-incubated (10 min at 20°C) with a 
five-fold molar excess of Maf1 was incubated for 30 min at 20°C with 5 pmol of a pre-annealed 
minimal nucleic-acid scaffold (template DNA: 3'-TTACTGGTCCGGATTCATGAACTCGA-5'; 
nontemplate DNA: 5'-TAAGTACTTGAG-3'; RNA: 5'-FAM-UGCAUUUCGACCAGGC-3'). Maf1 
was added at a five-fold molar excess followed by incubation for 5 min at 20°C. For RNA elongation, 
complexes were incubated for 10 min with 1 mM NTPs at 28°C in TB. Reactions were stopped and 
RNA products were separated and visualized as above. 
 
Complete Complementary scaffold (bead based) 
Bead-based assays were carried out as described with some modifications (Dengl et al., 2009). Briefly, 
per reaction 10 pmol RNAP III, optionally pre-incubated with a 10-fold molar excess of Maf1 were 
added to 20 pmol of an annealed DNA/RNA scaffold (RNA: FUGCAU UUCGACCAGGC3’; 
template DNA:3’TGCGCACCACGCTTACTGGTCCGAACGCCTG TCCTCGACCA5´). This 
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mixture was incubated 15 min at 20°C and mild shaking. 40 pmol nontemplate DNA 
(ACGCGTGGTGCGAATGACCAGGCTTGCGGACAGGAGCTGGT–3’) was added and incubated 
15 min at 25°C. Beads (Dynabeads MyOneTM Streptavidin T1 from Invitrogen) were added to 
preassembled elongation complexes (ECs) for assembly and incubated for 30 min at 25°C. Beads were 
subsequently washed with TB containing 0.1% Triton-X, TB containing 0.2 M (NH4)2SO4, and with 
TB. Beads were re-suspended in TB. For RNA extension assays including time course experiments, 
different amounts of NTPs (Jena Bioscience) were added, the mixture was incubated at 28°C and 
reactions were stopped at different time points by addition of an equal volume of 100 mM EDTA, 
essentially as described (Brueckner et al., 2007; Dengl et al., 2009). The beads were transferred into 
urea loading buffer, samples were heated to 95°C and loaded on a 20% polyacrylamid gel containing 7 
M Urea. The FAM 5’-labeled RNA products were visualized with a Typhoon 9400 scanner (GE 
Healthcare).  
2.3.1.9 EMSA assays 
Nucleic acids binding activities of h.sapiens and s.cerevisiae Maf1 were analyzed using the 
electrophoretic mobility shift assay (EMSA). Complexes of protein and DNA migrate through a native 
polyacrylamide (PAA) gel more slowly than free oligonucleotides. Nucleic acid probes included 
double-stranded h.s. U6 promoter sequence, double-or single-stranded s.c. U6 promoter sequence, and 
a random double-stranded sequence, each 60 bp long. Doublestranded DNA probes ware obtained by 
annealing complementary synthetic single strands. 80 pmol DNA were incubated with 5-fold molar 
excess of Maf1 in 20 μl buffer E for 30 min on ice as described. Bound and free probes were resolved 
by electrophoresis in 1% agarose gels tained with SYBR-Safe (Invitrogen) and afterwards restained in 
gel staining solution containing coomassie blue. This ensured colocalization of nucleic acid-protein 
complexes. 
2.3.2 Endogenous Maf1  
2.3.2.1 Yeast strains generation 
Yeast strains Y03945 (maf1) and Y10000/ Y00000 (wild type) were obtained from Euroscarf (see 
Table 3). Genomic manipulation of the maf1 strain in form of a kanMX cassette at the maf1 loci in 
the yeast genome was verified by performing colony PCR reactions with primers upstream and 
downstream of the mutated site and DNA sequencing after agarose gel separation and isolation of the 
PCR-product. 
To achieve deletion or point mutants of Maf1, Y03945 cells were transformed (see 2.2.1) with 
digested pRS316 vector and PCR products that allowed for homologous recombination and growth of 
transformants on selective plates (Baudin et al., 1993). Colonies were restreaked, plasmid DNA of 
potential positive clones isolated (2.2.2) and verified by test digestion and sequencing. 
2.3.2.2 In vivo phenotyping assays 
Phenotype analyses of wildtype and Maf1 deletion or point mutants were performed from cultures 
grown to stationary phase in YPD or –Ura medium, respectively. Cells were diluted to an OD600 nm of 
1.0, washed, and spotted in serial dilution onto plates. Growth defect assays were performed with YPD 
plates, YP plates containing 3% glycerol (YPGly), and YPD plates containing 2.0 µg/mL Rapamycin 
at 30°C and 37°C. Yeast growth was detected after 2-5 days. 
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2.3.3 Endogenous RNA Polymerase III and its recombinant transcription factors 
2.3.3.1 Purification of endogenous RNA Polymerase III 
The purification protocol was established in the laboratory by Dr Alesssandro Vannini. The 
Saccharomyces cerevisiae strain NZ16 (Lannutti et al., 1996), carrying the gene for an N-terminally 
His6-FLAG4-RET1-tagged C128 subunit on the parent plasmid pYE(CEN3)30 was grown to OD600 = 
6-7 at 30°C in YPD media in a 200 L fermenter (Infors ABEC). The cells were harvested by 
continuous flow centrifugation (Padberg) and lysed by bead beating in ice-cooled buffer G. All 
subsequent steps were performed at 4°C. Glass beads were separated by filtration prior to clearing the 
lysate by centrifugation (60 min, 8000 g, Sorvall SLA-1500). A whole cell extract was obtained after 
centrifugation at 125,000 g for 90 min (Beckman Ti45) by separating the clear upper-middle phase 
from the turbid lower phase. The supernatant was further processed by step-wise ammonium sulfate 
precipitation. 35% (NH4)2SO4 was slowly added to the sample, allowed to stir for 30 min and cleared 
by centrifugation (60 min, 8000 g , Sorvall SLA-1500). The supernatant was precipitated by adding 
70% (NH4)2SO4 and left stirring over night. The pellet was recovered by centrifugation (60 min, 8000 
g, Sorvall SLA-1500) and resuspended in 3 L of buffer H. The sample was applied to a 250 mL Biorex 
resin column (Biorad). Bound proteins were eluted with buffer I. The eluting proteins were loaded 
onto a 12 ml Ni-NTA Agarose (Qiagen) column. Subsequent washing steps were performed with 
buffer I (but 10 mM imidazole) and buffer J. Proteins were eluted with buffer J (but 250 mM 
imidazole) and loaded onto a HiTrap Heparin 5 mL column (GE Healthcare) and fractionated by 
applying a salt gradient from 250 mM to 1000 mM (NH4)2SO4 with buffers K. The pooled RNAP III-
containing fractions were diluted 5-fold with buffer K, loaded onto a Mono Q anion exchange column 
(Mono Q 10/100 GL, GE Healthcare), and fractionated by applying a salt gradient from 50 mM to 
1000 mM (NH4)2SO4 with buffers L. The pooled RNAP III-containing fractions were diluted to reach 
a final concentration of 50 mM (NH4)2SO4, supplemented with a 4- fold molar excess of recombinant 
full-length C53/37 heterodimer (2.3.3.2) and incubated for 60 min to overcome the endogenous 
substoichiometry of this subcomplex (Lorenzen et al., 2007). The sample was concentrated to a 
volume of 1 ml using an Amicon Ultra-4 centrifugal filter unit (MWCO 10kDA, Millipore) and 
applied to gel-filtration chromatography on a Superose 6 column (Superose 6 10/300 GL, GE 
Healthcare) with buffer M. RNAP III containing fractions were pooled, concentrated to 1 mg/mL 
using an Amicon Ultra-4 centrifugal filter unit (MWCO 10kDA, Millipore) and flash-frozen in liquid 
N2 after addition of 10% glycerol. 
2.3.3.2 Purification of recombinant C53/37 subcomplex 
His6-tagged C53/37 from Saccharomyces cerevisiae was purified from 6 L of IPTG induced 
expression culture (2.2.3). Cells were lysed using a Sonifier Cell Discruptor 250 (Branson) in buffer N 
(see Table X). After 1h centrifugation imidazole was added to a final concentration of 10 mM to the 
supernatant and the sample was loaded onto two 3 ml Ni-NTA columns (Qiagen) equilibrated with 
buffer O. The columns were washed with 20 column volumes (CVs) of buffer O and 10 CVs of buffer 
B containing 150 mM NaCl. Elution was performed with buffer O containing 300 mM imidazole and 
150 mM NaCl. The fractions were analyzed for recombinant protein by SDS-PAGE (see 2.2.5). 
Proteins were purified by anion exchange chromatography (Mono Q, GE Healthcare). The column was 
equilibrated with buffer P and proteins were eluted with a linear gradient of 20 CVs from 10 mM to 1 
M NaCl. Peak fractions and flowthrough of this chromatography step were checked by SDS-PAGE 
(2.2.5) for the presence of recombinant protein. Fractions containing C53/37 were pooled and 
II ■ Molecular basis of RNAP III transcription repression by Maf1                                        Materials & Methods 
39  
concentrated (Amicon Ultra centrifugal filter devices, cutoff 10k, Millipore). Afterwards samples were 
applied to a Superose 6 10/300 size exclusion column (GE Healthcare) equilibrated with buffer M. 
Peak fractions were pooled and concentrated to 1 mg/ml. 
2.3.3.3 Purification of recombinant Brfc/TBPc/Brfn triple fusion protein 
His6-tagged Brfc/TBPc/Brfn from Saccharomyces cerevisiae was purified from 6 L of IPTG induced 
expression culture in LSSB medium (2.2.3). Purification was performed as described before 
(Kassavetis et al., 2005) using buffers Q-V. 
2.3.3.4 Experimental design, assembly, and sample preparation for RNA Polymerase III PIC 
analysis with cryoEM 
A minimal RNAP III PIC consists of RNAP III, Brfc/TBPc/Brfn and a dsDNA (RNA) complex. The 
used scaffold is 60 bp long and comprises a bubble from -11 until +2 (template DNA:3´-
AAAGCCGATGATATTTTTTTACAAAAAAAGCGTTGATACACAAGCGCTTC 
ATTGGGAAGC-5´; nontemplate DNA: 5´- TTTCGGCTACTATAAAAAAATGTTTTTTT 
GCGTCGACATCGATCGCGAAGTAACCCTTCG -3´; RNA: 5´- ACUAUGU -3´).  
RNAP III purification and assembly with C53/37 was performed as described (2.3.3.2). Brfc/TBPc/Brfn 
protein was supplemented after MonoS with 20-fold excess of the scaffold, incubated 30 min at 4°C 
and purified on a Superose 6 10/300 size exclusion column (GE Healthcare). 50 µmol purified RNAP 
III was added with a 10-fold molar excess of Brfc/TBPc/Brfn-scaffold complex, diluted in buffer M to 
10 mL and incubated 20 min at 4°C. After concentration (Amicon Ultra centrifugal filter devices, 
cutoff 10k, Millipore) the sample was loaded on a Superose 6 10/300 size exclusion column using 
buffer M, PIC containing fractions analyzed using SDS-Page and silver-stained gels (2.2.5), pooled 
and concentrated to 100-200 µg/mL concentration. CryoEM grids were frozen using a vitrification 
robot (Vitrobot, FEI). 
2.3.4 Cryo EM specific procedure 
Nanogold labelling of RNAP III-Maf1 complex and cryo-EM structure determinations of RNAP III, 
RNAP III EC and RNAP III-Maf1 complex were performed by Dr Anselm Kusser and Dr Alessandro 
Vannini as described (Vannini et al., 2010). 
First reconstructions of the RNAP III-PIC were performed by Dr Anselm Kusser. 
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3 Results and Discussion 
3.1 RNAP III EM structure reveals C82/34/31 mobility 
We established a large-scale purification protocol for tagged RNAP III from the yeast Saccharomyces 
cerevisiae (2.3.3.1). Pure RNAP III samples comprised all 17 subunits, were monodisperse, and 
appeared homogeneous in EM with negative stain (Figure 1 A and B). We collected high-quality cryo-
EM data after vitrification under native conditions.  
 
 A reconstruction of RNAP III from 20,480 single particles led to a map at 21 Å resolution 
(Figure 1C and E). The cryo-EM map showed good agreement with previously and later published 
maps (Fernandez-Tornero et al., 2007; Fernandez-Tornero et al., 2010). The core RNAP III homology 
model plus the C25/17 crystal structure (Jasiak et al., 2006) or the 12-subunit RNAP II crystal 
structure (Armache et al., 2005) could both be fitted unambiguously to the map (Figures 1E).  
 
 After this fitting, two extended additional densities remained, one on top of the clamp 
adjacent to C25/17, and one at the lobe near Rpb9 (Figure 1E). Densities at the lobe and clamp were 
attributed to subcomplexes C53/37 and C82/34/31, respectively (Fernandez-Tornero et al., 2007).  
The density at the lobe was fitted with a homology model of the C53/37 dimerization module based on 
the crystal structure of the A49/34.5 module in RNAP I (Geiger et al., 2010) (Figure 1E and 2). 
Adjacent densities protruding towards the C160/C11 jaw and the funnel were explained by extensions 
from the dimerization module. The location of C53/37 agrees with the previously reported association 
of C53/37 with C11 (Chedin et al., 1998b) and with the location of the dimerization domain of TFIIF, 
the distant homologue of C53/37 (Cramer et al., 2008) on the RNAP II lobe (Chen et al., 2010; 
Eichner et al., 2010).  
The additional density at the clamp could only account for a small part of the 138 kDa subcomplex 
C82/34/31, indicating intrinsic flexibility (Figure 1E and 2). 
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Figure 1. Cryo-EM reconstruction of RNAP III and RNAP III-DNA-RNA complexes. 
(A) SDS-PAGE gel of purified yeast RNAP III. The 17 subunits are indicated. The identity of the bands was confirmed by 
mass spectrometry (not shown). (B) EM micrographs of RNAP III in negative stain (left) and vitrified ice (right). White 
circles indicate particles in vitrified ice. Scale bars are 10 nm in length. (C) Different views of the RNAP III reconstruction 
(first row) with corresponding raw single particle images (second row), low-pass filtered single particle images (middle row), 
class averages (forth row) and reference free averages (bottom row). (D) DNA-RNA scaffold used in the RNAP III-DNA-
RNA complex (Brueckner et al., 2007). (E) Cryo-EM reconstruction of RNAP III (green) and RNAP III-DNA-RNA complex 
(blue). The 10-subunit RNAP III core homology model and the C25/17 crystal structure (Jasiak et al., 2006) were fitted to the 
map and are shown as ribbon models. 
 
 
3.2 Nucleic acid binding restricts C82/34/31 mobility 
To see how nucleic acid binding influences the RNAP III structure, we determined the cryo-EM 
structure of a RNAP III complex with a minimal DNA-RNA scaffold (Figure 1D, Experimental 
Procedures). This complex mimics an active elongation complex (Brueckner et al., 2007).  
 
 A reconstruction at 19 Å resolution was obtained from 11,965 single particles (Figures 1E, 
Experimental Procedures). As expected, the reconstruction revealed density for nucleic acids in the 
cleft, but also a structural ordering of the C82/34/31 subcomplex, giving rise to an extended density 
between the top of the clamp, the Rpb5 jaw, and C25/17 (Figure 1E), all the mass of the 138 kDa 
subcomplex. A long continous density between the clamp and the jaw (Figure 1E) could be fitted with 
the crystal structure of the human C82 homologue (Lefevre et al., 2011) (Figure 2A).  
II ■ Molecular basis of RNAP III transcription repression by Maf1                                     Results and Discussion 
42  
 A prominent density remained between the clamp and the protrusion, forming a suspension 
over the cleft (Figures 1E and 2B). We assigned this density to subunit C34 since its two lobes fitted 
the structures of two winged helix (WH) domains in the N-terminal region of C34 (PDB codes 2dk5, 
2dk8), and since C34 cross-links to promoter DNA around position -21 (Bartholomew et al., 1993) 
that is nearby in the homologous RNAP II closed and open promoter complex models (Kostrewa et al., 
2009).  
 
 The remaining globular density near zinc site Zn8 in C160 between the clamp and C25/17 
(Figure 2) was assigned to C31 since this position explains the known interactions with subunits C160, 
C82, C34, and C17 (Chedin et al., 1998b; Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 
2002), the requirement of the zinc site for C82/34/31 binding (Werner et al., 1992), and association of 
C31 with RNAP III after dissociation of the C82/34 heterodimer (Lorenzen et al., 2007).  
We note that alternatively one C34 domain could be placed into the density assigned to C31, but this 
assignment could not explain the published biochemical data. Taken together, we could assign all 
RNAP III subunits to EM densities in a way that is consistent with known interactions. 
 
 
 
Figure 2. Subunit architecture of RNAP III. 
(A) RNAP III-specific subunits placed into the cryo-EM envelope of the RNAP III-DNA-RNA complex. A homology model 
of the C53/37 dimerization domain (green, (Geiger et al., 2010)), the human C82 homolog crystal structure (blue, (Lefevre et 
al., 2011)) and the two C34 WH domain crystal structures (purple) are shown as molecular surfaces. The 10-subunit RNAP 
III core homology model and the C25/17 crystal structure (Jasiak et al., 2006) are shown as green ribbon models. (B) Close-
up view of RNAP III-specific subunits fitted in the cryo-EM envelope of RNAP III-DNA-RNA complex. Terminal 
extensions of the C53/37 dimerization module are highlighted in red. (C) Localization of RNAP III-specific subunits on the 
core homology model and the C25/17 crystal structure (Jasiak et al., 2006). (D) Schematic representation of C82/34/31 
subcomplex organization on RNAP III. (E) Domain organization of RNAP III specific subunits. Indicated domains were 
either revealed by homology modelling (C53, C37), X-ray crystallography (C34), or HHPred and secondary structure 
prediction (C82). 
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3.3 Maf1 structure determination 
To elucidate RNAP III repression by Maf1, we determined the Maf1 structure by X-ray 
crystallography. We subjected recombinant S. cerevisiae and human Maf1 to limited proteolysis with 
subsequent Edman sequencing (2.2.4 and 2.2.5). Cutting sites at amino acid positions 56, 59, 72, 74, 
114 in human and positions 161, 208 in S. cerevisiae were identified. Together with secondary 
structure predictions and multiple sequence alignmnents two flexible regions were revealed, a mobile 
insertion (human residues 50-82, yeast residues 50-224), and an acidic C-terminal tail (Figure 3 A). 
Based on this we constructed and purified Maf1 variants for crystallization trials.  
 
Crystals were obtained for a human variant that lacked both mobile regions (Figure 3C). Analysis of 
these crystals confirmed, that they are comprised of human Maf1 1-20536-82 (Figure 3B). 
 
 
 
Figure 3. Maf1 crystal structure determination. 
(A) Mutiple sequence alignment and structural conservation of Maf1 from Homo sapiens (H.s.), Schizosaccharomyces pombe 
(S.p.) and Saccharomyces cerevisiae (S.c.). Secondary structure elements are indicated above the sequence (cylinders for 
helices, arrows for -strands). Red elements are included in the structure. Identical and conserved residues are highlighted 
in green and orange, respectively. The mobile region includes proteolytic cleavage sites (this work), phosphorylation sites 
(Dephoure et al., 2008; Lee et al., 2009; Moir et al., 2006), and the N-terminal NLS (Nt-NLS). The C-terminal NLS (Ct-
NLS) is also indicated. Regions that are not present in the crystal structure are indicated by dashed lines. The crystallized 
protein was a human Maf1 variant comprising residues 1-35 and 83-205. (B) Purified and crystallized Maf1 variants. Lane 1 
and 6 show Broad range marker, stained with coomassie and silver, respectively. Lane 2 shows purified s.c. Maf1 fulllenght, 
lane 3 purified h.s. Maf1 fulllenght, lane 4 purified h.s. Maf1 1-20536-82, and lane 5 washed, dissolved and silverstained 
crystals of h.s. Maf1 1-20536-82, which are shown in (C). Shown crystals were grown in reservoir solution containing 50 
mM MES pH 6.0, 175 mM NaOxalate or 50 mM MES pH 6.80, 250 mM NaOxalate, respectively (2.3.1.2). 
 
 
 
The structure was solved by bromide phasing using a MAD data set with peak, remote, and inflection 
wavelengths. Refinment with a native data set revealed a Rfree of 21.15% and a Rwork of 18.81% at 1.55 
Å resolution (Table 13).  
II ■ Molecular basis of RNAP III transcription repression by Maf1                                     Results and Discussion 
44  
Table 13. Maf1 X-ray diffraction and refinement statistic. 
 
Data set  NaBr soak  Native 
Data collection     
Space group  P 212121  P 212121 
Unit cell axis 
a, b, c (Å) 
 48.07,48.34, 
80.50 
 48.39,48.81, 
79.32 
 Peak Remote Inflection  
Wavelength (nm) 0.9196 0.9211 0.9200 0.91870 
Resolution (Å)* 26.83-1.9 26.83-1.9 26.83-1.9 25.974-1.55 
Rmerge (%)* 7.7 (50.7) 6.0 (39.2) 7.0 (51.3) 5.2 (58.9) 
I/σ (I)* 22.0 (2.5) 22.7 (3.0) 22.0 (2.4) 22.3 (1.2) 
Completeness (%)* 99.0 (99.5) 98.8 (99.4) 98.9 (99.5) 94.3 (87.4) 
Redundancy* 3.9 (4.0) 3.8 (3.9) 3.8 (4.0) 3.0 (1.9) 
Refinement     
Resolution (Å)    1.55-25.97 
No. reflections    26,183 
Rwork (%)    18.81 
Rfree (%)    21.15 
No. atoms     
    Protein    1313 
    Water    142 
B-factors (Å2)     
    Protein    33.64 
    Water    43.95 
r.m.s.d. from ideal     
    Bond lengths (Å)    0.006 
    Bond angles (°)    0.959 
 
*Highest resolution shell is shown in parenthesis. 
Rmerge = Σ |I - <I >|/Σ | where I is the integrated intensity of a given reflection. 
R = Σ ||Fobs| - |Fcalc||/Σ | Fobs|. Rfree was calculated using 5% of data excluded from 
refinement. 
 
 
 
3.4 Maf1 structure is globular, not modular  
Maf1 forms a globular structure with a central five-stranded antiparallel -sheet that is flanked by a 
single helix on one side, and by three helices on the other (Figure 4A). The Maf1 fold is frequently 
found in proteins, but not in proteins involved in transcription, as revealed by DALI (Holm and Park, 
2000; Krissinel and Henrick, 2004). The Maf1 structure is apparently conserved among eukaryotes, 
since hydrophobic core residues are conserved from yeast to human (Figure 3A).  
 
 The Maf1 structure shows that the previously defined conserved sequence boxes A, B, and C 
(Desai et al., 2005; Pluta et al., 2001; Reina et al., 2006), do not correspond to structural modules or 
defined surface patches (Figure 4B). Thus, previous functional analyses of Maf1 deletion constructs, 
lacking one or more of these boxes, must be re-evaluated taking into account that the variants may 
adopt non-native structures.  
To characterize the Maf1 structure into more detail, in vivo complementation assays were performed 
with scMaf1 deletion and point mutation strains (Appendix IV 1.1 and 1.2). 
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Figure 4. Maf1 crystal structure. 
(A) Two views of a ribbon model of the human Maf1 crystal structure. Secondary structure elements are labelled according 
to A. (B) Ribbon model of human Maf1 with the conserved A-, B- and C-boxes highlighted in blue, purple, and rose. Colors 
were chosen as in Figure 3A. 
 
 
3.5 Regulated Maf1 cellular localization  
The Maf1 crystal structure reveals that the two NLS sequences (yeast residues 205- 208 and 328-332; 
(Moir et al., 2006)) are accessible on the domain surface (Figure 4A).  
The C-terminal NLS (Ct-NLS) is located between strands 4 and 5, and the N-terminal NLS (Nt-
NLS) is part of the directly adjacent mobile region (Figure 4A). The adjacent location suggests that 
phosphorylation of the mobile insertion regulates nuclear localization by masking the NLS sequences 
(Lee et al., 2009; Moir et al., 2006). This mechanism is apparently conserved from yeast to human, 
although the exact phosphorylation sites within the mobile insertion differ (Dephoure et al., 2008; Lee 
et al., 2009; Moir et al., 2006; Shor et al., 2010). The Ct-NLS and the residues at the mobile insertion 
form the only positively charged region on Maf1 (Figure 5B). Point mutants that led to defects in 
phosphorylation, growth on glycerol at 37°, or RNAP III repression (Moir et al., 2006; Roberts et al., 
2006) (Figure 3E), cluster in this surface region.  
 
 
 
Figure 5. Maf1 crystal structure analysis. 
(A) Surface conservation of Maf1. Identical and conserved residues are highlighted in green and yellow, respectively. 
Residues labelled in blue were analyzed for a role in RNAP III interaction (Figure 19). Residues labelled in red, pink, and 
wheat show severe, mild, or no phenotypes, respectively (Dephoure et al., 2008; Moir et al., 2006; Roberts et al., 2006). (B) 
Surface charge distribution of Maf1. Red, blue, and white areas indicate negative, positive, and neutral charges, respectively. 
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3.6 Maf1 binds the RNAP III clamp and rearranges C82/34/31  
To investigate how Maf1 binds yeast RNAP III, we prepared full-length yeast Maf1 as a recombinant 
protein and a variant that lacked both mobile regions and corresponded to the crystallized human 
protein. Both variants formed a complex with RNAP III that could be purified by size-exclusion 
chromatography (Figure 6, lanes 3 and 4). Maf1 binding was specific, as human Maf1 did not bind 
yeast RNAP III (not shown). Thus, the two mobile regions are not required for RNAP III binding, and 
the human Maf1 crystal structure is relevant for the understanding of the RNAP III-Maf1 interaction.  
 
 
Figure 6. Binding properties of Maf1 fulllenght and crystallized construct to yeast RNAP III. 
Binding experiments were performed as described in (2.3.1.4). Lane 2 shows RNAP III, lane 3 the RNAP III complex with 
the s.c. Maf1 variant corresponding to the crystallized human variant (s.c. Maf1 1-34536-224), and lane 4 shows the RNAP 
III complex with full-length sc Maf1. 
 
 
We collected cryo-EM data of the pure RNAP III-Maf1 full-length complex and used 16,974 particles 
to obtain a reconstruction at 18.5 Å resolution (Figures 7A).  
 
 The structure revealed a continuous density for C82/34/31, similar to the density in the 
RNAP III-DNA-RNA complex (Figure 7A). Maf1 was assigned to a new density on top of the clamp, 
with the help of calculated difference maps. The Maf1 X-ray structure fitted this density well (Figures 
7A and C).  
 
 To provide additional support for the Maf1 location, we labelled the C-terminal 
hexahistidine tags on Maf1 and the RNAP III subunit C128 with Ni-NTA-Nanogold™ and located the 
labels by 2D cryo-EM image analysis. The locations of the labels were consistent with Maf1 binding 
on top of the clamp domain (Figure 7B). This location also agreed with published biochemical and 
genetic interactions of Maf1 with the N-terminal region of C160 that forms most of the clamp (Boguta 
et al., 1997; Oficjalska-Pham et al., 2006; Reina et al., 2006) (Figure 7D). Further consistent with this 
location, C160, C82, and C34 are the top interacting partners of Maf1 in the yeast interactome (Gavin 
et al., 2006).  
 
 A detailed comparison of the EM structures revealed that the C82/34/31 density observed in 
the RNAP III-Maf1 complex differed from that in the RNAP III-DNA-RNA complex. In particular, it 
appears that most of the density assigned to the C34 WH domains in the RNAP III-DNA-RNA 
complex is absent in the RNAP III-Maf1 complex, as an effect of a Maf1-dependent displacement of 
these domains. Probably these domains are shifted and become partially mobile, as suggested by the 
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presence of a shifted residual density, attributed to the second C34 WH domain (Figure 7F). The 
densities assigned to C31 and C82 undergo a similar change in location towards the Rpb5 jaw domain, 
giving rise to additional density in this region (Figures 7C and 7F).  
Consistently, Maf1 overlaps with the assigned locations of the C34 second WH domain and with C82 
and C31 in the RNAP III-DNA-RNA complex (Figures 7C and 7E). 
 
 
Figure 7. Cryo-EM structure of the RNAP III-Maf1 complex. 
(A) Comparison of cross section of EM structures of the RNAP III-Maf1 complex (red) and the RNAP III-DNA-RNA 
complex (blue) reveals an additional density for Maf1. (B) Different views of reference projections of the RNAP III-Maf1 
reconstructions (top row), corresponding thresholded Nanogold-labeled RNAP III-Maf1 particles used for alignment (second 
row), raw Nanogold-labeled particles (middle row), Nanogold particles with outline of RNAP III-Maf1 structure and circles 
indicating the location of the Nanogold labels (forth row), and surface representations of RNAP III-Maf1 reconstructions 
with N-terminus of C128 and location of Maf1 indicated by white and yellow dots, respectively (bottom row). The Nanogold 
signals are consistent with the location of Maf1 shown in A. (C) Fit of the Maf1 X-ray structure (red molecular surface) to 
the RNAP III-Maf1 EM map (red grid). For comparison, the cryo-EM map of the RNAP III-DNA-RNA complex is also 
shown (blue surface). (D) Ribbon representation of RNAP III-Maf1 complex. RNAP III homology model is depicted in green 
while Maf1 X-ray structure is depicted in red. The clamp domain of C160 (residues 1-245) is highlighted in yellow. The 
RNAP III-Maf1 cryo-EM map is shown as a red mesh. (E) Maf1 (red ribbon) sterically clashes with C34 (purple) and C82 
(cyan) as positioned in the RNAP III-DNA-RNA complex. (F) Comparison of cross section of EM structures of the RNAP 
III-Maf1 complex (red) and the RNAP III-DNA-RNA complex (blue) reveals a shift of the density attributed to the 
C82/34/31 subcomplex upon Maf1 binding. (G) Close-up view of the region over the clamp. Most of the density attributed to 
the two C34 WH domains in the RNAP III-DNA-RNA complex (blue) is absent in the RNAP III-Maf1 complex (red). 
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3.7 Maf1 impairs closed promoter complex formation  
To analyze how the structural changes induced by Maf1 binding could repress RNAP III transcription, 
we constructed a model for the RNAP III-Brf1-TBP closed promoter complex. Brf1 resembles the 
RNAP II initiation factor TFIIB in its N-terminal region, but contains a specific C-terminal extension 
that binds TBP (Khoo et al., 1994). We therefore combined the RNAP II-TFIIB-TBP closed promoter 
complex model (Kostrewa et al., 2009) with the structure of TBP bound to the Brf1 C-terminal 
residues 437-507 (Juo et al., 2003).  
 
 Comparison of the resulting RNAP III closed promoter complex model with the EM 
densities revealed that C34 was well positioned for interacting with both the Brf1 N- and C-terminal 
regions (Figure 8A), consistent with both regions interacting with C34 (Andrau et al., 1999; Brun et 
al., 1997; Khoo et al., 1994). In the RNAP III-Maf1 complex, C34 is locked in a different position that 
is apparently incompatible with Brf1 interaction, suggesting that Maf1 impairs RNAP III recruitment 
to Brf1-containing promoters (Figure 8A and B).  
 
 
Figure 8. Mechanism of RNAP III transcription repression by Maf1. 
(A) Model of RNAP III-Brf1-TBP-DNA closed promoter complex. The RNAP III core homology model and C25/17 crystal 
structure (Jasiak et al., 2006) are depicted as gray ribbons. The C34 WH domains are depicted as magenta surfaces. The Brf1 
Nterminal domain (green ribbon) and the closed promoter DNA (cyan and blue ribbons) are based on the RNAP II-TFIIB-
TBP-DNA closed promoter complex model (Kostrewa et al., 2009). TBP (dark purple) and the Brf1 C-terminal domain 
(orange) are depicted as ribbons and are based on the Brf1-TBP-DNA crystal structure (Juo et al., 2003). (B) Schematic 
model for Maf1-dependent repression of RNAP III-Brf1-TBP-DNA closed promoter complex formation, coloured as in A. 
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 To test this model for the Maf1 repression mechanism, we investigated by size exclusion 
chromatography whether the RNAP III-Maf1 complex can bind to a preassembled, transcriptionally 
functional, Brf1-TBP fusion protein-DNA promoter complex (Kassavetis et al., 2005). We used U6 
snRNA promoter DNA from position - 40 to +20 relative to the transcription start site +1. Whereas 
free RNAP III formed a stable closed promoter complex (Figure 9B, lane 3), the RNAP III-Maf1 
complex did not bind the Brf1-TBP-DNA complex, even when a five-fold molar excess was used 
(Figure 9 lane 5). When we repeated the experiment with a mismatched bubble region at positions –11 
to +2 (Figure 9A), the same result was obtained (Figure 9B, lanes 6 and 7). Further, pre-assembled 
RNAP III-Brf1-TBP promoter complexes were unable to bind Maf1, even when a five-fold molar 
excess was used (lane 4).  
 
 These experiments indicate that the interaction of RNAP III with Maf1 and a Brf1-TBP-
DNA complex are mutually exclusive, showing that Maf1 impairs formation of a closed promoter 
complex. This is consistent with evidence that Maf1 binds RNAP III and prevents promoter 
interaction (Desai et al., 2005; Moir et al., 2006; Roberts et al., 2006). 
 
 
3.8 Maf1 does not inhibit RNAP III activity  
The above model predicts that Maf1 inhibits binding of promoter DNA over the active center cleft but 
not in the cleft.  
 
 To test this, we compared pure RNAP III and RNAP III-Maf1 complexes in an initiation 
factor-independent transcription assay using a 3’-tailed DNA template and a priming RNA 
dinucleotide ((Bardeleben et al., 1994), 2.3.1.7) that bind directly in the cleft. Consistent with the 
model, both complexes were equally active in RNA synthesis, and an excess of Maf1 or DNA did not 
change activity (Figure 9C).  
 
 We additionally performed RNA extension assays using a minimal DNA-RNA scaffold 
(Damsma and Cramer, 2009). The presence of Maf1 neither prevented scaffold binding nor elongation 
to the end of the template, and this was independent of the order of factor addition (Figure 9D).  
 
 To rule out that nucleic acids displace Maf1 from RNAP III or prevent its binding, we tested 
by size-exclusion chromatography whether RNAP III is capable of binding Maf1 and nucleic acids 
simultaneously. RNAP III-Maf1 complexes with 3’-tailed template or bubble scaffold could be 
purified, independent of the order of addition (Figure 9E). Thus, Maf1 neither prevents nucleic acid 
binding in the active center cleft nor DNA dependent RNA synthesis. The observation that RNAP III 
can simultaneously bind Maf1 and nucleic acids suggests that the increased Maf1 occupancy at RNAP 
III genes under repressive conditions (Geiduschek and Kassavetis, 2006; Oficjalska-Pham et al., 2006; 
Roberts et al., 2006) is due to Maf1 binding to RNAP III elongation complexes. Such Maf1-containing 
RNAP III elongation complexes would be unable to re-initiate, explaining the observation that Maf1 
represses multiple-round but not single-round transcription by RNAP III (Cabart et al., 2008). 
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Figure 9. Maf1 impairs closed promoter complex formation but not RNAP III activity. 
(A) Nucleic acid scaffolds. (B) Competition assays reveal that Maf1 impairs binding of RNAP III to a Brf1-TBP-DNA 
complex. Preassembled RNAP III-Brf1-TBP-DNA or RNAP III-Maf1 complexes were incubated with a 5-fold molar excess 
of competing factor or complex as indicated and subjected to gel filtration, and the peak fraction was analyzed by SDS-
PAGE. In lanes 3, 4, and 6, the presence of DNA was revealed by the high A260/A280 ratio (~1) compared to the A260/280 
ratio (~0.6) in lanes 2, 5, and 7. (C) Factor-independent RNAP III transcription assays. Preincubated RNAP III-DNA (lanes 
3–5) and RNAP III-Maf1 complexes (lanes 6–8) efficiently transcribe the tailed template (A). Addition of increasing 
amounts of Maf1 to preincubated RNAP III-DNA complexes does not impair transcription (lanes 4 and 5). Increased 
amounts of scaffold have no effect (lanes 6–8). (D) RNA extension assay. The elongation scaffold (A) was efficiently 
transcribed to produce run-off product (+15) by RNAP III upon addition of NTPs (lane 3). Preincubation or addition of Maf1 
(lanes 4 or 5, respectively) did not impair activity. (E) RNAP III can simultaneously bind Maf1 and nucleic acids. 
Preassembled RNAP III-Maf1 and RNAP III-DNA complexes were incubated with 5-fold molar excess of DNA or Maf1, 
respectively, and subjected to gel filtration, and the peak fraction was analyzed by SDS-PAGE and silver staining. Staining of 
a RNAP III-Maf1 complex (without DNA) is identical to that in lanes 4, 5, and 6. 
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4 Conclusions and Outlook 
Our results complement the published data on the mechanism of RNAP III-specific transcription 
repression by Maf1. Cellular stress leads to dephosphorylation of a mobile surface region in Maf1 that 
unmasks adjacent NLS sequences, leading to nuclear import of Maf1. In the nucleus, Maf1 binds free 
RNAP III at its clamp domain and rearranges the C82/34/31 subcomplex. This impairs RNAP III 
binding to a TBP-Brf1-promoter complex and specifically abolishes initiation from RNAP III 
promoters, which require Brf1. Maf1 also binds RNAP III that is engaged in transcription elongation, 
leaving activity intact but preventing reinitiation. Since RNAP III genes are short and elongation is 
fast, this leads to rapid shutdown of all RNAP III transcription. 
 
 Based on this repression mechanism of RNAP III transcription by Maf1 new questions and 
starting points for follow up projects arise. 
 
 Firstly, the Maf1 protein itself can be analyzed into more detail. Important residues which 
are not included in the crystal structure due to construct design could be identified and their function 
investigated. Phosphorylation/dephosphorylation in the cytoplasm and in the nucleolus as well as 
nuclear import/export has to be regulated by binding to kinases/phosphatases, masking/demasking of 
the NLS sequences, and by interaction with transporter proteins (Ciesla et al., 2007; Moir et al., 2006; 
Oficjalska-Pham et al., 2006; Reina et al., 2006; Roberts et al., 2006; Towpik et al., 2008; Wei and 
Zheng, 2010). Presumably, different regions, binding surfaces and conformational states of Maf1 play 
a role here. Deletion mutants of Maf1 can be designed based on the structure and used in in vivo 
phenotyping assays and in binding assays with regulatory proteins to elucidate these functional parts 
and binding surfaces. First experiments have already been performed and preliminary results are 
shown in the appendix (Appendix IV). 
 
 Additionally, Maf1 structures of other species can explain observed differences in its 
activity, like repression of TBP expression by human Maf1 (Johnson et al., 2007). Also, from an 
evolutionary perspective, these structures may shed light on species specific regulatory mechanisms in 
the RNAP systems. Crystallization of a Saccharomyces cerevisiae Maf1 variant was successful in this 
study, but structure solution failed (Appendix IV 1.5). These results can serve as a starting point for 
successive projects. 
 
 Secondly, the Maf1/RNAP III interaction can be analyzed further. We were able to position 
Maf1 on the RNAP III complex with the help of cryo EM. However, no information about the 
orientation and only scant information about directly interacting subunits were available (Gavin et al., 
2006; Oficjalska-Pham et al., 2006). Maf1 point mutants and analysis of its RNAP III binding 
properties can be used to identify interacting surfaces of Maf1. Initial trials with Maf1 point mutants 
were used in this study for in vivo phenotyping assays and binding studies to RNAP III (Appendix IV 
1.2). Additionally, binding studies of scMaf1 fl to interacting RNAP III subunits should be perfomed. 
In this study only binding to C34 and C160 was analyzed (Appendix IV 1.3).  
 
 Thirdly, the interaction of Maf1 with TFIIIB can be the focus of further analysis. It was 
shown that human and yeast Maf1 bind to Brf1 very weakly (Desai et al., 2005; Reina et al., 2006; 
Rollins et al., 2007). Whether this interaction plays a physiological role and how the binding looks on 
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an atomic level is not known. Therfore assembly of a stoichiometrically bound complex is a first step 
for subsequential structure investigation. Preliminary trials are summed up in the appendix (Appendix 
1.3). 
   
 A more longterm perspective would be to understand the molecular interactions of the 
potential tumor suppressor Maf1 with RNAP III, TFIIIB, and regulatory proteins, like kinases, 
phosphatases, and transporter proteins, and may help to develop therapies against diseases with 
uncontrolled rRNA and tRNA levels (White, 2008). 
 
 Additionally, a cryo EM reconstruction of a minimal RNAP III PIC should be focus of 
further studies, allowing the mechanism of transcription initiation and its regulation on a molecular 
level to be elucidated. So far only binding site mapping of a RNAP PIC could be obtained (Chen et al., 
2010; Cramer, 2007; Kassavetis et al., 2003). This is probably due to its flexibility in different 
conformational intermediate states and thereby generating heterogeneous samples. Recent findings, 
that an enlarged bubble (-16 until +2) compared to a normal bubble (-9 until +2) in the RNAP II leads 
to a more homogeneous sample assembly and bubble position ((Andrecka et al., 2009) and 
unpublished results) may solve this problem.  
Our published results comprise a RNAP III EC cryo EM reconstruction whith better defined RNAP III 
specific subunits, compared to RNAP III reconstructions. Also assembly of the triple fusion protein 
Brf1N-TBPC-Brf1C with RNAP III is possible (Vannini et al., 2010). Altogether these data serve as a 
good starting point for extensive studies of a minimal RNAP III PIC. RNAP III, Brf1N-TBPC-Brf1C, 
and a promoter scaffold with enlarged bubble can be used to assemble a minimal PIC. Analysis with 
cryo EM can potentially lead to a first structure of a minimal eukaryotic PIC. Experimental design, 
complex assembly and first reconstructions were performed in this study (Appendix IV 2).   
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1 Introduction  
1.1 Mitochondrial functions  
Mitochondria are dynamic subcellular organelles with cell type-specific appearance (Westermann, 
2010). They are responsible for metabolic energy production in the form of ATP. This is generated by 
oxidative phosphorylation using the electron transport chain (ETC) in the inner mitochondrial 
membrane and coupled chemiosmosis. Furthermore, mitochondria are involved in a number of 
catabolic and anabolic reactions, including the citric acid cycle, -oxidation of fatty acids, and the 
biosynthesis of certain phospholipids and other metabolites (Scheffler, 2001). Additionally, 
mitochondria play an important role as key regulators in apoptosis and are suggested to be a major 
initiator and target of reactive oxygen species (ROS) -mediated aging and integrator of stress-evoked 
mitochondrial pathways, which can lead to longevity (Bonawitz et al., 2006; Durieux et al., 2011).  
 
 This plethora of functions already indicates the impact of mitochondria in disease. Mutations 
and deletion of mtDNA in yeast lead to cells showing a petite phenotype, since Saccharomyces 
cerevisiae can survive on fermentable carbon sources (Bernardi et al., 1970). In mammals many 
diseases are suggested to be linked to mutations in mtDNA, but are hard to investigate, since cells 
often show heteroplasmy and only accumulation and segregation of these genomes result in a 
phenotype (Ono et al., 2001). Mitochondrial diseases are often age-associated and mostly affect cells 
with high energy consumptions, like muscle cells and neurons. Neuromuscular disorders, certain 
tumors, and diabetes as well as Parkinson’s, Alzheimer’s, and Huntington’s disease are linked to 
mutations in mtDNA (Narendra and Youle, 2011; Wallace, 2005).  
 
1.2 The mitochondrial genome  
As described above the mitochondrion originates most likely from an -proteobacterium, which 
developed early in evolution a symbiotic relationship with a primitive eukaryotic cell (Andersson et 
al., 2003). Based on phylogenetic relationships, a monophyletic origin is supposed (Gray et al., 1999). 
Gene content and organization in eukaryotes is very diverse, mostly ranging from 15-60 kbps and 
from circular to linear molecules, with the human mitochondrial genome comprising of 16,600 bps 
(Burger et al., 2003). Mammalian mitochondria show significant diversification in the sequence of 
individual genes to enable compatible interactions of its proteins with nuclear-encoded proteins 
(Boore, 1999).  
 
 Gene transfer took place from the mitochondrion to the nuclear genome and only a small 
number remained in the mitochondrion. In humans, about 1000 mitochondrial proteins are encoded in 
the nucleus and just 13 proteins, which are involved in oxidative phosphorylation, are encoded in the 
mammalian mtDNA (Scheffler, 2001). Genes which encode for essential mitochondrial transcription 
and translation proteins are nuclear (Adams and Palmer, 2003). The 1000-10000 copies of mtDNA in 
human cells encode additionally two rRNAs and 22 tRNAs that are used during mitochondrial 
translation, and have just one longer non-coding region, which contains the control elements for 
transcription and replication (Gaspari et al., 2004b).  
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The two mtDNA strains differ in their G+T content and can be separated into a heavy (H)- and light 
(L)-strand. Each strand harbours only one promoter for transcriptional initiation. Transcription 
initiation by usage of the transcription factors TFB2M and TFAM as well as mitochondrial RNAP 
regulation was described earlier (General Introduction 2.2).  
 
The transcription product of each strand is a polycistronic precursor RNA, which are processed to 
tRNA, rRNA and mRNA (Bonawitz et al., 2006; Falkenberg et al., 2007).  
 
 
Maturation of mitochondrial transcripts and mitochondrial DNA replication 
 
In human, the two polycistronic precursor RNAs are processed by endonucleolytic cleavage into 
individual rRNAs, mRNAs and intervening tRNAs (Ojala et al., 1981). According to the “tRNA 
punctuation model” endonucleolytic excision of tRNA sequences also generates matured mRNAs and 
rRNAs (Ojala et al., 1981). Cleavage of 5´ ends of tRNA is catalyzed by a mitochondrial RNase P, 
consisting of three proteins only (Holzmann and Rossmanith, 2009), subsequent generation of 3´ends 
is performed by a 3´ processing activity (Manam and Van Tuyle, 1987). Further processing of mRNAs 
involves polyadenylation of the 3´end, which is performed by human mitochondrial poly(A) 
polymerase (Tomecki et al., 2004). This produces an UAA stop codon in many mitochondrial mRNAs 
(Anderson et al., 1981) and increased mRNA stability (Temperley et al., 2003). tRNAs undergo base 
modifications and addition of a CCA tail at the 3´end, whereas rRNAs become oligoadenylated at their 
3´ends (Taanman, 1999).  
 
 Interestingly, the mitochondrial RNAP also assists mtDNA replication by synthesis of 
primers, thereby serving as a primase (Fuste et al., 2010). According to the strand-displacement 
model, de novo primer synthesis starts at the L-strand promoter (OriH) and terminates at a conserved 
sequence block II 100 bps downstream (Pham et al., 2006), where mitoRNAP dissociates and transfers 
the primer with an unknown mechanism to the replication machinery. The mitochondrial replication 
machinery consists of the Twinkle helicase, DNAP, and single-strand DNA binding protein, which 
are all encoded in the nucleus. Twinkle and DNAP likely share ancestry with T7 phage proteins 
(Shutt and Gray, 2006). 
 
 The replication machinery uses the synthesized primer to replicate the leading strand (Chang 
and Clayton, 1985). When reaching the second replication start site (OriL) on the H-strand, DNA 
forms a single-stranded hairpin, and mitoRNAP transcribes, without the help of TFAM and TFB2M, a 
second primer in reverse direction, which gets 25-35 nt long before DNAP takes over again and 
replicates the missing DNA strand (Fuste et al., 2010). Replication is completed when the DNA circles 
are ligated to form continuous strands (Shadel and Clayton, 1997). Since changing energetic needs of 
cells lead to varying amounts of mitochondria and mtDNA (Wallace, 2001) and also the localization 
of the mitochondrion in the cell plays a role for the replication probability (Davis and Clayton, 1996), 
regulation of this replication process in an adaptive and signal-dependent manner is needed and likely 
performed at least partly by regulating mitoRNAP activity.  
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1.3 Mitochondrial RNA polymerase  
Regulated expression of the mitochondrial genome is crucial for cell viability and the ability to adapt 
to changing energetic needs (Wallace, 2005). Transcription of the mitochondrial genome is driven by 
the nuclear-encoded DNA-dependent mitoRNAP. This RNAP belongs to a family of ss RNAPs that is 
distinct from the multisubunit cellular RNAPs and also includes chloroplast RNAP and RNAPs from 
bacteriophages such as T7 and N4.  
 
 
Comparison with known ss RNAP structures  
 
All ss RNAPs share high sequence homology in their carboxy-terminal domains (CTD) that form a 
fold resembling a right hand (Jeruzalmi and Steitz, 1998). The conserved palm and the mobile fingers 
subdomain of the CTD comprise the catalytic core of these enzymes. The CTD fingers subdomain also 
contains the specificity loop, a -hairpin that binds the major groove of promoter DNA and forms 
base-specific contacts (Cheetham et al., 1999). The third subdomain in the CTD is the thumb, with a 
long  helix that takes part in RNA/DNA heteroduplex separation (Yin and Steitz, 2004).  
 
 
 
Figure 10. T7 RNAP structures. 
(a) Structure of T7 RNAP initiation complex (PDB 1QLN) with a 17/22mer DNA (blue for template strand and cyan for non-
template strand) and 3mer RNA (red). Three loops are essential for promoter recognition, binding and melting, which are 
indicated as AT-rich recognition loop (organge), specificity loop (brown) and intercalating hairpin. The CTD is shown in 
gray and consists of the thumb, palm, and fingers subdomains, which also bild the active center, including the O-helix. Te 
active site is in an open, inactive state. The NTD consists of the protein binding domain (PBD) (pink), the C-helix (yellow), 
and the subdomain H (green) and undergoes major refolding in the transition from initiation to the elongation state, shown in 
(b). (b) Structure of T7 RNAP elongation complex (PDB 1H38) with 18/10 mer DNA and 12mer RNA (just 8 nt of RNA 
were seen in electron density). The colour code is the same as in (a). The CTD is in a closed, active state. The refolding of the 
NTD leads to lost of promoter DNA contacts, seen in the positional changes of the three loops and to the formation of an 
RNA exit tunnel by the subdomain H and the CTD specificity loop, 
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 Structural studies with T7 RNAPs elucidated the mechanisms of the four steps in the 
nucleotide addition cycle during elongation (Tahirov et al., 2002; Temiakov et al., 2004; Yin and 
Steitz, 2002; Yin and Steitz, 2004).  
The substrate NTP binds with its triphosphates to Lys631 and Arg627 of the fingers O-helix and 
initially base-pairs in an open conformation (pre-insertion substrate complex) (Temiakov et al., 2004). 
Conformational changes by a rotation of five helices in the fingers subdomain around a pivot point in 
the O-helix result in a closed conformation of the active center, so that the substrate NTP is properly 
positioned for insertion (insertion substrate complex) (Yin and Steitz, 2004). Nucleotide addition can 
take place with the help of two catalytic Mg2+-ions and leads to a closed product complex with bound 
pyrophosphate forming an ionic crosslink between the Mg2+-coordinated Asp537 and Arg627 (Yin and 
Steitz, 2004). Dissociation of the PPi results in an open complex again and accompanied translocation 
of the DNA/RNA heteroduplex (post-translocation complex) (Tahirov et al., 2002; Yin and Steitz, 
2002). The conformational changes in the fingers subdomain resulting from PPi dissociation is 
associated with the unwinding of the downstream heteroduplex by one bp at the Y-helix concomitant 
with translocation by 3.4 Å (Yin and Steitz, 2004). In the post-translocation conformation the Tyr639 
is stacked on the primer template bases, inhibiting backtracking and blocking the insertion site. Only 
after binding of the next substrate NTP in the pre-insertion site can another round of nucleotide 
addition take place.  
 
 Since all catalytic residues are conserved also in mitoRNAP, one can expect similar 
nucleotide binding and addition mechanisms. However, there are some differences in the product 
length of initiation RNA (8 nt in T7 RNAP and 13 nt in yeast mitoRNAP) and abortive initiation 
which may be explained by structural adaptions. 
 
 In contrast, the amino-terminal regions of ss RNAPs show very limited homology and differ 
in size. In phage RNAPs, they contain a promoter binding domain (PBD) (Durniak et al., 2008; 
Gleghorn et al., 2008). In T7 RNAP, the PBD forms a six-helix bundle that includes two DNA-binding 
elements, the intercalating hairpin and the AT-rich recognition loop (Cheetham et al., 1999; Durniak et 
al., 2008) (Figure 10a). The intercalating hairpin separates DNA strands during promoter melting and 
interacts with the DNA template strand (Cheetham et al., 1999; Gleghorn et al., 2008). The AT-rich 
recognition loop binds the minor groove of upstream promoter DNA (Cheetham et al., 1999). In N4 
RNAP, the AT-rich recognition loop is altered, to specifically recognize hairpin promoters (Davydova 
et al., 2007; Gleghorn et al., 2008).  
 
 Structural studies with T7 RNAPs show that the N-terminal domain (NTD) refolds 
massively in the transition from initiation to elongation (Figure 10). In the elongation state promoter 
DNA contacts are lost and processive transcription is enabled through formation of a RNA exit tunnel 
by the subdmain H, PBD, and specificity loop (Tahirov et al., 2002; Yin and Steitz, 2002). 
 
 Since the amino-terminal regions of mitochondrial and chloroplast RNAPs share essentially 
no sequence homology with phage RNAPs it is unknown whether they contain similar structural 
elements with a role in promoter recognition and transcription processivity. 
 
 Human mitoRNAP relies on two essential transcription factors, TFAM and TFB2M (Gaspari 
et al., 2004b; Litonin et al., 2010), which are described in more detail in part 2.2 of this work. These 
factors likely control promoter binding and melting during transcription initiation (sin-Cayuela and 
Gustafsson, 2007; Sologub et al., 2009). A similar functional role was demonstrated for the yeast 
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TFB2M analog, Mtf1, whose C-terminus was shown to contact the template strand in an active 
initiation complex at nt positions -3/-4 (Savkina et al., 2010). Importantly, the structure of Mtf1 was 
solved before (Schubot et al., 2001). While the components of the transcription initiation complex (IC) 
are known, their spatial arrangement and the molecular mechanisms of promoter binding and melting 
remain unknown.  
 
 No structure of any mitoRNAP has been solved yet, which would hopefully reveal the 
mechanistic adaptations that occurred during evolution of a self-sufficient T7-like RNAP to become 
regulated by transcription initiation factors. 
 
 
PPR motif 
 
MitoRNAP has two putative pentatricopeptide repreat (PPR) motifs in its N-terminal region 
(Rodeheffer et al., 2001). Genome wide analysis for a variety of organisms revealed that PPR motifs 
are specific to eukaryotes and most prominent in plants, with 441 PPR motif containing proteins 
predicted in A.thaliana, 7 in H.sapiens, and 5 in S.cerevisiae (Lurin et al., 2004, Mili et al., 2003). 
Each of these proteins contains 2 to 26 PPR motifs per molecule (Small and Peeters, 2000). Only few 
PPR proteins are characterized so far but are all implicated in RNA-processing in mitochondria and 
chloroplasts (Mili and Pinol-Roma, 2003). Prediction programs reveal that nearly 65% of all PPR 
proteins are targeted to mitochondria and another 16% to plastids and targeting experiments with 45 
randomly chosen PPR proteins show that mitochondria or plastids are the only observed subcellular 
localization (Lurin et al., 2004). The seven human PPR proteins are all predicted to be mitochondrial 
(Lurin et al., 2004). 
 
 The function of PPR proteins remains unclear and only few individual proteins were 
analyzed so far. Interestingly, mutants pet309 and cya5 in yeast and N.crassa are affected in stability 
and translation of mitochondrial cytochrome c oxidase subunit 1 (Cox1) transcripts, a similar 
phenotype to a mutation in a human PPR motif containing gene (LRPPRC) which is linked to Cox1 
deficiency (Coffin et al., 1997; Manthey et al., 1998; Mootha et al., 2003). Also Crp1, a PPR protein 
of Z.mays, plays a role in processing and translation of plastid transcripts (Fisk et al., 1999). And 
recently RNA processing factor 1 (Rpf1), a PPR protein in A.thaliana, was characterized to play a role 
in processing the 5´ends of mRNA transcripts (Holzle et al., 2011). Additionally, also the third protein 
subunit of human mitochondrial RNAse P, MRPPR3, which is involved in tRNA maturation, has two 
tandem PPR-motifs (Holzmann and Rossmanith, 2009). 
These examples illustrate that PPR proteins play a role in organelle gene expression. Additionally, 
initial nucleic acid binding studies show preferential binding of poly(G) RNAs (Lurin et al., 2004). 
Therefore it suggests that PPR proteins operate in protein/RNA interactions. 
 
 The 35-amino acid PPR motif is predicted to consist of two  helices and in contrast to 
tetratricopeptide (TPR) motifs, which form a related and well-studied protein class, the PPR motifs 
show sequence conservation in their connecting loops, likely building a conserved positively charged 
groove on top of the helices. Speculatively, this groove could be part of the suggested RNA-binding 
activity of PPR motifs. So far no structure of any PPR motif containing protein was solved, but could 
help to elucidate conserved structural elements, which explain the suggested functions.  
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1.4 Aims and Scope 
Mitochondrial RNAPs evolved from interaction of three distinct entities, namely the host cell, a 
bacterium and a phage. Therefore mitochondrial transcription shares a number of features with phage, 
bacterial, and eukaryotic transcription and is unique among well studied bacteriophage and multi-
subunit RNAPs (Table 2, General introduction). On the one hand mitochondrial RNAPs recognize its 
promoters in a self-sufficient manner like T7 RNAPs. On the other hand they need transcription 
factors for efficient initiation (Cheetham et al., 1999; Gaspari et al., 2004b; Shutt et al., 2010). 
Additionally, transcription in mitochondria is highly regulated by additional transcription factors and 
cofactors (Woo and Shadel, 2011). This regulated initiation resembles the structurally unrelated multi-
subunit RNAPs.  
 
 Thereby, investigation of mitochondrial RNAP´s molecular transcription and regulation 
mechanisms establishes ties between the evolutionary diversification of RNAPs and is very 
meaningful in this perspective. To date no structural data for any mitochondrial RNAP is available. 
Since structures of multi-subunit RNAPs in bacteria, archaea, and eukaryotes as well as structures of 
ss RNAPs, like bacteriophage T7, were solved over the last decades, the structure of the mitochondrial 
RNAP will fill the last remaining gap. 
 
 Furthermore, mitochondrial dysfunctions lead to aging and a number of human diseases 
(Narendra and Youle, 2011; Wallace, 2005). Therefore investigation of mitochondrial RNAP 
functions and molecular mechanisms will also help to understand human disease related dysfunctions 
of mitochondria. 
 
 The aim of this study was to solve the structure of mitochondrial RNAP by X-ray 
crystallography. This can help to understand the unique features of mitochondrial RNAPs on a 
molecular level and to shed a light on its transcription activity mechanism. 
 
 Subsequent structure analysis by comparing a mitochondrial RNAP structure with other ss 
RNAP structures like T7 and N4 RNAPs, and model building of functional states can help to reveal 
the mechanistic adaptations that occurred during evolution of a self-sufficient T7-like RNAP to 
become regulated by transcription initiation factors. 
 
 Accordingly, this structure can serve as a basis for new experimental designs to elucidate a 
complete picture of the mitochondrial transcription system. New mitochondrial RNAP variants can be 
designed and analyzed in functional assays to obtain more structure/function relationships.  
Additionally, the structure can be used as a model for structural follow up projects, i.e. to elucidate 
structures of mitochondrial RNAP in different functional states or structures of complexes with 
transcription and regulation factors.  
 
 
 In a more long term view the deeper understanding of the molecular mechanisms and unique 
features of transcription by mitochondrial RNAP can help in future to find more effective 
mitochondrial-targeting and antiviral drugs. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains 
Table 14. E. coli strains. 
 
Strain Genotype Source 
XL-1 Blue rec1A; endA1; gyrA96 ; thi-1 ; hsdR17; supE44 ; relA1 ; lac[F´proAB 
lacI qZDM15 Tn10(Tetr)] 
Stratagene 
 
BL21-CodonPlus 
(DE3)RIPL 
B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3); 
endA; Hte [argU proL Camr] [argU ileY leuW Strep/Specr] 
Stratagene 
 
 
2.1.2 Plasmids and primers 
Table 15. List of vectors used in this study. 
 
Vector Inserts/ Description Type Tag Restr. 
sites 
Primer 
RR096 cloning vector (mutation in NcoI 
cutting site) 
pProExHtb - - - 
RR097 Intein_RNAP (AA 109-1230) 
plasmid 
(by Dmitry Temiakov) 
    
RR105 RNAP 760-1230 pProExHtb Nt His XhoI, 
NcoI 
AM 37 for 
AM 37 rev 
 
 
Table 16. List of primers used in this study. 
 
ID Primer Sequenz (5´- 3´) 
RRP01 AM 37 for GTTCCATGGGTCATCACCATCACCATCACGAGCTGGCGCACT 
RRP02 AM 37 rev GGTGGTCTCGAGTTATCAGCTGAAGAAGTAGGTGGAACGCT 
 
2.1.3 Media and additives 
Media and additives were used as in chapter II. 
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2.1.4 Buffers and solutions 
Table 17. Human mitochondrial RNA Polymerase purification buffers. 
 
Name Description 
Buffer A 50 mM Tris 8.0; 0.25 M NaCl; 5% Glycerol; 5 mM ß-mercaptoethanol; 1x protease 
inhibitor 
Buffer B 40 mM Tris 8.0; 1.5 M NaCl; 15 mM Imidazole; 5% Glycerol; 5 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer C 40 mM Tris 8.0; 1.5 M NaCl; 200 mM Imidazole; 5% Glycerol; 5 mM ß-
mercaptoethanol; 1x protease inhibitor 
Buffer D 40 mM Tris 8.5; 0.3 M NaCl; 5% Glycerol; 1mM EDTA; 10 mM ß-mercaptoethanol 
Buffer E 100 mM Tris 7.7; 300 mM NaCl; 5% Glycerol ; 1 mM EDTA ; 10 mM DTT 
 
 
 
 
2.2 General methods 
General methods were used as described in chapter II. Cloning of all human mitoRNAP constructs 
was performed by Dmitry Temiakov (UMDNJ, New Jersey, USA).  
 
2.3 Specific procedures 
2.3.1 Purification of recombinant human mitochondrial RNA polymerase variants 
Variants of human mitoRNAP were purified from 20 L of IPTG induced expression culture (I 2.2.3). 
Cells were resuspended in 500 mL buffer A (see Table 17) and lysed using a Sonifier Cell Discruptor 
250 (Branson). 
 After centrifugation the supernatant was loaded onto two 750 µL Ni-NTA columns (Qiagen) 
equilibrated with buffer B. Each column was washed with 20 mL of buffer B. Elution was performed 
with 8 mL buffer C for each column. The fractions were analyzed for recombinant protein by SDS-
PAGE (see 2.2.5). Dialysis of protein fractions was performed in buffer D o.n. at 4°C. Proteins were 
purified by cation exchange chromatography (HiTrap Heparin 5mL column, GE Healthcare). The 
column was equilibrated with buffer D and proteins were eluted with a linear gradient of 8 CVs from 
300 mM to 1.5 M NaCl. Peak fractions were checked by SDS-PAGE (2.2.5) for the presence of 
recombinant protein. Fractions containing the corresponding human mitoRNAP variant were pooled 
and concentrated (Amicon Ultra centrifugal filter devices, cutoff 50k, Millipore). Afterwards samples 
were applied to a Superdex-200 16/10 size exclusion column (GE Healthcare) equilibrated with buffer 
E for crystallization experiments. Peak fractions were pooled and concentrated to 4-9 mg/ml for 
crystallization. 
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2.3.2 Crystallization of human mitochondrial RNA polymerase variants 
An intial search for crystallization conditions using different protein variants was performed (MPI 
Martinsried, Department of E. Conti) with crystallization screens supplemented with 10% glycerol to 
prevent excessive precipitation, and analyzed as described in 2.2.7. Promising hits were refined in 24 
well sitting or hanging drop plates (Easy Xtal Tool, Qiagen) by varying precipitant and/or salt 
concentrations. Diffraction quality crystals of mitoRNAP variant D150 were obtained by in situ 
proteolysis crystallization and subsequent seeding. Thereafter the purified protein at a concentration of 
9.5 mg/mL was mixed with trypsin in a molar ratio of 900:1 (RNAP:trypsin) in size exclusion buffer E 
and incubated on ice for 1h. 2 µL of trypsin-treated protein was mixed with 2 µL of reservoir solution 
containing 40 mM MES pH 6.5, 97.5 mM (NH4)2SO4, 12% PEG5000, 12.5% Xylitol, and 120 mM 
DTT. Initial crystals appeared within two days at 20°C in hanging drops and used for subsequent 
microseeding. Crystal seed stocks were produced by crushing initial crystals by dilution with 50 µl of 
the respective reservoir solution and vortexing in a Seed Bead microcentrifuge tube (Hampton 
Research). Seeds were diluted 10-1000 times in reservoir solution. Plates were set up by mixing 2 µL 
proteolysed protein with 2 µL seed stock solution of different dilutions. Microseeding produced 
diffracting crystals, approximately 250x90µm in size after 3 days (Figure 1B). Crystals were 
transferred into reservoir solution containing 15% glycerol and 25% PEG4000 and were flash cooled 
in liquid nitrogen.  
2.3.3 Data collection, X-ray structure determination and refinement 
Diffraction data for in situ proteolysed human mitochondrial RNAP variant D150 were collected in 
0.5° increments at 100 K on a MarCCD or PILATUS 6M detector at the Swiss Light Source (SLS), 
Villigen, Switzerland (Table 18). Raw data were integrated with MOSFLM (Leslie et al., 1986), the 
spacegroup confirmed with POINTLESS (Evans, 2006), and scaled with SCALA (Evans, 2006). The 
structure was solved by molecular replacement with the program PHASER (McCoy et al., 2007), by 
using the structure of T7 RNAP (PDB 1QLN). 1QLN was mutated to a poly-alanine sequence 
(program Chainsaw) and reduced to residues 246-354, 392-568, 691-741, 766-883. The molecular 
replacement solution was subjected to rigid body refinement with Refmac5 (Murshudov et al., 1997) 
and revealed initial R factors of Rwork= 43.2% and Rfree= 44.1%. The model was iteratively built with 
COOT (Emsley and Cowtan, 2004) and refined with autoBuster (Global Phasing Ltd) and 
phenix.refine (Adams et al., 2010), using TLS. TLS groups were determined with TLSMD (Painter 
and Merritt, 2006), and the model refined to a final free R-factor of 22.2% (Table 18). Evaluation of 
the X-ray structure with MolProbity (Davis et al., 2004) revealed 1.06% residues as outliers and 
95.87% residues in highly favoured regions of the Ramachandran plot. The structure and diffraction 
data of h.s. mitochondrial RNAP have been deposited in the Protein Data Bank under the accession 
code 3SPA. Figures were prepared with Pymol (Schrödinger, LLC). 
2.3.4 Transcription run-off assay 
Transcription run-off reactions were performed by the laboratory of Prof Dmitry Temiakov, (UMDNJ-
SOMStratford, NJ, USA) and were carried out using synthetic DNA templates containing LSP 
promoter as described elsewhere (Sologub et al., 2009). 
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3 Results and Discussion 
3.1 Structure determination of human mitochondrial RNAP 
We determined the structure of human mitoRNAP by X-ray crystallography. Limited proteolysis 
experiments and subsequential Edman sequencing with human mitoRNAP variants and trypsin or 
chymotrypsin revealed cutting sites at amino acid positions 154, 157, 598, 761, 776, 1089, and 1111. 
Together with secondary structure prediction and sequence alignments with bacteriophage T7 RNAP 
this revealed flexible regions in the N-terminal region (AA 1-150), the intercalating hairpin (AA 591-
624), the thumb region (AA 730-790), and the specificity loop (AA 1085-1108) (see Appendix IV 4). 
A variant lacking the first 150 AA (mitoRNAP150) or the first 104 AA (mitoRNAP104) showed 
improved solubility and the latter is fully functional, as it requires the presence of both TFAM and 
TFB2M for efficient transcription initiation on double-stranded promoter DNA (Figure 24 in 
Appendix IV 3).  
Both variants were used for crystallization trials and in situ proteolysis with trypsin or Arg C and 
revealed crystals (Figure 11A and B and 2.3.2). Analysis of mitoRNAP150 crystals, which grew 
after in situ proteolysis with trypsin, showed, that they are comprised of at least two RNAP fragments 
and do not contain trypsin (Figure 11C). Trypsin- and Arg C-digested mitoRNAP150 and 104 
produced crystals in same conditions and with same shape.  
 
 
 
Figure 11. Human mitoRNAP crystallization. 
(A) Purified and crystallized RNAP variants. Lane 1 shows Broad range marker. Lane 2, 3, and 4 show purified human 
mitoRNAP variants 150-1230, 104-1230, and 44-1230, respectively, stained with coomassie. (B) Crystallization trials with in 
situ proteolysis. Upper left picture shows spherulite crystals grown in 96 well plate at 20°C in reservoir solution (20% PEG 
3350; 0.2M Potassium phosphate) using human mitoRNAP variant 150-1230 (c= 9 mg/mL) proteolysed with trypsin (ration 
(m/m) = 750:1) for 1 h on ice before seting drops. Upper right picture shows crystals in 24 well plate at 20° in reservoir 
solution (40 mM Mes 6.5; 97.5 mM (NH4)2SO4; 12% PEG 5000; 12.5% Xylitol; 120 mM DTT) using using human 
mitoRNAP variant 150-1230 (c= 9 mg/mL) proteolyzed with trypsin (ration (m/m) = 900:1) for 2 h on ice before seting 
drops. Lower left picture shows crystals in 24 well plate at 20° in reservoir solution (40 mM Mes 6.5; 80 mM (NH4)2SO4; 
12% PEG 5000; 12.5% Xylitol; 120 mM DTT) after microseeding. Lower right picture shows single crystal, which grew 
after 2-3 days up to 250x90 µm. (C) Crystal content analysis. Lane 1 shows Broad range marker. Lane 2 shows washed, 
dissolved and silverstained crystals of human mitoRNAP 150-1230 (in situ proteolysed), which are shown in (B, lower 
panel). Lane 3 and 4 show the digestion pattern of human mitoRNAP 150-1230 with trypsin and used trypsin protein, 
respectively.  
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 A first structure (data set A3, mitoRNAP150 treated with trypsin, crystal size 250x70x20 
µm) was solved by molecular replacement using T7 RNAP core (pdb 1QLN and AA 246-354, 392-
568, 691-741, 766-883 all as poly Alanin sequence) as searchmodel. Phaser revealed a rotation 
function Z (RTZ)-score of 16.69 and a translation function Z (TFZ)-score of 38.2 for the best solution 
and rigid body refinement with Refmac5 (Murshudov et al., 1997) revealed initial R factors of Rwork= 
43.2% and Rfree= 44.1%. Iterative model building and refinement with autoBuster revealed a final Rfree 
of 25.92% for this first data set.  
 
 Subsequently, this model was used for molecular replacement with a second data set (data 
set J1, mitoRNAP104 treated with ArgC, crystal size 250x90x40 µm), which showed improoved 
data collection statistics, probably because of a larger crystal size. The final model was refined to a 
Rwork= 18.47% and Rfree= 22.20% at 2.4 Å resolution (Table 18 and 2.3.3). This model was used for 
subsequent structure analysis and interpretation. 
Evaluation of the X-ray structure with MolProbity (Davis et al., 2004) revealed 1.06% of the residues 
as Ramachandran outliers and 95.87% Ramachandran favoured residues, as well as 0% bad bonds, 
1.04% bad angles, and 4.03% poor rotamers, mostly in loop regions with high B-factor sidechains and 
missing electron density.  
 
Table 18. Human mitochondrial RNAP X-ray diffraction and refinement statistic 
 
Data set Native (A3) Native (J1) 
Data collection   
Space group I 41 I 41 
Unit cell axis 
a, b, c (Å) 
212.24, 212.24, 60,44 211.26, 211.26, 60.46 
Unit cell angles 
 () 
90, 90, 90 90, 90, 90 
Wavelength (nm) 1.0717 1.0000 
Resolution (Å)* 41.99-2.80 58.128-2.40 
Rmerge (%)* 8.8 (90.7) 5.1 (89.6) 
I/σ (I)* 7.0 (1.2) 14.2 (1.4) 
Completeness (%)* 99.5 (99.4) 99.8 (99.3) 
Redundancy* 3.3 (3.3) 3.8 (3.8) 
Refinement   
Resolution (Å) 41.99-2.81 24.00-2.40** 
No. reflections 32879 52497 
Rwork (%) 22.94 18.47 
Rfree (%) 25.92 22.20 
No. atoms   
    Protein 7069 7588 
    Ligand/ion 1 2 
    Water - 228 
B-factors (Å2)   
    Protein 105.3 92.7 
    Ligand/ion 135 132 
    Water - 73.9 
r.m.s.d. from ideal   
    Bond lengths (Å) 0.009 0.009 
    Bond angles (°) 1.37 1.18 
 
*Highest resolution shell is shown in parenthesis. 
Rmerge = Σ |I - <I >|/Σ | where I is the integrated intensity of a given reflection.  
R = Σ ||Fobs| - |Fcalc||/Σ | Fobs|. Rfree was calculated using 5% of data excluded from refinement. 
** AutoBuster deleted 50 low resolution reflections during refinement leading to a lower (24 Å) high resolution limit. 
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 Visible in the structure are amino acids 218-1230, just lacking a loop adjacent to the 
intercalating hairpin (AA 592-602), the tip of the intercalating hairpin (AA 613-614), parts of the 
thumb (AA 736-769) and the specificity loop (AA 1086-1105) (Figure 12). This is consistent with 
flexible and protease-digested parts. To elucidate wether some of these non-visible parts are lacking 
because of protease-digestion, point mutations in human mitoRNAP were introduced at Arg residues 
adjacent to these breaks and providing enough space in crystal packing (R598A, R601A, R613A and 
R1108A). The solved structure (data set B4) of this mutant did not provide additional density in the 
missing parts, pointing to flexibility  
Interestingly, density for one additionally bound negatively loaded ligand was found in the active 
center. Since the crystallization buffer only revealed (NH4)2SO4 as a salt, SO42- was build in this 
density.  
3.2 Conserved C-terminal catalytic domain 
MitoRNAP belongs to the pol A family of nucleotidyltransferases and shows the characteristic shape 
of a right hand with palm, fingers, and thumb subdomains (Figure 12).  
 
 
Figure 12. Crystal structure of human mitoRNAP.  
(a) Two views of a ribbon model of the human mitoRNAP structure with the major domains and structural elements 
indicated. The C-terminal domain (CTD) that is conserved in all ss RNAPs is coloured in dark gray, the N-terminal domain 
(NTD) is in silver, and the PPR domain is in blue. The N-terminal extension helix is shown in sand. The active site is 
indicated by a magenta sphere for a modelled catalytic metal ion. (b) Schematic comparison of mito and T7 (PDB 1QLN) 
RNAPs. Prominent structural elements are indicated. MitoRNAP-specific residues 1-368 include the mitochondrial targeting 
signal, the N-terminal extension, and the PPR-domain. Regions in mitoRNAP that are not visible in the crystal structure 
include residues 592-602, 736-769, and 1086-1105. 
 
 
Note that throughout this manuscript, we use the canonical polymerase domain nomenclature, and also 
the previously defined names for T7 RNAP functional elements (Cheetham et al., 1999; Durniak et al., 
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2008), even if these names include a functional implication that is specific for T7 RNAP and not born 
out in mitoRNAP.  
The highly conserved palm in the CTD superimposes well with the corresponding palm in T7 RNAP 
(r.m.s.d. 1.0 Å over 121 backbone atoms). The high conservation of the active center, including the O-
helix, suggests that the mechanisms of substrate binding and selection are conserved between 
mitoRNAP and T7 RNAP (Temiakov et al., 2004; Yin and Steitz, 2004). The O-helix binds a sulphate 
ion with its residues R987, K991, and K853 of the palm subdomain (Figure 13a and b) near the 
position of the phosphate groups of an incoming nucleoside triphosphate (NTP) in the T7 RNAP 
elongation complex (EC) (Temiakov et al., 2004; Yin and Steitz, 2004). While a portion of the thumb 
(residues 736-769) and the flexible specificity loop (residues 1086-1105) are not visible in the 
mitoRNAP structure, the adjacent elements in the CTD occupy almost identical positions as in T7 
RNAP, suggesting a similar orientation and functional role for these elements.  
 
 The most notable difference between the CTD of T7 RNAP and mitoRNAP is the position of 
the fingers subdomain, which is rotated ~25° as a rigid body approximately around the axis of the O-
helix, accompanied by a tilting of the O- and Y-helices (Figure 13a). These movements result in a 15 
Å translation of the N-terminus of the Y-helix towards the PBD. The observed position of the fingers 
domain is distinct from the previously observed positions in the ’closed‘ EC structure of T7 RNAP, in 
which the O-helix is positioned to deliver the substrate NTP into the active site (Yin and Steitz, 2004) 
(Figure 13b). We refer to this novel RNAP conformation as ’clenched‘. In the clenched conformation, 
the entrance to the active site is occluded by Y-helix residue Y1004, a conserved residue in ss RNAPs 
implicated in downstream duplex melting (Tahirov et al., 2002; Yin and Steitz, 2002). Thus, the 
clenched conformation is unlikely to occur during the nucleotide addition cycle. 
 
 
 
Figure 13. Active center region.  
(a) A superimposition of the active center regions of mitoRNAP (gray) and the T7 RNAP initiation complex (PDB 1QLN) 
(light pink) reveals a rigid body rotation of the fingers domain around the O helix axis. Template DNA is in blue, RNA is in 
red. The clenched, catalytically incompetent conformation of the fingers domain in mitoRNAP results from a ~25° rotation 
around the O-helix. Conserved catalytic residues, residues implicated in NTP binding, and a sulphate ion are shown with 
sticks. (b) A superimposition of the active center regions of human mitoRNAP (gray) and the T7 RNAP elongation complex 
(PBD 1S76) (light pink) reveals the difference between the clenched (mitoRNAP) and closed conformation (T7 RNAP) of 
the fingers domain. The incoming ATP and the catalytic Mg2+ ions (magenta spheres) in the T7 structure are depicted. 
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3.3 Distinct N-terminal domain 
The large N-terminal region of mitoRNAP (residues 1-647, Figure 12b) shares no sequence homology 
with T7 RNAP. Nonetheless, the C-terminal part of this region (residues 369-647) is structurally 
similar to the N-terminal domain of phage RNAPs, and we thus refer to it as N-terminal domain 
(NTD). In particular, the six-helix bundle of the PBD in phage RNAPs, which includes helices D, E, 
F, G, I and J, has a counterpart in mitoRNAP (Figure 14). However, there are notable changes in the 
orientation of the helices in the PBDs of mitoRNAP and T7 RNAP, resulting in a very high r.m.s.d. 
value of 9 Å for 109 backbone atoms. Compared to T7 RNAP, the N-terminal part of the PBD 
(residues 425-519) is rotated by 32°, whereas the C-terminal part (residues 567-654) is rotated by 24° 
in mitoRNAP.  
The structure reveals the loops corresponding to the intercalating hairpin and the AT-rich recognition 
loop of T7 RNAP. The hairpin connects the conserved helices I and J, and has a 14- residue insertion 
that is partially visible in the mitoRNAP structure (Figure 14a). The loop that connects helices D and 
E of the PBD corresponds to the AT-rich recognition loop, but is shorter, whereas the D-helix is 
extended as compared to T7 RNAP (Figure 14b and c). Other significant differences in the NTD of 
mitoRNAP involve the absence of a distal helix C, shortening of the F and G helices, and an 
alternative fold of the region located at the position of subdomain H in T7 RNAP. In contrast to N4 
RNAP, where subdomain H is absent (Figure 14d), it is likely that this structural element of the 
mitoRNAP NTD undergoes refolding during the transition from initiation to elongation, to form a part 
of an RNA exit pore, as described for T7 RNAP (Tahirov et al., 2002; Yin and Steitz, 2004). 
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Figure 14. Variation in RNAP N-terminal domains. 
(a) Sequence alignment and structural conservation of human mitoRNAP and T7 RNAP (PBD code 1QLN). Secondary 
structure elements are indicated above and below the sequences for mitoRNAP (residues 368-654) and T7 RNAP, 
respectively (cylinders for α-helices, arrows for β-strands, lines for loops). The promoter-binding domain (PBD) is in pink, 
the C-helix in yellow, and subdomain H in green. The AT-rich recognition loop (orange) and the intercalating hairpin are 
indicated. Identical residues are highlighted in red. Dashed lines indicate regions that are not visible in the mitoRNAP 
structure. (b-d) Comparison of the NTDs of mitoRNAP (residues 368-676) with ICs of T7 RNAP (PBD 1QLN) and N4 
RNAP (PBD 3Q24). Structures are aligned with respect to their conserved palm subdomains. Colour code and residue 
borders of the elements of the NTD are the same as in (a). RNA is in red, the template strand DNA in blue, and the non-
template strand in cyan. From the CTD (gray or light pink), only the palm subdomain (residues 790-831, 911-937, and 1125-
1178) and the thumb (residues 677-790) are shown. 
 
 
3.4 Unique PPR domain and N-terminal extension 
The NTD of mitoRNAP is connected through a rigid proline-rich linker to a unique helical domain 
(Figure 15). This domain (residues 218-368) consists of nine α-helices, of which four compose two 
PPR motifs found in plant and mitochondrial proteins (Lightowlers and Chrzanowska-Lightowlers, 
2008; Small and Peeters, 2000). We therefore refer to this domain as the ‘PPR motif-containing’ 
domain, or PPR-domain. PPR motif-containing proteins are suggested to be involved in RNA editing 
or processing (Aphasizheva et al., 2011; Hammani et al., 2011), but their structures are unknown.  
 
 Our structure of the PPR domain shows that the conserved residues of the PPR motif form 
the hydrophobic core of a helix-turn-helix fold, and the interface between antiparallel α- helices (αD´ 
with αE´, αE´ with αF´, and αF´ with αG´) and parallel helices (αE´ with αG´) (Figure 15a, b). The 
PPR domain is tightly attached to the NTD as the helices αA´ and αB´ form a large hydrophobic 
interface (~950 Å2) with the tip of the AT-rich recognition loop and its flanking helices αE and αD 
(Figure 15c). The interactions of the PPR domain with the NTD are stabilized by a salt bridge between 
R225 and E574 and numerous hydrogen bonds (Figure 15c).  
 
 It was reported that the gene encoding mitoRNAP undergoes alternative splicing, resulting in 
a truncated version (spRNAP IV, residues 263-1230) that lacks a mitochondrial targeting signal and 
localizes to the nucleus (Kravchenko et al., 2005). The structure of mitoRNAP suggests that removal 
of the first 262 residues will truncate and disconnect the PPR domain from the mitoRNAP body. This 
would expose large hydrophobic surfaces on both the N-terminal domain and the PPR motif 1 (more 
than 1000 Å2). Consistent with this, attempts to express a previously described nuclear single-
polypeptide RNAP IV (Kravchenko et al., 2005) in both prokaryotic and eukaryotic systems resulted 
in an insoluble protein (Sologub and Temiakov, personal communication).  
 
 Most of the region N-terminal of the PPR domain, called here the N-terminal extension, is 
invisible in the structure, except a single unassigned α-helix bound to a hydrophobic pocket formed by 
αF´ and αG´ of the PPR domain (Figure 15b). The mobile N-terminal extension of human mitoRNAP 
is required for function since deletion of the N-terminal 200 residues results in a truncated polymerase 
that is catalytically active but unable to initiate promoter-directed transcription (Figure 24 in Appendix 
IV 3). This is in contrast to yeast mitoRNAP (RPO41) in which even a larger deletion of the N-
terminal region (270 residues) has no effect on transcription activity (Paratkar et al., 2011). 
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Figure 15. PPR domain. 
(a) Sequence alignment of human mitoRNAP PPR domain, including PPR motifs 1 and 2, with predicted PPR motifs in 
mitoRNAPs of different species (lines 2-4), and chloroplast-targeting proteins of plants (lines 5,6). Abbreviations are as 
follows: H.s. Homo sapiens, M.m. Mus musculus, X.l. Xenopus laevis, D.m. Drosophila melanogaster, Z.m. Zea mays, A.t. 
Arabidopsis thaliana. Residues that are identical, highly conserved, conserved, or distinct, are highlighted in red, orange, 
yellow, and green, respectively. (b) Structure of PPR domain (blue) with PPR motif 1 (light cyan) and 2 (light blue). Each 
PPR motif shows a helix turn helix fold. Helices αA´ and αB´ are adjacent to the NTD (silver) and interact with the AT-rich 
recognition loop (orange). PPR motif 1 interacts with a helix in the N-terminal extension (sand). (c) Interface between PPR 
domain and NTD. Colours are as in (a). Interface residues are shown in stick representation. 
 
 
3.5 Promoter binding  
An intriguing question in mitochondrial transcription is what structural changes in mitoRNAP, relative 
to T7 RNAP, render mitoRNAP reliant on the initiation factors TFAM and TFB2M. Foot-printing 
experiments suggest that mitoRNAP (in complex with TFB2M) occupies a relatively small region of 
upstream DNA when compared to T7 RNAP - 14 vs. 17 bps, respectively (Gaspari et al., 2004a; 
Sologub et al., 2009) (Figure 16a). The rest of the upstream promoter region in mammalian mitoDNA 
(-35 to -15) is covered by a TFAM dimer (Gangelhoff et al., 2009; Gaspari et al., 2004a) suggesting 
that mitoRNAP and T7 RNAP use different modes of promoter binding.  
 
 To explore this, we modeled the putative trajectory of upstream promoter DNA in 
mitoRNAP by superimposing the palm subdomains of mitoRNAP and the T7 RNAP IC (Figure 16b). 
In the model, upstream promoter DNA runs along the NTD, and the template single strand descends 
into the mitoRNAP active site (Figure 16b and 13). The model predicts that the tip of the specificity 
loop may reach into the major groove of promoter DNA and read the sequence between -6 and -11 bps 
while its base may interact with the phosphodiester backbone of a single-stranded DNA, similar to its 
role in phage RNAPs (Cheetham et al., 1999; Gleghorn et al., 2008). This is consistent with functional 
analysis of point mutations in the specificity loop of yeast RPO41 (Nayak et al., 2009).  
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 The model further indicates that the AT-rich recognition loop has distinct functions in the 
two systems. Compared to T7 RNAP, helix D is rotated away from the minor groove of DNA by 45° 
and the tip of the AT-rich recognition loop is shifted by 22 Å in mitoRNAP (Figure 16c). The loop is 
sequestered by extensive interactions with the PPR domain (Figure 15c) and cannot bind DNA during 
initiation. Consistent with this, a mitoRNAP variant that lacks the PPR domain cannot initiate 
transcription (Figure 24 in Appendix IV 3) although it is predicted to contain a free AT-rich 
recognition loop. The positively charged residues important for promoter interactions by T7 RNAP are 
not conserved in the mitoRNAP loop (Figure 16d), and mutations R458A/R464A have no effect on 
transcription activity (Figure 25 in Appendix IV 3). These results indicate that human mitoRNAP does 
not use its AT-rich recognition loop for promoter binding, explaining why it depends on transcription 
factors for initiation. The AT-rich recognition loop also has a different structure and function in RNAP 
of phage N4, where it recognizes a hairpin promoter (Gleghorn et al., 2008) (Figure 14d).  
 
 Unlike human mitoRNAP, yeast RPO41 does not require a TFAM homolog for initiation 
(Dairaghi et al., 1995a). Foot-printing data indicate that the DNA region from -17 to -13 in the AT-
rich yeast promoter is protected from DNase I cleavage by RPO41/Mtf1 (Schinkel et al., 1988) (Figure 
16a). Analysis of the putative AT-rich recognition loop of RPO41 from various yeast RNAPs indicates 
the presence of a highly conserved arginine at a position analogous to T7 RNAP R99, which is 
responsible for interactions with the phosphodiester backbone in promoter DNA between bases -16 
and -17 (Cheetham and Steitz, 1999) (Figure 16d). Thus mitoRNAPs from lower eukaryotes may use 
the AT-rich recognition loop for promoter binding. In addition, the PPR domain may contribute to 
promoter binding as suggested by its close proximity to upstream DNA in the IC model (Figure 16b). 
 
 
 
Figure 16. Promoter binding.  
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(a) Differences in topology of the ICs of T7, yeast and mammalian mitochondrial transcription machineries, based on foot-
printing data and functional assays. Mammalian mitochondrial transcription critically depends on the presence of TFB2M 
and TFAM that occupies upstream promoter region, whereas yeast RPO41 requires only Mtf1 for efficient transcription. (b) 
Modelled location of upstream promoter DNA on mitoRNAP, based on a superimposition with the T7 RNAP IC structure 
(PDB ID 1QLN). MitoRNAP is depicted as a molecular surface. Loops in mitoRNAP that interact with DNA in the T7 
system are indicated. The portion of the specificity loop not visible in the structure is modelled based on the corresponding 
T7 loop (dashed line). The AT-rich recognition loop is buried by the PPR domain (blue) and not seen. The intercalating 
hairpin (rose) is shifted by 7 Å compared to its position in T7 RNAP, and clashes with the template DNA strand. The clash is 
also observed between the fingers domain and the +1 template base. (c) Superposition of the PBDs of mitoRNAP (silver) and 
T7 RNAP (PBD 1QLN, salmon). The AT-rich recognition loop (orange) is shifted and rotated by 45°. (d) Sequence 
alignment of AT-rich recognition loop and adjacent helices in mitoRNAPs of mammals and yeast, and in T7 RNAP. 
Abbreviations are the following: H.s. Homo sapiens; A.m. Ailuropoda melanoleuca; B.t. Bos taurus; M.m. Mus musculus; 
R.n. Rattus norvegicus; C.f. Canis lupus familiaris; M.d. Musca domestica; S.c. Saccharomyces cerevisiae; Z.r. 
Zygosaccharomyces rouxii; L.t. Lachancea thermotolerans; C.g. Candida glabrata; K.l. Kluyveromyces lactis; A.g. Ashbya 
gossypii; P.p. Pichia pastoris; C.l. Candida lusitaniae; L.e. Lodderomyces elongisporus; S.p Schizosaccharomyces pombe. 
The colour scheme is the same as in Figure 4. Percent homology is indicated to the right of the panel. The positions of 
nonconserved arginines in human mitoRNAP AT-rich recognition loop are indicated by arrows. Asterisks indicate residues in 
T7 RNAP involved in promoter interactions. 
 
 
3.6 Promoter melting 
The mitoRNAP structure reveals two major differences to T7 RNAP that help rationalize the loss of 
the enzyme’s ability to melt DNA by itself, explaining why TFB2M is required for promoter melting. 
First, the position of the intercalating hairpin is not compatible with promoter melting as observed in 
T7 RNAP (Figure 14b and c). The tip of the loop is translated 7 Å away from its position in T7 and 
clashes with the template strand of DNA (Figure 16b). Second, a 25° rotation of the fingers domain 
towards the NTD (Figure 13a) blocks access of the single-stranded DNA to the active site. This brings 
the tip of the intercalating hairpin within contact distance of the Y helix, suggesting that 
rearrangements of these two elements may be coupled (Figure 12).  
 
 Two mechanisms of promoter melting may be anticipated that involve TFB2M. First, 
binding of TFB2M may reposition the intercalating hairpin so it can function as in T7 and N4 RNAP 
(Cheetham et al., 1999; Gleghorn et al., 2008). Second, unlike the situation in phage RNAPs, the 
intercalating loop may not function in DNA melting, and instead an unidentified structural element in 
TFB2M may trigger melting.  
 
 To investigate this, we constructed variants of mitoRNAP lacking five residues at the tip of 
the intercalating hairpin (Δ613−618), or an insertion to this loop (Δ591-601) that is not present in 
phage RNAPs. We found that these enzymes had an activity similar to the wild type on a premelted 
‘bubble‘ LSP promoter template (Figure 17a). However, when analyzed in run-off assays using 
double-stranded LSP, the activity of the mutant RNAPs was dramatically decreased suggesting defects 
in promoter melting and thus the importance of the intercalating hairpin region for this process (Figure 
17a).  
These results indicate that TFB2M binding to mitoRNAP repositions the intercalating hairpin so it can 
participate in DNA melting. 
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Figure 17. Promoter melting. 
(a) An intercalating hairpin region is required for promoter melting in mitoRNAP. Transcription run-off assays with wild-
type and mutant RNAPs were performed using bubble (left panel) and double stranded (right panel) LSP promoter templates 
for 30 min at 35°C. Transcription factors TFAM (50nM) and TFB2M (150 nM) were added to the reactions that involved the 
double stranded template (right panel, lanes 1-6) while transcription using the bubble template was factor-independent (left 
panel, lanes 1-3). Products of the reaction were resolved using 20% PAGE containing 6M urea, and analyzed using a 
PhospoImager. (b) Model of mitochondrial transcription IC. The Mtf1 yeast homolog structure (PDB 1I4W) is shown as a 
violet ribbon. MitoRNAP is shown as an outline and the promoter DNA was modelled as in Fig. 5. The intercalating hairpin 
and specificity loop (light pink ribbon) are shown to occupy positions as in T7 RNAP IC. Positioning of Mtf1 was done as 
described in the text, enabling the C-terminal tail of Mtf1 to use the passage between the thumb and the intercalating hairpin 
to reach the active site. (c) Opening for TFB2M insertion region passage to the mitoRNAP active site. Regions in 
mitochondrial, T7 and N4 RNAPs involving the thumb, intercalating hairpin and adjacent helices are presented in the same 
orientation of the corresponding CTDs. Note that only in mitoRNAP there is an opening for the Mtf1/TFB2M insertion 
region to reach the active site. 
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3.7 Initiation complex model 
To further explore the initiation mechanism, and to rationalize the available biochemical and genetic 
data, we built a model of a mitochondrial transcription IC.  
 
 Since the human TFB2M structure is unknown, we combined the structure of its yeast 
homolog (Schubot et al., 2001) with the human mitoRNAP, which is expected to closely resemble its 
yeast counterpart RPO41 (Figure 17b). During modeling, we placed Mtf1 onto mitoRNAP without 
generating steric clashes, and assumed that the Mtf1 N-terminal region contains RNAP-binding 
determinants (Shadel and Clayton, 1995), that the Mtf1 C-terminal domain reaches the active site 
(Savkina et al., 2010), that the 16 most C-terminal residues of Mtf1 contact promoter DNA (Savkina et 
al., 2010; Schubot et al., 2001), that Mtf1 binding involves the specificity loop and intercalating 
hairpin (Cliften et al., 2000), and that Mf1 interacts mostly with the promoter at positions -7 to +3 
(Savkina et al., 2010). We further assumed that binding of Mtf1 involves the NTD of mitoRNAP that 
likely undergoes refolding upon the transition from IC to EC as in T7 RNAP, thereby displacing Mtf1 
upon RNA synthesis (Mangus et al., 1994).  
 
 The model suggests that the Mtf1 C-terminal ‘insertion’ domain reaches the templating +1 
DNA base via a narrow opening between the intercalating hairpin and the thumb domain (Figure. 
17b). The mobile extension of the insertion domain may occupy the predicted RNA path, consistent 
with biochemical data (Savkina et al., 2010; Sologub et al., 2009). The region that constitutes the 
opening for Mtf1/TFB2M passage is substantially different in structures of phage RNAPs. In T7 
RNAP, the opening is blocked by the loop between helices F and G (FG loop) and helix J at the base 
of the thumb (Figure 17c). In N4 RNAP, a large insertion into the FG loop (’plug’, Figure 17c) 
occludes the RNA/DNA hybrid binding cavity (Gleghorn et al., 2008; Murakami et al., 2008).  
 
 These considerations indicate that penetration of TFB2M into the opening leading to the 
active site could reposition the intercalating hairpin and the fingers subdomain, such that these 
elements function in promoter melting. In addition, TFB2M may stabilize an early transcribing 
complex by binding to the melted template strand and/or the incoming NTPs as suggested previously 
(Sologub et al., 2009). 
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4 Conclusions and Outlook 
The first structure of a mitoRNAP reveals N- and C-terminal domains that are related to phage 
RNAPs, but also contain pronounced structural differences, and a novel PPR domain and a flexible N-
terminal extension. Some surface loops that function in phage RNAPs to bind and melt promoter DNA 
are structurally trapped or altered, explaining the need for initiation factors. During evolution, an early 
phage-like mitoRNAP apparently acquired additional structural features, and lost functions in 
promoter binding and melting, that are now provided by initiation factors in trans. This may have 
enabled regulation of mitochondrial gene transcription and adaptation of mitochondrial function to 
changes in the environment. Similarly, multisubunit cellular RNAPs use a large variety of initiation 
factors to enable transcription regulation and to create promoter specificity. 
 
 
 Based on the structure of human mitoRNAP and the elucidated structural adaptions that 
enable mitoRNAP to become regulated by transcription initiation factors, new starting points for 
follow up projects arise. These should help to elucidate a complete picture of the mitochondrial 
transcription system. 
 
 
Functional assays to elucidate mitoRNAP specific mechanisms into more detail 
 
This work established the structural basis for the unique transcription initiation mechanism by 
mitoRNAP, assisted by TFAM and TFB2M. To confirm the hypotheses drawn from the structure, new 
mitochondrial RNAP mutants should be designed and analyzed in functional assays.  
Namely, it was already shown in this work by mutation of R458A/R464A, that the AT-rich 
recognition loop lost its function, at least in this mitoRNAP conformation. Additionally, the tip of the 
intercalating hairpin (613-717) and the adjacent loop (591-601) were deleted and transcription 
activity tested. Defects in promoter melting show the importance of these regions for melting and 
indicate that TFB2M binding to mitoRNAP probably repositions the intercalating hairpin so it can 
participate in DNA melting. Since V237 in the intercalating hairpin of T7 RNAP was shown to 
separate the template and non-template strand of DNA, mutation of V615 at the tip of mitoRNAP 
hairpin would probably have a similar functional role. 
Hence transcription assays with mitoRNAP carrying mutations in the specificity loop and intercalating 
hairpin should be performed. A likely conserved function of the specificity loop, a sequence-specific 
recognition of promoters, and identification of essential residues can be investigated with these 
mutants.  
 
 
Structural investigations of full length or of larger variants of mitoRNAP 
 
Since this work finished with the published mitoRNAP structure, which misses the N-terminal 
extension (AA 1-217), and parts of the thumb (AA 736-769) and specificity loop (AA 1086-1105) (see 
also Appendix IV 4), a new focus should lie on investigation of full-length mitoRNAP.  
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 An analysis of the N-terminal extension could be highly rewarding. It was shown in this 
work that mitoRNAP200 (deletion of AA 1-200) is catalytically active but unable to initiate 
promoter directed transcription. Since the same deletion in yeast mitoRNAP has no effect on 
transcription activity (Paratkar et al., 2011), the N-terminal extension in human mitoRNAP may 
contain additional elements required for transcription initiation. Additionally, a splicing variant, which 
lacks the AA 1-262 (nuclear single-polypeptide RNAP IV) was identified and showed transcription 
activity in the nucleus (Kravchenko et al., 2005). Nevertheless, deletion of the N-terminal parts (sp 
RNAP IV) leads to insoluble protein (unpublished data by Sologub and Temiakov). 
 
To crystallize a larger variant of mitoRNAP, co-crystallization with nucleic acids or interacting 
proteins like TFB2M and/or TFAM should be used, since previous crystallization trials with the apo-
enzyme were part of this study and only produced very tiny crystals. They grew to only 50-80 µm long 
needle-like crystals, diffracting only up to 14 Å and therefore were not sufficient for structure 
determination.  
 
 Also parts of the thumb, specificity loop and AT-rich recognition loop adjacent regions were 
not resolved in the structure. Attempts in this study to mutate possible cutting sites of the used 
trypsin/Arg C proteases in these regions (R598, R601, R613, and R1108) did not help to resolve the 
missing residues, suggesting that flexibility is the reason for the failure. Structure solution of these 
parts will be simplified by crystallization of mitoRNAP with scaffolds, since these motifs are adjacent 
and will hopefully be stabilized by nucleic acids.  
 
 
Structure/ function analysis of the novel PPR domain 
 
The structure of mitoRNAP also presents the first atomic model for a PPR-motif containing domain. 
However the proposed function as a RNA-binding domain or other functions still have to be 
investigated. The mitoRNAP structure reveals a positively charged surface patch on the PPR domain, 
which indicates a possible enlarged trajectory for promoter DNA or a role of the PPR domain in 
building a RNA binding surface comparable with the RNA exit tunnel found in T7 RNAP ECs. A 
structure of mitoRNAP with a bound promoter DNA or longer elongation scaffolds would help to 
establish a functional role of the PPR domain. Also binding and transcription assays of promoter DNA 
or elongation scaffolds with mitoRNAP proteins, whose PPR residues that build the surface accessible 
charged patch are mutated, can help to identify these possible roles of PPR domains. 
 
 
Crystallization of mitoRNAP in numerous functional states and in complex with transcription 
factors 
 
Furthermore the structure should serve as a model for structural follow up projects to elucidate 
structures of mitochondrial RNAP trapped in different functional states.  
 
 Experimental strategies can be copied from the T7 RNAP field. By binding of mitoRNAP to 
different RNA/DNA bubble scaffolds and adding either nonhydrolyzable substrate NTPs or 
3´deoxyNTP and PPi, elongation states can be mimicked, like an insertion (substrate) complex, pre-
translocation (product) complex (compare (Yin and Steitz, 2004)), post-translocation complex 
(Tahirov et al., 2002; Yin and Steitz, 2002), and a pre-insertion (substrate) complex (Temiakov et al., 
III ■ Structure of human mitoRNAP                                                                                  Conclusions and Outlook 
76  
2004). Structural changes at the active site of mitoRNAP during one nucleotide addition cycle can be 
analyzed and the exact substrate selection, binding, nucleotidyl transfer reaction and translocation 
mechanisms investigated. Since ss RNAPs do not have proofreading activity (Huang et al., 2000), 
these steps are extremely important to impede extended misincorporations. Although all catalytic 
residues are conserved between mitoRNAP and T7 RNAP, these mechanisms may differ, since a 
unique, “clenched” active site conformation was found in the structure of mitoRNAP (movements of 
fingers subdomain and F/G-helices, and occlusion of active site by Y1004).  
 
 Also initiation states of the mitochondrial transcription system should be structurally 
analyzed in future projects. IC conformations involve binding of mitoRNAP to promoter ds DNA, 
TFB2M and TFAM, whereby TFB2M interacts with both TFAM and mitoRNAP as well as with 
promoter DNA and possibly bridges and stabilizes promoter contacts during initiation (Litonin et al., 
2010; Sologub et al., 2009). Both transcription factors can be purified recombinantly (Sologub et al., 
2009) and used for in vitro IC reconstitutions and crystallization trials. Possible ICs, described 
subsequently from low to higher complexity, include the complex of mitoRNAP and TFB2M, the 
complex of mitoRNAP with TFB2M and a bubble ds DNA and the complex of the complete IC with 
mitoRNAP, TFB2M, TFAM, and ds DNA. 
 
 An interesting feature of mitoRNAP is its activity as a primase for mitoDNA replication. 
Molecular details of the initiation of primer synthesis in the replication process can be structurally 
investigated. Since mitoRNAP transcribes the reverse primer at the second replication start site (OriL) 
on the H-strand, where DNA forms a single-stranded hairpin, without the help of TFAM and TFB2M 
this hairpin promoter can be used to elucidate this special initiation process.  
 
 It is suggested that transition from initiation to elongation takes place, when the growing 
RNA clashes with the F/G helices, leading to abortive initiation and in the case of T7 RNAP, refolding 
of the N-terminus. For mitoRNAP, maybe the same transition releases TFB2M. To elucidate transition 
from initiation to elongation into more detail, scaffolds with different lengths of RNA can help to 
identify and crystallize transition states, like an intermediate state, where the mitoRNAP is bound to 
both the promoter and downstream DNA (compare (Steitz, 2009)). Thereby possible refolding of the 
N-terminal domain, as found in T7 RNAP, can be structurally investigated as well as subsequent 
changes and loss of the interaction with (TFAM and) TFB2M.  
 
 
Crystallization of mitoRNAP with regulatory proteins 
 
 Furthermore, complex structures with regulatory factors (and DNA) beside the decribed 
TFAM and TFB2M can be attempted. For example mTERF is an interesting candidate. In human four 
mTERF proteins are predicted (Linder et al., 2005) and suggested to have termination activity. 
However direct association with mitoRNAP was not tested so far (Gaspari et al., 2004b). 
 
 
 77  
 
 
 
 
 
 
 
 
 
IV 
 
 
■ ■ ■ 
 
 
Appendix 
 
 
 
 
 
 
IV ■ Appendix                                                                                                                                               to part II 
78  
Unpublished results to part II 
Beside the published Maf1 structure and functional and biochemical assays, which were combined 
with cryo EM reconstructions of RNAP III, RNAP III EC and RNAP III/Maf1 and thereby led to the 
investigation of the molecular basis of RNAP III transcription repression by Maf1, additional 
experiments were carried out. First the Maf1 structure and protein was characterized into more detail 
and second initial trials of the structural investigation of RNAP III-PIC were performed. This chapter 
can serve as an overview and for experimental design of future projects. 
1 Further Maf1 analysis 
1.1 Maf1 activity is possibly controlled by an internal 16 AA predicted 
helix 
The Maf1 protein was analyzed into more detail. ScMaf1 variants, which lacked striking parts of the 
protein, were designed based on the structure. Analyzed scMaf1 variants corresponded completely or 
partially to the crystallized h.s. Maf1 variant and fulllenght h.s. Maf1 and were used for in vivo 
phenotyping with complementation assays in yeast (Figure 18). Maf strains show a temperature 
sensitive growth defect on YPGly (Boguta et al., 1997). Interestingly, scMaf1 1-345, which lacks the 
complete acidic tail of 50 AA, fulfils normal Maf1-function under this stress condition. In contrast, the 
truncated crystallized Maf1 variant (sc Maf1 1-34536-224), which is able to bind to RNAP III 
(Figure 6), has a maf1 phenotype. This underlines the importance of the flexible linker, which was 
cut for crystallization reasons, in vivo. This linker comprises regulatory PKA-phosphosites and the Nt-
NLS sequence. Since scMaf1 mutants with destroyed NLS sequences or PKA-posphosites were shown 
to exhibit a wt growth on YPGly (37°C) (Moir et al., 2006), this phenotype is not explainable by 
deletion of these sequence motifs but rather by other effects. Additionally, also scMaf1 1-39636-52, 
which misses just a predicted helix at the N-terminus of the cut flexible linker, has a maf1 
phenotype. Thereby AA 36-52 are essential for the in vivo function of Maf1 but not for in vitro 
binding to RNAP III. Possible functions of this predicted helix include the binding of upstream 
regulators (phosphatases), of nuclear transport factors or of target proteins beside RNAP III (TFIIIB) 
and have to be further elucidated. 
Concordantly to binding experiments human Maf1 fl. is not able to complement the scMaf1 protein in 
yeast.  
 
 
Figure 18. In vivo properties of Maf1 variants. 
Described variants of s.cer. and h.s. Maf1 were analyzed in in vivo phenotyping assays as described (2.3.2.2). On the left 
panel serial spot dilutions on a YPD plate incubated at 37°C with normal growth of all yeast strains are shown. Right hand 
panel shows spot dilutions on a YPGly plate incubated 37°, indicating phenotyping effects with maf1 and some Maf1 
variants. 
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1.2 Single point mutations in Maf1 have no effect in vivo nor on RNAP 
III binding  
We wanted to analyze if single aminoacid residues on the Maf1 surface could influence scMaf1 
properties in vivo or its´ binding to RNAP III in vitro. Thereby one may identify residues, which are 
essential for Maf1´s activity.  
Based on the structure and sequence analysis of Maf1, conserved surface residues were mutated. Some 
of these residue mutations were already described in literature (Moir et al., 2006; Roberts et al., 2006). 
Namely, we could reproduce the in vivo phenotyping results that D248A, D250A, K329A/K331A 
showed no effect in glycerol growth assays (Figure 19C). Additionally, we investigated novel mutants, 
E272A, K233A, G316E, S263R, and D40N/R232H, which all did not change the phenotype and 
conclusively the Maf1 activity. May slight effects could be found with the point mutation R232H and 
D40A (Figure 19C), convergent with published observations of a growth phenotype of D40A/R41A 
and R232H (Moir et al., 2006; Roberts et al., 2006). Anyway, these phenotypes are probably not 
strong enough to draw any conclusion. Unfortunatly, the slight phenotypic mutants R232H and D40A 
were not tested in pulldown assays. 
Consequentially to a wild type phenotype of mutants D248A, K233A, and G316E also did not abolish 
RNAP III binding in vitro (Figure 19B). 
 Since no tested single point mutation showed a deficient in vivo phenotype nor reduced 
binding to RNAP III, the Maf1 binding surface to RNAP III and regulatory proteins is not affected. 
Propably, a larger surface takes part in this interaction.  
 
 
 
Figure 19. Analysis of Maf1 single point mutants.  
(A) Ribbon model of Maf1 structure (1-20536-82). Investigated residues are shown in ball and stick representation. 
Residues labeled in blue were analyzed by pulldowns in this study and did not abolish RNAP III binding. Other indicated 
residues were analyzed in in vivo phenotypic assays (see (C)). (B) Pulldown assays with endogenous RNAP III and 
recombinantly expressed and partly purified scMaf1 mutants. Gels show partly purified Maf1 mutants used for binding (lanes 
1, 4, 7, 12), negative control of unspecific Maf1 binding to the resin (lanes 2, 5, 8, 13) and the eluted fractions, indicating that 
all point mutants can still bind RNAP III (lanes 3, 6, 9, 14). (C) Described point mutants of yeast Maf1 f.l. were analyzed in 
in vivo phenotyping assays as described in (2.3.2.2). Serial spot dilutions of each Maf1 point mutant are shown in each line, 
respectively and growth on YPGly at 37°C was documented after 4 days.  
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1.3 Binding of scMaf1 to RNAP III is stronger than to TFIIIB and 
probably supported by interactions with multiple RNAP III subunits 
ScMaf1 binds recombinant Brf1 very weakly but specifically, which was shown in pulldown assays 
with autoradiography (Desai et al., 2005). Also human Maf1 associates weakly with Brf1, whereas 
binding to Brf2 is inconsistently found and even weaker (Reina et al., 2006; Rollins et al., 2007).  
For in vitro binding competition and transcription assays, we used the triple fusion protein Brf1N-
TBPC-Brf1C. We performed size exclusion chromatography experiments (2.3.1.4) to first check if we 
can detect binding of scMaf1 with Brf1N-TBPC-Brf1C and to compare the affinity with RNAP III 
binding. And secondly, to figure out if DNA-binding of Brf1N-TBPC-Brf1C potentially increases its 
affinity to Maf1, since this was not tested before but could be part of the inhibition mechanism. 
Under the chosen conditions no binding of Brf1N-TBPC-Brf1C with or without ds DNA could be 
detected, confirming a lower affinity compared to RNAP III and impairing a DNA-induced increase of 
affinity for TFIIIB (Figure 20A). Additionally, heavy degradation of Brf1N-TBPC-Brf1C in the absence 
of DNA could be detected (Figure 20A left panel). 
 
Additionally, we wanted to elucidate RNAP III subunits, which participate in Maf1 binding, into more 
detail, since a strong binding of scMaf1 to the complete RNAP III complex was shown (Figure 6). 
Firstly, the RNAP III subunit C34, which was found as one top interacting partner of Maf1 in the yeast 
interactome (Gavin et al., 2006), was analyzed. Pulldown and size exclusion binding experiments of 
scMaf1 fl with recombinantly purified C34 were performed (2.3.1.4). No binding could be detected 
(Figure 20B). 
Secondly, the N-terminal part of C160 (AA 1-235), which shows genetic interactions (Pluta et al., 
2001) and whose N-terminal 235 AA coimmunopurify with Maf1 from crude extracts in western blots 
(Oficjalska-Pham et al., 2006), was analyzed (2.3.1.5). The N-terminal part of C160 (AA 1-235) was 
cloned with a His6-Tag and cotransformed with a plasmid carrying scMaf1 fl. Coexpression and 
copurification did not succeed (Figure 20C). Possible reasons for failure can be suboptimal expression 
conditions, insufficient detection sensitivity (Coomassie-staining vs immunoblotting), and unproper 
folding of Nt-C160. 
These results may indicate that rather an overlapping binding surface of RNAP III can be expected to 
take part with multiple interactions in scMaf1 binding or a direct binding to C82, that was not tested or 
posttranslational modifications on RNAP III.  
 
 
Figure 20. Binding of scMaf1 fl to Brf1N-TBPC-Brf1C and RNAP III subunits.  
(A) Binding of sc Maf1 fl to the triple fusion protein Brf1N-TBPC-Brf1C (B´). Sample preparation and size exclusion runs on 
a Superdex 200 (10/300) column (GE Helathcare) were carried out with or without adding a 60 bp scaffold to Brf1N-TBPC-
Brf1C in advance (2.3.1.4 and 2.3.3.4). Each experiment was carried out with 2.5 nmol Brf1N-TBPC-Brf1C, a 2-fold molar 
excess of scMaf1 fl and a 2-fold molar excess of scaffold, when indicated. The left chromatogram shows the Maf1 control 
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curve (brown) and the assembled complex curve (blue). The right chromatogram shows only the complex assembly (orange 
curve). Peaks were analyzed by overlaying curves and on SDS-PAGEs. (B) Binding of scMaf1fl to scC34fl. Sample 
preparation, size exclusion runs on a Superose 12 (10/300) column (GE Helathcare), and pulldown assays were performed as 
described (2.3.1.4). The chromatrogram shows a control run with scMaf1 fl (green curve) and the assembled complex (blue 
curve). The SDS-PAGE of the pulldown experiment shows purified scC34fl (lane 1), partly purified scMaf1 fl (lane 2), and 
the pulldown sample of preassembled Maf1 and C34 (lane 3). (C) Binding of scMaf1fl to scC160 (1-235). Coexpression and 
purification was performed as described (2.3.1.4) with N-terminal His-tagged C160 and Maf1 without tag. The SDS-PAGE 
shows a sample after induction (lane 1), the soluble supernatant (lane 2), the first washing step on a Ni-column (lane 3), and 
eluted proteins (lane 4). Maf1 could be identified on the SDS-PAGE, C160 (M= 26 kDa) was not detected after 
overexpression or in later purification steps. 
 
1.4 Maf1 binds nucleic acids unspecifically 
Purification of Maf1 variants co-incidenced often with nucleic acids contaminations. ChIP 
experiments revealed an increased Maf1 occupancy on RNAP III-transcribed genes upon stress 
conditions (Oficjalska-Pham et al., 2006; Roberts et al., 2006), conversely to published data, which 
could not detect any direct or indirect interaction of Maf1 with DNA (Desai et al., 2005).  
To find out, if Maf1 can bind nucleic acids specifically, EMSA assays were performed (2.3.1.9). Since 
the Maf1 structure revealed positively charged surfaces, nucleic acid binding is supported and 
specificity can be assigned only sequence-wise. Double-stranded and single-stranded U6- and random-
sequence DNA were tested with scMaf1 fl and human Maf1 fl proteins (Figure 21). A band shift of 
double- and single-stranded scU6 DNA with increasing amounts of scMaf1 fl can be detected (Figure 
21A, left panel), indicating nucleic-acid binding properties of scMaf1 fl. Anyway, also double- and 
single-stranded random DNA bound to scMaf1 fl and led to band shifts (Figure 21A, right panel). 
Conclusively, scMaf1 fl binds ds and ss DNA in significant amounts but this binding is sequence 
unspecifically. Therefore it cannot be concluded if this binding is due to unspecific interactions with 
the positively charged surface or if it points to a scMaf1-property in vivo, for example a kind of 
scanning mechnism on DNA. 
Also human Maf1 fl protein binds to ds and ss U6 promoter DNA but to a much less extend (Figure 
21B). Maybe human Maf1 exhibits in vivo different properties compared to yeast, namely a reduced 
abilty to bind (U6 promoter) DNA. Different species-specific properties of Maf1 were described 
before, i.e. the ability of human Maf1 to repress TBP gene transcription (Johnson et al., 2007). 
Additionally, it was suggested, that human Maf1 does not affect transcription from U6 promoters 
((Reina et al., 2006) and unpublished data), thereby indicating a human specific mechanism on U6 
promoters. Or yeast Maf1 specific properties, like the longer flexible linker, leads just in in vitro 
EMSA assays to different results, thereby indicating non-specific and non-meaningful interactions 
with DNA. 
To elucidate these open questions more DNA-binding assays, including different promoter types have 
to be performed. 
 
IV ■ Appendix                                                                                                                                               to part II 
82  
 
Figure 21. Maf1 binding to nucleic acids.  
(A) Purified sc Maf1 fl protein was used for EMSA assays with ds and ss scU6 promoter DNA. Band shifts were inspected 
on 7.5% native polyacrylamidgels, stained first with SybrSafe (Invitrogen) (top row) and sequentially with Coomassie 
(bottom row). Gels On top on bottom are the same, respectively. 450 pmol sc or human Maf1 were loaded as negative 
controls (first lanes in boxes) and for each binding reaction and negative control 22.5 pmol DNA were used. (B) Same as (A), 
just human Maf1 fl instead of scMaf1 fl and human U6 promoter DNA instead of scU6 promoter DNA.  
1.5 Crystallization of sc Maf1 1-34552-224 
After solving the structure of a human variant of Maf1 (1-20536-82) we focused in a side project on 
crystallization of yeast variants. Thereby new structural and evolutional insights could be gained, 
namely by including missing parts of the Maf1 structure (missing -helix 2 or acidic tail) and solving 
the structure of another species, which we also had to use for all binding and activity experiments with 
yeast polymerase.  
The minimal soluble yeast variant was identified and lacked the flexible acidic tail (1-345). Since this 
construct failed in crystallization, we tested various constructs with different lengths of internal 
deletions spanning the flexible insertion and/ or predicted -helix 2, as done in human Maf1. Yeast 
variant 1-34552-224 gave initial crystals, which could be reproduced and improved by additives up 
to 250 µm and nice shape (Figure 22). Crystals were measured at the synchrotron, but diffracted just 
up to 4 Å and revealed high mosaicity. No structure determination could be obtained with collected 
data sets. Since reproducibility of growing nice crystals was not always given, future attemps should 
focus on crystallization protocols and improvement of freezing procedure.  
 
 
Fig 22. Reproduction and optimization of s. cer. Maf1 1-34552-224 crystals.  
Left picture shows initial hits in crystallization facility in conditions 50mM MES pH6, 4% MPD, 80 mM NH42SO4, 10 % 
PEG 8000 with 30 mg/mL protein concentration Right pictures show reproduced crystals (conditions see above, c(protein)= 
11 mg/mL, which grow up to ~200µm crystals in 50 mM MES 6.0, 80 mM (NH4)2SO4, 10%PEG8000, 12% MPD (third 
picture) and up to ~250µm crystals in conditions additionally adding 10 mM NaCl (right picture). 
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1.6 Transcription assays 
The activity of Maf1 to repress RNAP III transcription was successfully investigated with an in vitro 
RNA extension assay using a minmal scaffold (2.3.1.8) and with an initiation factor-independent in 
vitro transcription assay using a tailed template and GpG RNA primer (2.3.1.7) (for results see Figure 
9). 
Anyway, in the course of this study also in vitro RNA extension assays with complete complementary 
scaffolds (bead based) (2.3.1.8) and initiation factor-dependent in vitro transcription assays (2.3.1.6) 
were tried to establish. With the latter assay effects of transcription factors together with Maf1 can get 
analyzed in a more in vivo-like situation using Brf1N-TBPC-Brf1C and a template with a minimal 
bubble (-9 until -5) (Kassavetis et al., 2001). Unfortunatly, both assays did not work. Probably more 
effort has to be made to optimize the protocols for the RNAP III transcripton system. 
 
2 Cryo EM of minimal RNAP III PIC 
The minimal RNAP III PIC consists of promoter DNA bound to TFIIIB and recruited RNAP III 
(Joazeiro et al., 1994; Kassavetis et al., 1990). This complex composition is in highly purified systems 
sufficient to transcribe DNA of type III genes, which exhibit a strong TATA box, for example U6 
RNA genes (SNR6) (Gerlach et al., 1995). It was shown that the triple fusion protein Brf1N-TBPC-
Brf1C retains TBP and Brf1 function in vitro and is dedicated to RNAP III transcription (Kassavetis et 
al., 2005). The scaffold design based on recent findings, that an enlarged bubble (-16 until +2) 
compared to a normal bubble (-9 until +2) in the RNAP II leads to a more homogeneous sample 
assembly and bubble position ((Andrecka et al., 2009) and unpublished results). Additionally, TFIIIB 
footprinting results were used to design the U6 scaffold (Joazeiro et al., 1994). A 7mer RNA was used 
since the structure of RNAP II-TFIIB and a RNAP II PIC model (Kostrewa et al., 2009) revealed that 
a 8mer RNA still fits before transition from initiation to elongation and release of TFIIB takes place.  
A minimal RNAP III PIC was assembled (2.3.3.4). The peak fractions after size exclusion showed an 
A260/A280 ratio close to 1, a clear indication for binding of nucleic acids (Figure 23B). Coomassie 
and silver stained gels followed by MS-analysis confirmed the presence of all RNAP III subunits, the 
triple fusion protein Brf1N-TBPC-Brf1C, as well as the used scaffold (Figure 23C). The micrographs of 
the 100 µg/ml concentrated sample allowed careful particle picking and subsequent cryo EM 
reconstructions (Figure 23D and E). A reconstruction at 23 Å resolution from 10783 particles was 
performed by Dr. Anselm Kusser. 
 
 The resulting cryo EM structure of RNAP III generally agrees with the published RNAP III-
DNA-RNA complex (RNAP III EC) map (Vannini et al., 2010). Namely, the reconstruction revealed 
density for nucleic acids in the cleft and, compared to RNAP II, additional densities for C82/34/31 and 
C53/37 (Figure 23E), which were fitted according to unpublished crosslinking data (Stefan 
Jennebach). The well defined density for C53/37 at the lobe, which is larger as the corresponding part 
in the published RNAP-EC, demonstrates the quality of this reconstruction. Interestingly, density 
assigned to C82 is slightly shifted from the clamp to the Rpb5 jaw (middle and right panel of Figure 
23E). Two C34 winged helix domains (PDB 2dk5 and 2dk8) were positioned on top of the clamp. 
Since the triple fusion protein Brf1N-TBPC-Brf1C adds another 90 kDa to the PIC, additional density 
should be observed. Additional density compared to RNAP III-EC can be seen at the protrusion. 
Different folded parts can be observed close to the dock and wall domain. The RNAP III-Brf1-TBP 
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closed promoter complex model suggests that Brf1 can be expected here. However the additional 
density does not account for 90 kDa, which can be explained most probably with the flexibility of Brf1 
(Juo et al., 2003; Kassavetis et al., 1997) and substoichiometric issues imposed to the complex upon 
freezing on the grid.  
Interestingly, another area with additional density compared to RNAP III can be clearly seen at the 
funnel. This was described before for the RNAP III EC, but appears even more prominently in this 
reconstruction of the RNAP III PIC. Due to the lack of data this density cannot be explained for the 
time being. 
 
 
 
Figure 23. Cryo-EM reconstruction of RNAP III PIC complex. 
(A) 60 bp scaffold used for PIC assembly. (B) Size-exclusion chromatogram of PIC assembly, constituting of 50 µmol 
RNAP III supplemented with C53/37, 500 µmol Brfc/TBPc/Brfn and scaffold. For exact procedure see 2.3.3.4. (C) SDS-
PAGE gel of purified yeast RNAP III. Lane 2 shows the assembled PIC after size-exclusion. The identity of the bands was 
confirmed by mass spectrometry (not shown). The 17 subunits are present in lane 3. Lane 4 shows recombinantly purified 
Brfc/TBPc/Brfn . Recombinantly purified C53/37 subunits are shown in lane 5 and were supplemented to endogenous purified 
RNAP III. (D) EM micrograph of RNAP III in vitrified ice. White circles indicate particles. (E) Cryo-EM reconstruction of 
RNAP III (purple) and RNAP III-DNA-RNA (EC) complex (blue). The 12 subunit RNAP II crystal structure (ref…) or the 
10-subunit RNAP III core homology model and the C25/17 crystal structure (Jasiak et al., 2006) were fitted to the map and 
are shown as ribbon models in the left and middle panel, respectively. The locations of C82 and C34 were assigned by 
combining unpublished crosslinking results with the published envelope of the RNAP III EC complex (Vannini et al) to 
localize these subunits more accurately (Stefan Jennebach, unpublished results). 
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Supplemental and unpublished results to part III 
3 Characterization of human mitoRNAP mutants in run-off 
assays 
In order to analyze the functional activity of the crystallized human mitoRNAP mutant (AA 105-1230) 
and of mutants, which miss the N-terminal extension (1-200) and additionally the PPR domoin (1-
368), run-off transcription assays were performed in the laboratory of D. Temiakov. Results and 
discussion are described in chapter 3 part III of this work and part of the submitted manuscript.  
 
 
Figure 24. Activity of the N-terminal deletion mutants of human mitoRNAP. 
(a) Templates used in the transcription assays. The light strand promoter (LSP) templates were prepared as described 
(Sologub et al., 2009) using synthetic oligonucleotides. The pre-melted (“bubble”) template contains a 7 bps mismatched 
region in the non-template strand (highlighted in red). (b) Activity of deletion mutants on a pre-melted “bubble” promoter 
template. Transcriptions reactions were carried out as described (Sologub et al., 2009) using wild-type (WT), D104 (residues 
105-1230), D200 (201-1230) and D368 (369-1230) mitoRNAPs for 30 min at 35°C in the absence of transcription factors 
TFAM and TFB2M. (c) Activity of deletion mutants on a double-stranded promoter template. Transcriptions reactions were 
carried out with WT (lane 1) and mutant mitoRNAPs (lane 2-7) in the presence or absence of TFAM and TFB2M as 
described (Sologub et al., 2009). 
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To characterize the function of the AT-rich recognition loop into more detail, run off transcription 
assays were preformed using a human mitoRNAP with mutations R458A/R464A (compare Figure 
5d).  
 
Figure 25. Substitution of residues R458 and R464 in the AT-rich recognition loop of human mitoRNAP does not change its 
transcription activity. 
(a) R458A/R464A mutant mitoRNAP is fully catalytically active. Elongation complex formed using the mutant mitoRNAP 
and R8/TS1/NT1 scaffold containing P32-labeled RNA (0.25 mM,(Temiakov et al., 2002)) was extended in the presence of 
10 mM ATP for 2 min at 35°C. (b) Activity of the WT and R458A/R464A mitoRNAP on LSP promoter template. 
Transcription assays were performed as described in Figure 23 in the presence of TFAM (50 nM) and TFB2M (150nM) for 
30 min at 35°C. 
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4 Alignment of full-lenght human. mitoRNAP sequence 
and structure with T7 RNAP (PDB 1QLN) 
 
Figure 23. Alignment of human mitoRNAP with T7 RNAP. 
Sequence alignment and structural conservation of human mitoRNAP and T7 RNAP (using PBD 1QLN for secondary 
structure allocation). Shown are mitoRNAP res. 218-1230 and full length T7 RNAP. Secondary structure elements are 
indicated above and under the sequences for mitoRNAP and T7 RNAP, respectively (cylinders for -helices, arrows for -
strands, lines for loops) with colours in mitoRNAP blue for PPR domain, silver for N-terminal domain, and gray for C-
terminal core and in T7 RNAP salmon for N-terminal domain, and lightpink for C-terminal core.  
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AA aminoacids 
ABC  subunit prefix for RNAP I (A), II (B) and III (C) 
AC  subunit prefixes for RNAP I (A) and III (C) 
BdpI B double prime I 
Brf1 B-related factor 1 
C  subunit prefix for RNAP III (C) 
C. elegans Caenorhabditis elegans 
Cryo-EM  cryo-electron microscopy 
CTD carboxy-terminal domain 
C-terminus  carboxy-terminus 
Ct-NLS  C-terminal NLS 
cv column volume 
D.melanogaster Drosophila melanogaster 
DNA  deoxyribonucleic acid 
DNAP DNA dependent DNA poylmerase 
dsDNA double strand DNA 
DTT  dithiothreitol 
E.coli  Escherichia coli 
EDTA  ethylene diamine tetraacetic acid 
EM  electron microscopy 
ESRF European Synchrotron Radiation Facility (Genoble, France) 
ETC electron transport chain 
fl full lenght 
FSC  Fourier shell correlation 
G earth´s gravity 
GTF  general transcription factor 
h hour 
Hepes  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
H.sapiens  Homo sapiens 
H-strand heavy strand of mtDNA 
kbp kilo basepairs 
kDa kilo Dalton 
LB  lysogeny broth 
L-strand light strand of mtDNA 
MAD multiple-wavelenghts anormalous diffraction 
MES  2-(N-morpholino)ethanesulfonic acid 
mitoRNAP mitochondrial RNAP 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA  messenger RNA 
mtDNA mitochondrial DNA 
mTERF mitochondrial transcription termination factor 
NCBI National Center for Biotechnology Information 
Ni-NTA  Nickel-nitrilotriacetic acid 
NLS nuclear localization signal 
N-site NTP binding site 
nt nucleotides 
NTD N-terminal domain 
N-terminus  amino-terminus 
Nt-NLS  N-terminal NLS 
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NTP  nucleotide triphosphate 
o.n. over night 
OD optical density 
PBD promoter binding domain 
PCR polymerase chain reaction 
PDB  Protein Data Bank 
PI  protease inhibitor 
PIC  pre-initiation complex 
PKA protein kinase A 
PMSF  phenylmethylsulfonyl fluoride 
PPi pyrophosphate 
PPR pentatricopeptide 
P-site priming site 
PVDF polyvinylidene fluoride 
R-factor normalized linear residual between observed and calculated structure factor 
amplitudes 
RNA  ribonucleic acid 
RNAP  DNA dependent RNA polymerase 
ROS reactive oxygen species 
Rpb  prefix of RNAP II subunits 
rpm rounds per minute 
r.m.s.d. root mean sqare deviation 
rRNA  ribosomal RNA 
RT  room temperature 
RTZ rotation function Z-score 
S.cerevisiae  Saccharomyces cerevisiae 
SDG Saccharomyces genome database 
SDS-PAGE  sodium dodecylsulfate polyacrylamide gel electrophoresis 
SLS  Swiss Light Source 
snRNA  small nuclear RNA 
snoRNA  small nucleolar RNA 
S.pombe Schizosaccharomyces cerevisiae 
ss single subunit 
TBE  Tris/Borate/EDTA 
TBP  TATA-box binding protein 
TCEP tris(2-carboxyethyl)phosphine 
TF  transcription factor 
TFZ translation function Z-score 
TORC target of rapamycin complex 
TPR tetratricopeptide 
Tris  trishydroxymethylaminomethane 
tRNA  transfer RNA 
TSS transcription start site 
UTP  uridine triphosphate 
v/v volume per volume 
WH  winged helix 
Wt wild type 
w/v weight per volume 
YPD  yeast peptone dextrose 
YPGly yeast peptone glycerol 
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